# Chiu_2013_Therapeutic potential of mood stabilizers lithium and valproic acid beyond bipolar disorder.

1521-0081/65/1/105–142$25.00
PHARMACOLOGICAL REVIEWS
U.S. government work not protected by U.S. copyright

http://dx.doi.org/10.1124/pr.111.005512
Pharmacol Rev 65:105–142, January 2013

ASSOCIATE EDITOR: DAVID R. SIBLEY

Therapeutic Potential of Mood Stabilizers Lithium
and Valproic Acid: Beyond Bipolar Disorder

Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland

Chi-Tso Chiu, Zhifei Wang, Joshua G. Hunsberger, and De-Maw Chuang

Abstract. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
A. Lithium and GSK-3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
B. VPA and HDACs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
II. Neuroprotective Effects of Mood Stabilizers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
A. Neurotrophic and Angiogenic Factors Modulated by Lithium and VPA . . . . . . . . . . . . . . . . . . 109
1. BDNF. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2. GDNF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
3. VEGF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
B. Factors Affecting Apoptotic Signaling: Bcl-2, p53, Bax, Caspase Signaling, and HSP70 . . . . 110
C. Cell Survival Signaling Cascades . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
1. The PI3K/Akt Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
2. The Wnt/b-Catenin Pathway. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
3. The MEK/ERK Pathway. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
D. Oxidative Stress Pathways. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
E. Protein Quality Control Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
1. Induction of the Ubiquitin-Proteasome System and Autophagy
. . . . . . . . . . . . . . . . . . . . . . 113
2. GRP78 Upregulation.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
F. Augmented Protective Effects by Lithium and VPA Cotreatment . . . . . . . . . . . . . . . . . . . . . . . . . 114
1. Enhanced Neuroprotection by Cotreatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
2. Enhancing the Homing and Migratory Capacity of Stem Cells . . . . . . . . . . . . . . . . . . . . . . . . . 114
G. New Directions: miRNAs Targeted by Lithium and VPA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
III. Repurposing Mood Stabilizers for CNS Disorders Beyond BD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
A. Stroke. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
1. Lithium-Induced Effects in Experimental Stroke Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
a. Neuroprotection and behavioral improvement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
b. Anti-excitotoxic and anti-apoptotic effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
c. Anti-inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
d. Angiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
e. Neurogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
f. Effects on MSC migration after transplantation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
2. VPA-Induced Effects in Experimental Stroke Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
a. Neuroprotective effects and behavioral benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
b. Anti-inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
c. BBB protection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
d. Angiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
e. Neurogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
B. TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

1. Lithium-Induced Effects on Neurodegeneration, Neuroinflammation, Behavioral

Improvement, and Ab Accumulation in Models of TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

This work was supported by the Intramural Research Program of the National Institutes of Health National Institute of Mental Health,

Department of Health and Human Services (IRP-NIMH-NIH-DHHS).

Address correspondence to: Dr. De-Maw Chuang, Molecular Neurobiology Section, National Institute of Mental Health, National

Institutes of Health, Building 10, Room 3D38, 10 Center Drive, MSC 1363, Bethesda, MD 20892-1363. E-mail: chuang@mail.nih.gov

dx.doi.org/10.1124/pr.111.005512.

105

106

Chiu et al.

2. VPA-Induced Effects on Neurodegeneration, Neuroinflammation, and Functional

Recovery in Models of TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
3. Clinical Trials of VPA Treatment in TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
C. HD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123

1. Lithium-Induced Effects on Apoptosis, Cell Proliferation, and Neuroprotection in

Excitotoxic Models of HD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
2. Investigating Mood Stabilizers in Transgenic Models of HD . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
3. Effects of Mood Stabilizers on Clearance of mHtt. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
4. Effects of Combined Lithium and VPA Treatment on Behavior in Transgenic Models of HD 125
5. Clinical Trials of Lithium and VPA Treatment in HD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
D. AD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
1. Effects of Mood Stabilizers on GSK-3 Inhibition in AD Models. . . . . . . . . . . . . . . . . . . . . . . . . 127
2. Effects of Mood Stabilizers on Other Molecular Targets in AD Models . . . . . . . . . . . . . . . . . 127
3. Effects of Mood Stabilizers on Recovery of Cognitive Function in AD Models . . . . . . . . . . . 127
4. Clinical Trials of Lithium and VPA Treatment in AD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
E. ALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
1. Effects of Lithium Treatment in ALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
2. Effects of VPA Treatment in ALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
3. Clinical Trials of Lithium and VPA Treatment in ALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
F. FXS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
1. Therapeutic Potential of Lithium Treatment in FXS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
2. Therapeutic Potential of VPA Treatment in FXS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
IV. Limitations for Lithium and VPA Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
V. Conclusions and Future Directions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133

Abstract——The mood stabilizers lithium and val-
proic acid (VPA) are traditionally used to treat bipolar
disorder (BD), a severe mental illness arising from
complex interactions between genes and environment
that drive deficits in cellular plasticity and resiliency.
The therapeutic potential of these drugs in other central
nervous system diseases is also gaining support. This
article reviews the various mechanisms of action of
lithium and VPA gleaned from cellular and animal
models of neurologic, neurodegenerative, and neuropsy-
chiatric disorders. Clinical evidence is included when
available to provide a comprehensive perspective of the
field and to acknowledge some of the limitations of these
treatments. First, the review describes how action at
these drugs’ primary targets—glycogen synthase kinase-
3 for lithium and histone deacetylases for VPA—induces
the transcription and expression of neurotrophic,
angiogenic, and neuroprotective proteins. Cell survival

signaling cascades, oxidative stress pathways, and pro-
tein quality control mechanisms may further underlie
lithium and VPA’s beneficial actions. The ability of
cotreatment to augment neuroprotection and enhance
stem cell homing and migration is also discussed, as are
microRNAs as new therapeutic targets. Finally, pre-
clinical findings have shown that the neuroprotective
benefits of these agents facilitate anti-inflammation,
angiogenesis, neurogenesis, blood-brain barrier integ-
rity, and disease-specific neuroprotection. These mech-
anisms can be compared with dysregulated disease
mechanisms to suggest core cellular and molecular
disturbances identifiable by specific risk biomarkers.
Future clinical endeavors are warranted to determine
the therapeutic potential of lithium and VPA across the
spectrum of central nervous system diseases, with
particular emphasis on a personalized medicine ap-
proach toward treating these disorders.

ABBREVIATIONS: Ab, b-amyloid peptide; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AMD3100, 1,19-[1,4-phenylenebis
(methylene)]bis [1,4,8,11-tetraazacyclotetradecane]; AP-1, activator protein 1; APP, amyloid precursor protein; AR-A014418, N-(4-
methoxybenzyl)-N9-(5-nitro-1,3-thiazol-2-yl)urea; BBB, blood-brain barrier; Bcl-2, B-cell-lymphoma 2; BD, bipolar disorder; BDNF, brain-
derived neurotrophic factor; CGCs, cerebellar granule cells; CNS, central nervous system; CREB, cAMP response element-binding protein;
CXCR4, CXC chemokine receptor 4; DG, dentate gyrus; FXS, fragile X syndrome; GDNF, glial cell line-derived neurotrophic factor; GM6001,
N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide; GRP78, 78-kDa glucose-regulated protein; GSK-3,
glycogen synthase kinase-3; HD, Huntington’s disease; HDACs, histone deacetylases; HSF-1, heat shock factor-1; HSP70, heat shock protein
70; ITF2357, {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate; LPS, lipopolysaccharide; LY294002,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; MCAO, middle cerebral artery occlusion; miRNA, microRNA; MMP, matrix metal-
loproteinase; MSCs, mesenchymal stem cells; mHtt, mutant huntingtin; NF-kB, nuclear factor-kB; NMDA, N-methyl-D-aspartate; PI3K,
phosphatidylinositol 3-kinase; PSD-95, postsynaptic density-95; QA, quinolinic acid; ROS, reactive oxygen species; SB, sodium butyrate;
SB216763, 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; SMA, spinal muscular atrophy; SOD, superoxide dis-
mutase; SVZ, subventricular zone; TBI, traumatic brain injury; TSA, trichostatin A; U0126, 1,4-diamino-2,3-dicyano-1,4-bis[2-amino-
phenylthio]butadiene; UPS, ubiquitin-proteasome system; VEGF, vascular endothelial growth factor; VPA, valproic acid.

Therapeutic Potential of Mood Stabilizers

107

I. Introduction

The mood stabilizers lithium and valproic acid (VPA)
are primarily used to treat bipolar disorder (BD), a
common, severe, and chronic mental illness that affects
approximately 1%–3% of the population and is one of the
major causes of disability worldwide (for review, see
Goodwin and Jamison, 2007). However, accumulating
evidence indicates that these agents also hold promise for
treating neurologic and/or neurodegenerative diseases
via their diverse mechanisms of action. To provide a clear
and comprehensive picture of the mechanisms that may
underlie the beneficial effects of lithium and VPA, this
review focuses on two primary targets: glycogen synthase
kinase-3 (GSK-3) for lithium and histone deacetylases
(HDACs) for VPA. Here, we propose that GSK-3 and
HDAC inhibition are critical to the facilitation of the
numerous molecular mechanisms that may be exploited
for therapeutic use. We anticipate that novel therapies
will emerge from characterizing the mechanisms used by
lithium and VPA either as monotherapy or in combina-
tion; both will be considered in great detail in this review.
Although lithium and VPA have long been used to
treat BD, the mechanisms underlying their therapeutic
effects remain elusive. Furthermore, it is likely that the
interactions of many different genetic, epigenetic, and
environmental factors contribute to this complex and
heterogeneous mood disorder. Although the etiology of
BD remains poorly understood, it is believed to involve
multiple factors, including dysregulation of signaling
pathways and gene expression, loss of synaptic plastic-
ity, decreased cellular resilience, reduced brain cell
density, and abnormalities in neuroanatomical struc-
ture and function. Lithium may counteract some of
these deficits via its neurotrophic effects; for example, it
has been shown to affect brain derived neurotrophic
factor (BDNF) levels in individuals with BD (Suwalska
et al., 2010; de Sousa et al., 2011). In addition, lithium
treatment has been shown to increase gray matter
volume in patients with BD in whole brain, cortex,
hippocampus, and anterior cingulate (Sassi et al., 2002;
Bearden et al., 2007, 2008; Moore et al., 2000b, 2009).
Lithium also increases brain volume in limbic struc-
tures, such as the hippocampus (Yucel et al., 2007,
2008), that are implicated in emotional regulation.
Untreated patients with BD showed decreased left
cingulate volumes compared with either
anterior
healthy control subjects or lithium-treated patients
(Sassi et al., 2004). N-Acetyl-aspartate (NAA), a putative
marker for neuronal viability and function, was also
reported to be increased in the brain of patients with BD
after lithium treatment (Moore et al., 2000a; Hajek
et al., 2012). Of interest, increased gray matter volume
was found in patients with BD who responded clini-
cally to lithium, suggesting a therapeutic role for
this neurotrophic effect in clinical response to lithium

(Moore et al., 2009; Lyoo et al., 2010). Collectively, this
indirect evidence suggests that
lithium augments
neurotrophic mechanisms in BD and warrants further
investigation in other brain diseases.

This review discusses numerous mechanisms used by
lithium and VPA that may be effective in treating other
central nervous system (CNS) disorders. We scrutinize
neurologic disease mechanisms implicated in stroke,
traumatic brain injury (TBI), Huntington’s disease (HD),
Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS), and Fragile X Syndrome (FXS). In particular,
preclinical evidence of the mechanisms used by these
mood stabilizers to thwart disease processes and achieve
their beneficial effects will be presented. These include
neurotrophism, neuroprotection, oxidative stress, protein
quality control, anti-inflammation, stem cell migration,
neurovascular remodeling, blood-brain barrier (BBB)
integrity, and microRNA (miRNA) regulation. There
are similarities and differences in the biologic processes
affected by lithium and VPA (Gupta et al., 2012). Both
lithium and VPA have multiple targets in addition to
GSK-3 and HDACs; however, it is beyond the scope of
this review to consider all of these. The interested reader
is referred to several excellent reviews describing
additional targets (Jope, 2003, 2011; Gould and Manji,
2005; Zarate et al., 2006; Hunsberger et al., 2009; Chiu
and Chuang, 2010; Quiroz et al., 2010).

A. Lithium and GSK-3

For more than half a century, the monovalent cation
lithium has been the primary drug used to treat BD. It
is effective against acute mania, prophylactic for re-
current manic and depressive episodes, and reduces the
risk of suicide (Geddes et al., 2004; Cipriani et al., 2005;
Ohgami et al., 2009). It can also augment the efficacy of
antidepressants commonly used for the treatment of
major depressive disorder (MDD) (Crossley and Bauer,
2007). At therapeutic serum concentrations (0.621.2
mM), lithium is known to inhibit a group of phospho-
including inositol poly-
monoesterases in mammals,
phosphate 1-phosphatase,
inositol monophosphate
phosphatase, fructose 1,6-bisphosphatase, and bisphos-
phate nucleotidase, in addition to the metabolic enzyme
phosphoglucomutase and GSK-3. Downstream effectors,
such as adenylate cyclase, the phosphoinositol cascade,
and metabolism of arachidonic acid, are also affected by
lithium treatment (for a review, see Quiroz et al., 2004;
Gould et al., 2004c; Rao and Rapoport, 2009). Although
the mood-stabilizing effects of lithium may result from
inhibiting these enzymes, the multifaceted protein
GSK-3 is believed to be the main facilitator of lithium’s
mood stabilizing and neuroprotective effects, because of
its array of cellular and physiologic functions (Fig. 1).

GSK-3 is an evolutionarily conserved, ubiquitous
serine-threonine kinase consisting of a and b isoforms

108

Chiu et al.

(for a review, see Chiu and Chuang, 2010). GSK-3
dysfunction has been linked to the pathophysiology of
mood disorders, schizophrenia, AD, diabetes, and others
(reviewed in Meijer et al., 2004; Huang and Klein, 2006;
Jope et al., 2007; Chiu and Chuang, 2010; Li and Jope,
2010). In rodent models, the pharmacological inhibition or
gene knockout/knockdown of GSK-3 mimicked lithium’s
antidepressant and anti-manic effects (Kaidanovich-
Beilin et al., 2004, 2009; O’Brien et al., 2004; Gould
et al., 2004b; Rosa et al., 2008; Jope, 2011; Omata et al.,
2011). Despite limited clinical data, some evidence from
genetic and postmortem studies supports the role of
GSK-3 in mood disorders (for a review, see Jope, 2011).
For example, elevated GSK-3 activity was found in post
mortem samples from individuals with MDD (Karege
et al., 2007, 2011), whereas serine-phosphorylation of
GSK-3 in peripheral blood mononuclear cells was iden-
tified to be decreased with disease and increased after
therapy (Li et al., 2007, 2010b).

Lithium inhibits GSK-3 by binding directly to the
enzyme’s magnesium-sensitive site (Klein and Melton,
1996; Stambolic et al., 1996) and indirectly by enhancing
phosphorylation of this kinase at specific serine residues.
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway
was found to mediate the indirect inhibitory effects of
lithium on this enzyme by elevating phosphorylation of
GSK-3a at Ser21 (Chalecka-Franaszek and Chuang,
1999), providing the first evidence that lithium indirectly
inhibits GSK-3 via enhanced phosphorylation. In
addition, GSK-3b activity can also be negatively re-
gulated by its phosphorylation at Ser9 (Jope, 2003). To
date, multiple mechanisms have been identified that

contribute to GSK-3 phosphorylation, including the
39,59-cyclic adenosine monophosphate (cAMP)–dependent
activation of protein kinase A (PKA) (Jope, 1999); the
PI3K-dependent activation of protein kinase C (PKC)
(Kirshenboim et al., 2004); and the enhanced inhibition
of protein phosphatase-l through the action of inhibitor-2
complex, which auto-regulates GSK-3 (Zhang et al., 2003).
A mouse study further showed that lithium increased the
serine phosphorylation of GSK-3 by disrupting the
formation of b-arrestin 2/protein phosphatase 2A/Akt
complex that dephosphorylated and inactivated Akt
(Beaulieu et al., 2008). Because a complete analysis of
the neurobiology of GSK-39s action is beyond the scope of
the current review, we refer interested readers to several
excellent reviews on the subject (Jope, 2003, 2011; Meijer
et al., 2004; Rowe and Chuang, 2004; Huang and Klein,
2006; Jope and Roh, 2006; Rowe et al., 2007; Chiu and
Chuang, 2010; Li and Jope, 2010).

B. VPA and HDACs

Several anti-convulsants—VPA, carbamazepine, and
lamotrigine—are also effective in treating BD (Yatham,
2004). Similar to lithium, VPA has strong anti-manic
effects, but it is less effective against depressive episodes.
It has been suggested that the efficacy of VPA in BD
results from enhanced g-aminobutyric acid (GABA)
neurotransmission and the inhibition of enzymes
involved in GABA metabolism, such as succinate semi-
aldehyde dehydrogenase, succinate semialdehyde reduc-
tase, and GABA transaminase (for a review, see Gould
et al., 2004c). In addition, the anti-convulsive action of
VPA is thought to be mediated by its inhibitory effects on

Fig. 1. A schematic illustration of the central hypothesis of molecular actions of mood stabilizers lithium and VPA. Through the inhibition of GSK-3
and HDACs, respectively,
lithium and VPA are hypothesized to regulate the transcription and expression of factors critically involved in
neuroprotective, neurotrophic, anti-inflammatory, neurogenic and angiogenic, mood-stabilizing, antidepressant-like, and anxiolytic effects, in addition
to regulating stem cell migration and miRNAs. The underlying mechanisms of these actions have been elucidated by both in vitro and in vivo
experimental settings and are discussed in this review. Lines with solid arrows represent stimulatory connections; lines with flattened ends represent
inhibitory connections. Dashed lines represent pathways with reduced activity as a result of drug treatment.

Therapeutic Potential of Mood Stabilizers

109

the sodium channel at high frequencies (reviewed in
Macdonald and Kelly, 1995). VPA also inhibits HDACs
at therapeutic serum levels (0.420.8 mM) (Fig. 1).

Histone proteins organize DNA into nucleosomes,
which are regular repeating structures of chromatin.
This organization is required for the efficient packag-
ing of large amounts of eukaryotic genomic DNA. In
the process of deacetylation, HDACs remove charge-
neutralizing acetyl groups from the lysine residues on
tails of histones and favor a more transcriptionally
inactive chromatin conformation. In contrast, histone
acetyltransferases (HATs)
increase acetylation and
favor a more transcriptionally active chromatin con-
formation. Therefore, VPA inhibits HDACs to promote
a more transcriptionally active chromatin structure.

HDACs fall into at least two major classes: class I
contains isoforms 1–3 and 8, and class II contains
isoforms 4–7 and 9–10 (Chuang et al., 2009). At clinically
relevant levels, VPA effectively inhibits HDAC (Gottlicher
et al., 2001; Phiel et al., 2001), making it valuable for
investigations into the therapeutic role of chromatin
remodeling in disorders of the CNS. VPA and its analogs
inhibit the activity of HDAC isoforms from both classes,
although it appears not to affect HDAC6 and 10 isoforms
that belong to class IIb (Gurvich et al., 2004). VPA
significantly inhibits class I and, to a lesser extent, class
II HDACs (Gottlicher et al., 2001). However, a more
recent work indicated that VPA’s inhibition of class II
HDACs might be attributable to the contaminating
activities of class I HDACs (Fass et al., 2010). Additional
studies are necessary to clarify this issue. The epigenetic
control of genes through modification of histones and the
resultant remodeling of chromatin has been shown to
profoundly affect development, synaptic plasticity, learn-
ing, memory, drug abuse, alcoholism, circadian rhythm,
and the efficacy of antidepressants (Abel and Zukin,
2008; McClung and Nestler, 2008; Chuang et al., 2009).

II. Neuroprotective Effects of Mood Stabilizers

Harnessing the ability of mood stabilizers to enhance
neuroprotection has therapeutic implications for a wide
range of CNS diseases. We begin by highlighting the
critical signaling molecules and mechanisms that
contribute to the neuroprotective actions of lithium
and VPA, including selected neurotrophic, angiogenic,
and anti-apoptotic factors; survival signaling cascades;
oxidative stress pathways; and protein quality control
mechanisms. We then discuss the augmented therapeu-
tic effects of combined lithium and VPA treatment
achieved in primary cultured neurons and stem cells
and provide evidence for miRNAs as novel targets and
facilitators of lithium and VPA.

A. Neurotrophic and Angiogenic Factors Modulated by
Lithium and VPA

Most neurotrophic factors, which enhance the growth
and survival of developing neurons and maintain the
vitality of mature neurons, fall into one of three broad
families as follows: 1) neurotrophins (Huang and
Reichardt, 2001), 2) glial cell-line derived neurotrophic
factor (GDNF) family ligands (Paratcha and Ledda,
2008), and 3) neuropoietic cytokines (Bauer et al., 2007).
Angiogenic factors, which support the formation of new
vasculature from preexisting blood vessels, have been
implicated in numerous disease mechanisms (reviewed
in Carmeliet, 2003). This section focuses on BDNF,
GDNF, and angiogenic vascular endothelial growth
factor (VEGF), three key factors augmented after the
administration of lithium or VPA.

1. BDNF. BDNF, which signals through the TrkB
receptor to augment cortical development, synaptic
plasticity, neurogenesis, and neuronal survival, is known
to play a vital role in neuropsychiatric disorders (for
a review, see Autry and Monteggia, 2012). Evidence also
exists that the neuroprotective effects of lithium and
VPA are facilitated, at least in part, by the induction of
BDNF and activation of its receptor. Pretreatment with
lithium or BDNF, for instance, protected primary cortical
neurons against glutamate excitotoxicity (Hashimoto
et al., 2002b), and conversely, use of a Trk tyrosine kinase
inhibitor or BDNF-neutralizing antibody negated this
neuroprotection. An extension of this study demonstrated
that lithium treatment both increased BDNF protein
levels and activated its receptor and that lithium-induced
neuroprotection did not occur in cortical neurons derived
from both homozygous and heterozygous BDNF-knockout
mice.

Building on these findings, additional studies showed
that both lithium and VPA increased levels of exon
IV–containing BDNF mRNA and increased the activity
of BDNF promoter IV in cortical neurons (Yasuda et al.,
2009). In addition, GSK-3 inhibition contributed to
the lithium-induced activation of BDNF promoter IV,
whereas GSK-3 inhibitors mimicked this activation.
Conversely, HDAC inhibition contributed to VPA-induced
promoter IV activation. In hypoxia, chronic lithium
treatment is known to be neuroprotective (as measured
by cerebral glucose metabolic rate), apparently because
it elevates levels of BDNF protein and phosphorylated
cAMP response element binding protein (CREB)
(Omata et al., 2008). In addition to its neuroprotective
effects, BDNF has been found to enhance neurogenesis,
contributing further to the therapeutic effects of
lithium (Chen et al., 2000; Wexler et al., 2008) and
VPA (Hao et al., 2004; Laeng et al., 2004). Clinically,
lithium treatment augmented serum levels of BDNF in
patients with early AD (Leyhe et al., 2009). These results
support BDNF regulation in a clinical population and
suggest considerable potential of this regulation for the
treatment of neurodegenerative diseases.

Neurotrophic and angiogenic factors play vital roles
during neural development and synaptic plasticity.

2. GDNF. Lithium and VPA have been shown, in
vivo and in vitro, to regulate GDNF, in which pleiotropic

110

Chiu et al.

functions include migration, chemo-attraction, and dif-
ferentiation (on neuroblasts) and axonal growth, axonal
guidance, survival, and synapse function (on neurons)
(for a review, see Paratcha and Ledda, 2008). In rat
models of depression, six weeks of lithium treatment
increased GDNF protein levels in hippocampus, stria-
tum, and prefrontal cortex, and these increases appeared
to contribute to the drug’s antidepressant-like effects
(Angelucci et al., 2003). Both lithium and GDNF,
moreover, protected against mitochondrial and endo-
plasmic reticulum (ER) stress-mediated apoptosis in-
duced by aluminum (Savory et al., 2003).

VPA has also been shown, in primary neuronal-glial
cocultures from rat midbrain,
to protect against
neurotoxicity induced by lipopolysaccharide (LPS), in
part because of its inhibitory effects on pro-inflamma-
tory factors (Peng et al., 2005). In a similar midbrain
neuronal-glial coculture, astrocytes were shown to
release GDNF and BDNF, which mediate VPA’s
neuroprotective effects on dopaminergic neurons (Chen
et al., 2006). Other HDAC inhibitors have also been
demonstrated to exert neuroprotective effects.
In
neuronal-glial cocultures, for instance, sodium buty-
rate (SB) and trichostatin A (TSA) protected dopami-
nergic neurons by inducing GDNF and, possibly,
BDNF in astrocytes (Wu et al., 2008). Finally, after
spinal cord injury, GDNF and BDNF may have
contributed to the improvement of locomotion produced
by VPA treatment (Lv et al., 2012).

3. VEGF. VEGF is a prominent angiogenic factor
(Ferrara et al., 2003) that induces and promotes
angiogenesis to increase trophic support through the
formation of new blood vessels from existing vascula-
ture. Angiogenesis then should be considered as an
important mechanism that offers trophic and neuro-
protective effects to neuronal and glial cells, in addition
to enhancing neurogenesis and synaptic plasticity
where VEGF has been implicated (Newton et al.,
2003; Newton and Duman, 2004; Warner-Schmidt
and Duman, 2007). VEGF’s angiogenic signals are
mediated through two primary receptors, VEGFR-1
and VEGFR-2, that play a variety of roles. These
include inducing anti-apoptotic proteins (such as B-cell
lymphoma 2 [Bcl-2]) to preserve endothelial cells and
promoting monocyte chemotaxis in bone marrow–
derived cells to induce vascular leakage (reviewed by
Ferrara et al., 2003).

of antidepressants

VEGF has been shown to modulate neurogenesis
(Jin et al., 2002) and contribute to the behavioral
actions
(Warner-Schmidt and
Duman, 2007). In addition to antidepressants, VEGF
is also regulated by mood stabilizers. In cultured brain
cells, for instance, treatment with lithium increased
VEGF levels in both endothelial cells and astrocytes.
This increase in endothelial cells, moreover, was
associated with enhanced GSK-3b Ser9 phosphoryla-
tion, an effect mimicked by the GSK-3 inhibitor

SB216763 (Guo et al., 2009) and blocked by the PI3K
inhibitor LY294002. In contrast, SB216763 did not
mimic, nor did LY294002 affect, lithium upregulation
of VEGF in astrocytes, although LY294002 abolished
lithium-induced GSK-3 phosphorylation, suggesting
cell type–specific regulatory mechanisms.

In cultured endothelial cells, VPA enhanced VEGF-
induced angiogenesis (Jin et al., 2011). Chronic post-
insult treatment with VPA increased VEGF protein
levels in the ischemic cerebral cortex (Wang et al.,
2012). This VEGF upregulation was mediated by the
transcription factor hypoxia inducible factor-1a (HIF-
1a) and contributed to angiogenesis and functional
recovery after ischemic stroke in rats (see section III.A).

B. Factors Affecting Apoptotic Signaling: Bcl-2, p53,
Bax, Caspase Signaling, and HSP70

Apoptosis, or programmed cell death,

involves
numerous biochemical signaling cascades. Both lith-
ium and VPA increased mRNA expression of the anti-
apoptotic protein Bcl-2 in rat frontal cortex (Chen
et al., 1999b). In a mouse model of ALS, VPA and two
other HDAC inhibitors were shown to upregulate Bcl-2
mRNA in spinal cord (Rouaux et al., 2007). In primary
brain neuronal cultures challenged with glutamate
excitotoxicity mediated by N-methyl D-aspartate
(NMDA) receptors, lithium increased the expression
of Bcl-2, decreased the expression of the proapoptotic
proteins p53 and Bax, and suppressed the mitochon-
drial release of glutamate-induced cytochrome c (Chen
and Chuang, 1999). Pretreatment with lithium, more-
over, prevented the activation of caspase-3 cleavage of
lamin B1 that usually results from mitochondrial
release of cytochrome c. In addition to modulating
anti-apoptotic and proapoptotic proteins, lithium was
found to modulate NMDA receptor–mediated synaptic
activity and excitotoxicity by attenuating the constitu-
tive phosphorylation at Tyr1472 of the NR2B subunit
of the NMDA receptor, which is activated by the Src
tyrosine kinase Fyn (Hashimoto et al., 2002a, 2003a).
Heat shock proteins (HSPs) are a group of molecular
chaperones that assist in regulating protein folding
and refolding of misfolded proteins, where they help
restore cellular homeostasis and promote cell survival
(see section II.E). Studies have found that HSPs, such
as HSP70, exert a wide variety of neuroprotective
effects against apoptosis (Takayama et al., 2003)
through varied mechanisms, ranging from antagoniz-
ing apoptosis-inducing factors (Ravagnan et al., 2001),
inhibiting the activation of nuclear factor-kB (NF-kB)
by stabilizing IkB protein (Feinstein et al., 1996; Zheng
et al., 2008), stabilizing Akt-1 protein (Gao and
Newton, 2002), and preventing mitochondrial cyto-
chrome c release and caspase activation (Beere et al.,
2000). Of interest, HSP70 expression is regulated by heat
shock factor-1 (HSF-1), a transcription factor negatively
regulated by GSK-3b–dependent phosphorylation (Bijur

Therapeutic Potential of Mood Stabilizers

111

and Jope, 2000). The neuroprotective effects of lithium in
a stroke model are in fact associated with a marked
increase in the DNA binding activity of HSF-1 and
subsequent elevations in the expression of HSP70
protein in the ischemic brain (Ren et al., 2003).

Findings from an experiment of SH-SY5Y cells
challenged with the mitochondrial complex I inhibitor
rotenone suggest that VPA’s neuroprotective effects
may also involve HSP70 and may be associated with
reductions in the release of cytochrome c and the
cleavage of caspase-3 and -9 (Pan et al., 2005). In rat
cortical neuronal cultures, HSP70 participated in VPA
neuroprotection against short-term glutamate excito-
toxicity. This VPA-induced HSP70 was triggered by
inhibition of class I HDACs, as well as acetylation and
recruitment of the transcription factor Sp1 at the
HSP70 promoter (Marinova et al., 2009). In addition,
VPA-induced HDAC inhibition also altered methylation
levels of histone (H3K4Me2) at the HSP70 promoter
and caused its induction in both neurons and astrocytes
(Marinova et al., 2011). In various animal models,
overexpression of HSP70 has been recognized as
a potential therapeutic target against ischemic neuronal
injury and will be discussed in detail in the section III.A.

C. Cell Survival Signaling Cascades

Activated by the stimulation of trophic-factor recep-
tors on the cell surface, the neuroprotective mecha-
nisms of lithium and VPA involve multiple survival
signaling cascades, including the PI3K/Akt pathway,
Wnt/b-catenin pathway, and the MAP kinase-kinase
(MEK)/extracellular-signal regulated kinase (ERK)
pathway.

1. The PI3K/Akt Pathway. BDNF induction is an
early and essential step in lithium’s neuroprotection
against glutamate excitotoxicity. BDNF’s trophic action
is likely to be involved in lithium-induced activation of
the cell survival PI3K/Akt and MEK/ERK pathways.
Activation of Akt, a serine/threonine kinase regulated
by PI3K, involves phosphorylation at residues of Thr308
and Ser473 (Alessi and Cohen, 1998; Jacinto et al.,
2006). In cultured rat cerebellar granule cells (CGCs),
lithium treatment rapidly normalized glutamate-
induced inactivation of Akt by activating PI3K and
subsequently increasing the phosphorylation of Akt at
its Ser473 residue (Chalecka-Franaszek and Chuang,
1999). After activation, Akt in turn affects several anti-
including Bcl-2–associated death
apoptotic targets,
promoter, CREB, members of the forkhead family,
and procaspase-9 (Neri et al., 2002; Nicholson and
Anderson, 2002; Huang and Reichardt, 2003). In cultured
human neuroblastoma cells, caspase-3 activation induced
by neurotoxins that mimic neurochemical changes asso-
ciated with Parkinson’s disease was inhibited by lithium
treatment in a PI3K-dependent manner (King et al.,
2001). Against HIV-induced toxicity, both in vitro and in
lithium-induced neuroprotection appears to be
vivo,

mediated through the PI3K/Akt pathways (Everall et al.,
2002; Dou et al., 2005). However, because some studies
detected no changes in Akt phosphorylation levels at
specific time points after the application of lithium in
certain cell lines, the effects of lithium on the PI3K/Akt
pathway may be cell type–specific and time-dependent
(De Sarno et al., 2002; Zhang et al., 2003).

Although considered to be an HDAC inhibitor, VPA
has been reported to cause gradual
increases in
phosphorylation of Akt and GSK-3b at Ser473 and
Ser9 residues, respectively, under some in vitro con-
ditions (Chen et al., 1999a; De Sarno et al., 2002).
Because lithium and VPA can both upregulate BDNF
expression, VPA may increase GSK-3 phosphorylation
via BDNF-mediated activation of the PI3K/Akt pathway.
In fact, VPA has been implicated in the activation of both
the PI3K/Akt and MEK/ERK cellular signaling path-
ways (Kostrouchova et al., 2007). In cultured cortical
neurons, pretreatment with either a PI3K or Akt
inhibitor attenuated VPA-induced upregulation of
HSP70 (Marinova et al., 2009). In a rat cerebral ischemia
model, injection with other HDAC inhibitors augmented
HSP70 and reversed ischemia-induced downregulation
of Akt phosphorylation (Kim et al., 2007). A recent study
in cultured human neuroblastoma cells also demon-
strated that the effect of VPA on monoamine oxidase A
induction was mediated by the PI3K/Akt/forkhead
signaling pathway (Wu and Shih, 2011).

2. The Wnt/b-Catenin Pathway. By controlling
axon remodeling and synapse formation, the Wnt
pathway plays an important role in regulating neuronal
connectivity in the nervous system (Ciani and Salinas,
2005). GSK-3 activity is also negatively regulated by
Wnt-stimulated activation of the Frizzled receptor in
addition to the aforementioned protein kinases (e.g.,
PKA, PKC, and Akt). As a substrate of GSK-3, the
transcription factor b-catenin is part of
the Wnt
pathway, and its cytoplasmic levels are decreased by
GSK-3 through phosphorylation-dependent proteaso-
mal degradation (Jope and Johnson, 2004; Takahashi-
Yanaga and Sasaguri, 2007). In conjunction with
T cell–specific transcription factor (Tcf)/lymphoid en-
hancer binding factor (Lef), increases in cytoplasmic
accumulations of b-catenin facilitate its translocation
into the nucleus and, subsequently, enhance the
transcription of diverse genes, such as growth factors
(Sinha et al., 2005; Silva et al., 2007) and those involved
in apoptotic inhibition (Feng, 1979; Seidensticker and
Behrens, 2000; Huelsken and Behrens, 2002). Activa-
tion of the canonical Wnt/b-catenin pathway has been
shown to contribute to adult hippocampal neural
progenitor cell proliferation triggered by lithium treat-
ment (Wexler et al., 2008). At therapeutic concentra-
tions, treatment with lithium was also found to increase
b-catenin levels both in vitro (Stambolic et al., 1996;
Chen and Chuang, 1999) and in vivo (O’Brien et al., 2004;
Gould et al., 2004a) and to promote b-catenin–dependent

112

Chiu et al.

transcriptional events (Jope and Johnson, 2004; O’Brien
et al., 2004; Marmol, 2008).

Of interest, knockdown of b-catenin protein in mouse
brain resulted in a depression-like phenotype (Gould
et al., 2008), and overexpression of b-catenin mimicked
the antidepressant-like effects of lithium (Gould et al.,
2007). In addition, b-amyloid peptide (Ab) toxicity in
hippocampal slices was associated with loss of Wnt
signaling function (Inestrosa et al., 2000), whereas
chronic lithium treatment protected against Ab-
induced hippocampal neurodegeneration by activat-
ing the Wnt/b-catenin pathway in rat brains (De Ferrari
et al., 2003). Lithium also inhibited HIV replication in
a Wnt/b-catenin–dependent manner (Kumar et al., 2008).
As a result, the idea that lithium-induced accumulation
of b-catenin may account for much of its neuroprotective
and therapeutic effects has led some to propose elevated
b-catenin as a novel therapeutic strategy for treating
mood disorders.

VPA also alters Wnt signaling in cultured human
and animal cells and induces Wnt-dependent gene
expression at doses that cause developmental effects
(Wiltse, 2005). Upregulation of the Wnt/b-catenin
signaling pathway and the subsequent imbalance of
oxidative homeostasis produced by VPA administra-
tion during early pregnancy may facilitate susceptibil-
ity to autism (Zhang et al., 2012a). However, as
mediated through the b-catenin-Lef-Tcf–dependent
transcriptional activity, cotreatment with VPA was
found to potentiate lithium-induced neuroprotective
effects against excitotoxicity in aging CGCs (Leng
et al., 2008). In addition, VPA altered angiogenic
processes in human umbilical vein endothelial cells
by increasing the expression of b-catenin and enhanc-
ing spheroid sprout formation (Jin et al., 2011). It has
been suggested, in fact, that VPA-induced increases in
acetylation and the nuclear translocation of b-catenin
largely account for its ability to protect neurons from
hypoxia-induced apoptosis and to improve animal
survival after hemorrhagic shock (Leng et al., 2008).

3. The MEK/ERK Pathway. Another signaling
pathway mediating the trophic actions and effects of
lithium and VPA is the MEK/ERK cascade. The find-
ing that both K252a and the MEK inhibitor U0126
blocked antidepressant-like effects induced by BDNF
(Shirayama et al., 2002) supports the involvement of
TrkB in the activation of the MEK/ERK pathway.

ERK regulates several downstream effector systems,
such as NF-kB and ribosomal S6 kinase (RSK), and in
turn inhibits GSK-3b and activates CREB (Chang
et al., 2003; Steelman et al., 2004). CREB is a tran-
scription factor and a common downstream target of
both PI3K/Akt and MEK/ERK pathways. When acti-
vated through phosphorylation, CREB is involved in cell
survival by promoting the expression of cell-protective
proteins, such as BDNF and Bcl-2 (Finkbeiner, 2000).
Lithium treatment after ischemia was found to enhance

ERK phosphorylation, whereas lithium-induced increases
in BrdU-positive cells and improvement of cognitive
function were prevented by U0126 (Yan et al., 2007).
Because lithium has been reported to have opposite
effects on the MEK/ERK pathway in different types of
neural cells, it should be noted that lithium’s effects on
this pathway may also be cell type–specific (Pardo et al.,
2003).

VPA activates the ERK pathway, and activation of
this cascade has been associated with its neuroprotec-
tive effects in a variety of cell types. In fact, VPA
treatment not only increases the expression of ERK-
regulated genes (such as Bcl-2), it has also been shown
to promote neurite growth and cell survival in primary
neurons and in the cultured human neuroblastoma cell
line SH-SY5Y (Yuan et al., 2001; Di Daniel et al.,
2005). In human umbilical vein endothelial cells,
activation of the MEK/ERK pathway mediated VPA-
induced phosphorylation of Bcl-2 and inhibition of
serum starvation-induced apoptosis (Michaelis et al.,
2006); in peripheral Schwann cells, VPA used the same
signaling pathway to mediate the evocation of cell
proliferation (Fei et al., 2011). Moreover, in a sleep
deprivation animal model of manic-like behavior, VPA
treatment prevented the attenuation of ERK activa-
tion, CREB phosphorylation, and the expression of Bcl-
2 and BDNF in the frontal cortex (Park et al., 2012).

D. Oxidative Stress Pathways

Oxidative stress is caused by the imbalance between
reactive oxygen species and the cell’s ability to quench
these free radicals, which can lead to ensuing damage of
the cellular proteins, lipids, DNA, and organelles, such
as the mitochondria;
it can also activate numerous
stress-sensitive signaling processes (reviewed in Droge,
2002). Some of these stress-sensitive signaling processes
overlap with the aforementioned survival signaling
pathways (e.g., the MAPK signaling cascade), and others
involve autophagy and mitochondrial dysfunction (Lee
et al., 2012a). It is beyond the scope of this review to
delve into specific stress-sensitive signaling pathways;
we will only briefly discuss some of the evidence that
oxidative stress pathways are implicated in diverse CNS
disorders and facilitated by mood stabilizers.

Mood stabilizers have been reported to produce
antioxidant effects that may contribute to their neuro-
protective properties. For instance, chronic treatment
with lithium (1 mM) or VPA (0.6 mM) protected human
neural (SH-SY5Y) cell lines against oxidative stress,
but not glial (SVG and U87) cell lines (Lai et al., 2006).
This elegant study demonstrated that, when oxidative
stress was induced by either 5mM rotenone or 100 mM
H2O2, lithium and VPA treatment attenuated release
of cytochrome c and activation of caspase 3 in SH-SY5Y
cells. On the other hand, ER stress induced by 1 mM
thapsigargin was not protected by either lithium or
VPA. This suggests that the intrinsic mitochondrial

Therapeutic Potential of Mood Stabilizers

113

apoptotic pathway may be important for these neuro-
protective effects. In fact, the authors also reported that
both lithium and VPA upregulated Bcl-2, an anti-
apoptotic factor that can suppress release of cytochome
c, during oxidative stress but not during ER stress in
SH-SY5Y cells. However, another study found that
chronic lithium or VPA treatment protected against
thapsigargin-induced ER stress in PC12 cells (Hiroi
et al., 2005). These discrepancies might be attributable
to cell type differences and remain to be elucidated.
GSK-3b inhibition was also neuroprotective after
rotenone-induced oxidative stress but not H2O2-induced
oxidative stress (Lai et al., 2006). Clearly, multiple
mechanisms are at play to facilitate cell type–specific
neuroprotection.

Oxidative stress mechanisms have also been evalu-
ated in human B lymphoblast cell lines (BLCLs) from
both healthy control subjects and patients with BD. In
fact, increased reactive oxygen species (ROS) have been
found in both plasma and serum samples from patients
with BD (Kuloglu et al., 2002; Savas et al., 2006;
Andreazza et al., 2009). These ROS can be sensed by
a family of calcium-permeable ion channels, the tran-
sient receptor protein (TRP)
family that has been
implicated in the pathophysiology of BD-I (Xu et al.,
2006, 2009; Andreopoulos et al., 2004; Perova et al.,
2008). BLCLs were challenged with the oxidative
stressor rotenone (2.5 and 10 mM), cell viability was
monitored, and the expression and function of the TRP
family ion channel (TRPM2 and TRPC3) were deter-
mined (Roedding et al., 2012). Cell viability was de-
creased after rotenone treatment, with BLCLs from
individuals with BD-I found to be more susceptible to
oxidative stress than control subjects. This study further
implicates TRP family channels as contributing to the
pathophysiology of BD, because of the changes in their
regulation and functional response after oxidative stress.
Oxidative stress mechanisms have also been associ-
ated with manic episodes in BD. Elevated oxidative
including thriobarbituric acid
metabolism markers,
reactive substances, superoxide dismutase (SOD), and
catalase were found to be elevated in unmedicated
manic patients when compared with both lithium-
treated manic patients and control subjects (Machado-
Vieira et al., 2007). Furthermore, in healthy control
subjects treated with therapeutic doses of lithium (2–4
weeks), selective decreases in oxidative stress markers
were observed, including SOD and H2O2 (Khairova
et al., 2012). This supports the notion that lithium has
neuroprotective properties in healthy subjects, sug-
gesting that these benefits may extend to the treat-
ment of CNS diseases beyond BD. Oxidative stress has
also been reported to exacerbate the development of
symptoms in numerous human CNS disorders,
in-
cluding BD (Andreazza et al., 2008), stroke (Chen et al.,
2011), TBI (Ansari et al., 2008), HD (Klepac et al., 2007),
AD (Perry et al., 2002), and ALS (Barber and Shaw,

2010), suggesting that the antioxidant effects of mood
stabilizers, which enhance neuroprotective mecha-
nisms, may have broad utility in the treatment of
numerous CNS disorders.

E. Protein Quality Control Mechanisms

1. Induction of the Ubiquitin-Proteasome System and
Autophagy.
In eukaryotic cells, the ubiquitin-protea-
some system (UPS) and autophagy-lysosomal pathway
are two major intracellular quality control mechanisms
for protein clearance against abnormal protein accu-
mulation (Ross and Poirier, 2005). As noted above,
treatment with either lithium or VPA alone increased
HSP70 expression both in vitro and in vivo (Klionsky
and Emr, 2000; Levine and Kroemer, 2008). Through
the UPS and autophagy, HSPs promote the degrada-
tion of abnormally folded proteins (Hendrick and Hartl,
1993; Fink, 1999; Ma and Hendershot, 2001; Hartl and
Hayer-Hartl, 2002; Ross and Poirier, 2005). However,
short-lived proteins,
in general, are predominantly
degraded by proteasomes, whereas aggregation-prone
proteins appear to be better substrates for autophagic-
lysosomal degradation (Klionsky and Emr, 2000;
Levine and Kroemer, 2008).

Autophagy induction is considered to be a potential
neuroprotective mechanism. Rapamycin is currently
the most commonly used pharmacological agent for
inducing autophagy, which it does by inhibiting the
mammalian target of rapamycin (mTOR). Of note,
rapamycin has been shown to be beneficial in various
models of neurodegenerative diseases (Ravikumar
et al., 2004; Berger et al., 2006; Rubinsztein et al.,
2007). The ability of lithium to deplete free inositol and
subsequently decrease levels of inositol 1,4,5-trisphos-
phate (IP3), through inhibiting inositol monophospha-
tase and inositol transporters (Phiel and Klein, 2001),
was identified as a novel mTOR-independent route for
inducing autophagy (Sarkar et al., 2005; Sarkar and
Rubinsztein, 2006). VPA, carbamazepine, and other
mood stabilizers that decrease IP3 levels can also
induce autophagy (Sarkar et al., 2005). At therapeutic
concentrations, lithium not only facilitated the clear-
ance of mutant huntingtin (mHtt) and a-synuclein
(Sarkar et al., 2005) but also induced clearance of
protease-resistant prion protein in prion-infected cells
(Heiseke et al., 2009). This autophagy-inducing prop-
erty of lithium has been demonstrated to be protective
in ALS model mice (Fornai et al., 2008), and its use in
combination with rapamycin has been proposed as
a possible therapy in various animal models of HD
(Sarkar et al., 2008). Together, these mechanisms are
believed to be beneficial in neurodegenerative disorders
characterized by the accumulation of misfolded proteins
(Cuervo, 2004; Berger et al., 2006; Rubinsztein et al.,
2007; Levine and Kroemer, 2008).

2. GRP78 Upregulation. The ER is the primary site
for protein synthesis, folding, and trafficking. It acts as

114

Chiu et al.

an intracellular calcium repository and is highly
sensitive to perturbation of its intraluminal environ-
ment. In addition to upregulating Bcl-2, lithium or
VPA treatment was shown to protect against ER stress
by upregulating a molecular chaperone of the HSP70
family, the 78-kDa glucose-regulated protein (GRP78)
(Hiroi et al., 2005). GRP78 binds to calcium, partic-
ipates in protein folding, plays a role in stress-induced
autophagy, and protects cells from the deleterious
effects of misfolded proteins in the ER (Katayama
et al., 1999; Kaufman, 1999; Yu et al., 1999; Ni et al.,
2011). GRP78 can be induced by various apoptotic
insults, including the ER calcium-ATPase inhibitor
thapsigargin (Aoki et al., 1997; He et al., 2000).
Triggered by calcium release from the ER, transcrip-
tion factor c-Fos (a component of the activator protein 1
[AP-1] heterodimeric transcription factor complex)
appears to be involved in thapsigargin’s induction
of GRP78 (He et al., 2000), although the fact that
the GRP78 promoter contains no recognizable AP-1–
interacting sequence motifs (He et al., 2000) suggests
that AP-1’s role in regulating GRP78 is only indirect.
In addition to upregulating GRP78 (Wang et al., 2001;
Hiroi et al., 2005; Shao et al., 2006), lithium similarly
induced c-Fos expression and subsequent AP-1–binding
activity (Kalasapudi et al., 1990; Gao et al., 1993; Ozaki
and Chuang, 1997), but without affecting basal calcium
levels (Hiroi et al., 2005). Accordingly, lithium pretreat-
ment reversed thapsigargin-induced downregulation of
the anti-apoptotic protein Bcl-2 in PC12 cells, and its
cytoprotective effects included upregulation of c-Fos and
GRP78 and attenuation of thapsigargin-triggered in-
tracellular calcium release. These beneficial effects were
blocked, moreover, by curcumin (Hiroi et al., 2005), an
AP-1 inhibitor. On the other hand, VPA pretreatment
also upregulated this ER stress protein (Wang et al.,
1999, 2001; Bown et al., 2000; Hiroi et al., 2005), and
induced similar protective effects against ER stress in
PC12 cells (Hiroi et al., 2005), as well as oxidative damage
in primary cultured rat cerebrocortical cells (Wang et al.,
2003). Because ER dysfunction has been linked to
impaired synaptic plasticity and to the pathophysiology
of diseases, such as BD (Hough et al., 1999; Hayashi
et al., 2009), AD (Mattson et al., 2000), and cerebral
ischemia (Mattson et al., 2000), the induction of GRP78
by lithium and VPA against ER stress may well be
clinically relevant. In support of GRP78’s therapeutic
relevance, it was recently implicated in protection against
a-synuclein–induced neurotoxicity in a rodent model of
Parkinson’s disease (Gorbatyuk et al., 2012) and cell
death caused by mHtt aggregates in a cell culture model
of HD (Jiang et al., 2012).

F. Augmented Protective Effects by Lithium and
VPA Cotreatment

As mentioned previously, lithium and VPA have
diverse neuroprotective mechanisms, ranging from the

augmentation of neurotrophic factors (such as BDNF)
to the facilitation of anti-apoptotic factors (such as Bcl-
2) and the regulation of numerous survival-signaling
cascades (such as enhancing the PI3K/Akt signaling
pathway). These diverse signaling effects are primarily
mediated by inhibition of GSK-3 and HDAC. In the
following section, we examine how combination treat-
ment provides enhanced beneficial effects in different
model systems.

1. Enhanced Neuroprotection by Cotreatment.
As CGC neuronal cultures age, lithium loses its ability
to enhance serine phosphorylation of GSK-3 and
protect CGCs from glutamate-induced apoptosis. VPA
also has little protective effect against glutamate-
induced cell death in older CGCs. However, in the
first study to demonstrate these drugs’ synergistic
neuroprotective effects, Leng and colleagues showed
that cotreatment with lithium and VPA completely
blocked glutamate excitotoxicity in aging CGCs (Leng
et al., 2008). Gene silencing with siRNA to GSK-3a or
GSK-3b mimicked the ability of lithium to induce this
synergistic neuroprotection when used in combination
with VPA. Conversely, treatment with other class I
and II HDAC inhibitors or transfection with an
HDAC1 isoform-specific siRNA in conjunction with
lithium treatment also enhanced neuroprotection.

The neuroprotective effects elicited in intact neurons
cotreated with lithium and VPA, moreover, are closely
associated with a potentiation in GSK-3 inhibition, as
revealed by augmented phosphorylation of both GSK-
3a and b, and attenuated phosphorylation of tau
protein, a major GSK-3 substrate. In a cell-free system
of CGC lysate, combined treatment also induced a more
than additive decrease in GSK-3b enzymatic activity
(Leng et al., 2008). These observations suggest that
GSK-3 inhibition is a likely molecular target for this
enhanced neuroprotection, despite the fact that the
role of HDAC-regulated genes has yet to be investi-
gated. It is also important to note that although
combination treatment with lithium and VPA was no
more effective than lithium alone in preventing relapse
in patients with BD-I (The BALANCE investigators
and collaborators, 2010), recent data from preclinical
HD and ALS models indicate that this combined
treatment may be useful for treating these disorders
(see sections III.C and III.E).

2. Enhancing the Homing and Migratory Capacity of
Stem Cells. Over the past 20 years, stem cell therapy
has been investigated as a potential treatment of
neurodegenerative diseases (reviewed in Goldman,
2005; Lunn et al., 2011). After transplantation of stem
cells, directing migration and ensuring survival and
integration are essential for successful development of
these therapies for clinical use.

Mesenchymal stem cells (MSCs) derived from bone
marrow have been demonstrated to produce beneficial
effects in diverse animal models of neurodegenerative

Therapeutic Potential of Mood Stabilizers

115

diseases (Joyce et al., 2010). Although MSCs can reach
an injured brain region and release trophic factors to
hasten endogenous repair and regeneration,
it is
increasingly recognized that the poor homing and
migratory abilities of transplanted MSCs limit their
effectiveness as a treatment strategy (Karp and Leng
Teo, 2009). Enhancing the homing and migratory
capacity of transplanted MSCs could therefore be
expected to improve their therapeutic efficacy.

MSC migration toward ischemic brain lesions is
mediated by the interaction between stromal cell–
derived factor 1a (SDF-1a), a molecule endowed with
potent chemotactic activity, and its specific a-chemo-
kine receptor CXC-chemokine receptor 4 (CXCR4)
(Wang et al., 2008), in which expression in hematopoi-
etic stem cells is enhanced by VPA (Gul et al., 2009).
Because MSC migration is regulated by the Wnt
signaling pathway in which activation inhibits GSK-
3b (Neth et al., 2006), lithium’s ability to inhibit GSK-
3b allows it to activate the Wnt downstream signaling
pathway. For this reason, combined treatment with
lithium and VPA additively enhanced MSC migration
in vitro (Tsai et al., 2010).

Three-hour exposure of MSCs to 2.5 mM VPA
markedly increased the mRNA and protein levels of
CXCR4 (Tsai et al., 2010). This effect of VPA requires
inhibition of HDACs and involves histone hyperacety-
lation at the CXCR4 gene promoter. VPA treatment
also enhanced MSC migration mediated by SDF-1a,
which was completely blocked by the CXCR4 antago-
nist AMD3100. On the other hand, MSCs treated with
2.5 mM lithium for one day showed selective elevation
of mRNA and protein levels and enzymatic activity of
matrix metalloproteinase-9 (MMP-9), effects mimicked
by the pharmacological inhibition or gene silencing of
GSK-3b. Lithium treatment also potentiated MSC
migration across the extracellular matrix, which was
mediated by SDF-1a and suppressed by the MMP-9
inhibitors doxycycline and GM6001. Significantly,
where AMD3100 and GM6001 were both present, the
additive enhancement of MSC migration induced by
VPA and lithium cotreatment was completely blocked.
These findings suggest that the two drugs operate
through distinct targets and mediators to stimulate
MSC migration: VPA through HDAC-CXCR4 and
lithium through GSK-3b-MMP-9 (Tsai et al., 2010).
For a discussion of VPA and lithium cotreatment in
a model of ischemic stroke, see section III.A.

Hematopoietic stem cells (HSCs) from the peripheral
blood have been shown to transdifferentiate into
neurons and glial cells in the brain (Mezey et al., 2000;
Cogle et al., 2004; Sigurjonsson et al., 2005). Circulating
HSCs are decreased in early AD, and this decrease is
significantly correlated with age (Maler et al., 2006).
Transplantation of HSCs has been shown to promote
angiogenesis and enhance neuroplastic effects in the
ischemic brain (Shyu et al., 2006). Although HSCs have

the potential for wide clinical application, insufficient
cell numbers have limited their use. Attempts are now
being made to amplify these stem cells in an un-
committed state, while maintaining their differentiation
potential. The combination of VPA and lithium treat-
ment has been shown to delay hematopoietic stem/
progenitor cells (HSPCs) differentiation and to increase
the potential for cell survival (Walasek et al., 2012).
Specifically, VPA and lithium cotreatment preserved the
immature cell phenotype of HSPCs in the hematopoietic
differentiation-inducing culture and regulated transcrip-
tion factor networks at the molecular level by preserving
expression of stem cell–related genes and repressing
genes involved in differentiation. These findings provide
an ex vivo strategy to obtain sufficient autologous
HSPCs before transplantation by using a combination
of lithium and VPA. However, this study by Walasek
et al. did not investigate whether this combination
treatment would affect the transdifferentiating ability of
HSPCs. Further investigation is warranted.

G. New Directions: miRNAs Targeted by Lithium
and VPA

miRNAs are non–protein-coding RNAs of 21–24
nucleotides. Abundant in all multicellular organisms,
they function in translational repression and mRNA
degradation by binding either to the 392UTR of
mRNAs (Lai, 2002)
(predominantly) or to coding
regions (Forman et al., 2008), where they have the
potential to silence hundreds of genes. This mechanism
allows miRNAs to modulate complex transcriptomic
and proteomic networks and to play an important
regulatory role in nervous system function. Brain-
enriched miRNAs, for instance, have been reported to
regulate spine development and synaptic plasticity
(Schratt et al., 2006; Siegel et al., 2011).

The unique regulatory mechanisms used by miRNAs
have also been used to elucidate transcriptional mech-
anisms used by mood stabilizers. In the rat hippocam-
pus, in fact, chronic treatment with either lithium or
VPA has been found to selectively modulate miRNAs
(Zhou et al., 2009). It is particularly interesting to note
that among those miRNAs regulated by mood stabi-
lizers, three miRNAs (miR-24, -34a, -128) target six BD
susceptibility genes: calpain 6, dipeptidyl-peptidase 10,
estrogen-related receptor gamma, member A of family
with sequence similarity 126, metabotropic glutamate
receptor 7 (GRM7), and thyroid hormone receptor beta.
Future studies are warranted to strengthen the associ-
ation of these six BD susceptibility genes with both the
pathophysiology of BD and their potential regulation
via miRNA-mediated mechanisms. GRM7 regulation
via miR-34a has been confirmed in vitro (Zhou et al.,
2009). In vivo regulation of both miR-34a and GRM7
after long-term treatment with either lithium or VPA
has also been reported (Zhou et al., 2009). Another
study found that lithium regulates a select set of

116

Chiu et al.

miRNAs in human lymphoblastoid cells (Zhou et al.,
2009). Of interest, some of these lithium-responsive
miRNAs (miR-34a and miR-221) were identified in both
rats and humans, suggesting that the transition from
preclinical to clinical research will prove to be fruitful.
For instance, a recent preliminary study with a small
sample size correlating plasma miR-134 levels in
successfully medicated manic patients with BD (Rong
et al., 2011) further suggests an additional role for miRNAs
in psychiatry, where they may be effective biomarkers
to predict lithium response. Moreover, miR-134 has
recently been reported to be dysregulated in schizo-
phrenia in dorsolateral prefrontal cortex (Santarelli
et al., 2011). Clearly additional studies are warranted
to substantiate miRNA’s potential as biomarkers, but
these studies and others provide tantalizing hints in
support of their exciting promise.

Additional support exists for miRNA mechanisms
underlying the therapeutic actions of mood stabilizers.
For instance, alterations in the muscarinic acetylcholine
receptor system are thought to be associated with BD
(Goodwin and Jamison, 2007). Muscarinic M1-receptor
knockout mice exhibited mania-like behavioral deficits
(e.g., hypersensitivity to amphetamine-induced hyper-
locomotion), and lithium treatment normalized these
behavioral deficits in part by enhancing M1-receptor-
ERK pathway signaling (Creson et al., 2011). This
enhancement of M1 was attributable in part to down-
regulation of a previously recognized lithium responsive
miRNA (let-7b) (Zhou et al., 2009). Therefore, identify-
ing the miRNA mechanisms that mood stabilizers use to
achieve their therapeutic effects is likely to provide
insight into another transcriptional layer of regulatory
control that may identify numerous unrealized thera-
peutic targets.

In addition, miRNA dysregulation has been impli-
cated in many different pathologic conditions, including
neurodegenerative, neuropsychiatric, and neurologic
diseases (Hebert and De Strooper, 2009; Eacker et al.,
2009; Dinan, 2010; Kim et al., 2010; Moreau et al., 2011;
Hunsberger et al., 2012). A very recent article reported
miRNA regulation after ischemic stroke (e.g., miR-446f,
miR-446h, miR-155, miR-1224, and miR-297a) and the
potential for underlying the benefits of postinsult VPA
treatment (e.g., miR-885-3p and miR-331) in a rat model
of cerebral ischemia (Hunsberger et al., 2012). Collec-
tively, this support suggests that miRNAs may underlie
disease processes that contribute to numerous neuro-
logic disorders. Furthermore, insight into the miRNA
targets and pathways currently under investigation and
the in silico analysis for predicted targets (Dweep et al.,
2011) may provide critical knowledge for elucidating the
complex signaling networks underlying fundamental
disease processes.
In addition, uncovering which
miRNA binding sites in susceptibility genes are mu-
tated in patients will help link miRNA mechanisms to
genetic vulnerabilities and may help explain why some

patients respond to treatment with mood stabilizers and
others do not.

Because of the insights gleaned to date, miRNA
research appears to hold great promise for the identi-
fication of currently unknown mechanisms of transcrip-
tional regulation that contribute to the neurobiological
effects of mood stabilizers and of dysregulated signaling
networks that contribute to CNS disorders. Indeed,
a recent article by Salmena and colleagues provides
a unifying hypothesis detailing how mRNAs, tran-
scribed noncoding pseudogenes, and long noncoding
RNAs may communicate and interact using miRNA
binding sites (Salmena et al., 2011). In accordance with
this hypothesis, the presence of a noncoding pseudogene
with miRNA response elements may compete for
miRNAs and effectively switch from being a target to
a sponge to dampen the effect of a particular miRNA. It
has also been speculated that miRNAs in signaling
networks act as key regulatory nodes (Inui et al., 2010).
Theories such as these suggest that the ability to
modulate key miRNAs could be used to repress disease
pathology or activate the therapeutic mechanisms un-
derlying mood stabilizers in a manner not currently
achievable. A future challenge is how to integrate
transcriptomic and proteomic data to evaluate how the
myriad of regulatory controls (e.g., through miRNAs,
epigenetics, and posttranslational modifications) con-
tribute to therapeutic effects and to the dysregulation of
brain processes associated with CNS disorders. Over-
coming this challenge should provide unparalleled new
insights into the complex mechanisms of pathophysiol-
ogy and revolutionize current targets and methods of
treatment of neuropsychiatric and neurodegenerative
diseases.

III. Repurposing Mood Stabilizers for CNS
Disorders Beyond BD

Loosely defined, drug repurposing is using known
drugs to treat conditions for which they are not
currently intended. Lithium and VPA have a long
history of safe use in the treatment of BD and, in the
case of VPA, epilepsy. Because of their numerous
beneficial effects, they could be readily repurposed to
treat other CNS diseases. Indeed, the largest study of
its kind to date recently reported that long-term
lithium treatment augmented the neuronal viability
marker NAA in prefrontal cortex of patients with BD in
a two center study (Hajek et al., 2012). Decreased NAA
expression measured by noninvasive proton magnetic
resonance spectroscopy has been reported in both
neurologic and neurodegenerative conditions, where
it has been associated with loss of neurons and axons.
Clinical studies are now warranted to investigate the
long-term treatment effects of lithium and VPA in CNS
disorders beyond BD, perhaps with use of a methodol-
ogy similar to that use by Hajek et al. (2012). Tables 1

Therapeutic Potential of Mood Stabilizers

117

and 2 list preclinical studies supporting the neuro-
protective actions of lithium and VPA, respectively, in
various animal models of CNS diseases. Below, we
summarize evidence from selected models that support
the translation of these findings into highly anticipated
and needed clinical benefits.

A. Stroke

Stroke is the third leading cause of death in the
United States and a major cause of serious long-term
disability in adults. In addition, stroke victims are
frequently burdened with vascular depression and
dementia that is difficult to treat with convention-
al medicine. Of all strokes, 87% are ischemic and
the rest are hemorrhagic (Roger et al., 2011). For acute
ischemic
thrombolysis with intravenous
recombinant tissue plasminogen activator (rtPA) is
the only treatment approved by the US Food and Drug
Administration (FDA) to date. However, because of the
narrow therapeutic window of less than 4.5 hours and
risk of intracerebral hemorrhage, it is estimated that
rtPA is used in only 1.8%–2.1% of patients with
ischemic stroke (Barber et al., 2001; Kleindorfer
et al., 2008).

stroke,

Although there is clearly an urgent need to develop
novel treatments for stroke, poststroke pathophysiol-
ogy is complex and involves early- and late-phase
processes (such as apoptosis, neuroinflammation, BBB
breakdown, neurovascular repair, and neurovascular
regeneration). Accumulating evidence demonstrates
that lithium and VPA exert beneficial effects through-
out this pathophysiological process (for a review, see
Chuang et al., 2009, 2011; Wang et al., 2011b) and hold
clinical potential for its treatment.

1. Lithium-Induced Effects in Experimental Stroke

Models.

a. Neuroprotection and behavioral

improvement.
The neuroprotective effects of lithium against cerebral
ischemia were first demonstrated in a rat model of
permanent middle cerebral artery occlusion (pMCAO)
(Nonaka and Chuang, 1998). This pioneering study
showed that long-term pretreatment with lithium at
therapeutically relevant doses decreased scores in-
dicative of neurologic deficit and volume of brain
infarct. Chronic lithium pretreatment also reduced
apoptotic death in the penumbra of the ischemic cortex
in a transient MCAO (tMCAO) model (Xu et al., 2003).
In addition to pretreatment, subcutaneous injection of
therapeutic doses of lithium into tMCAO rats three
hours after the onset of occlusion markedly decreased
infarct volume and suppressed neurologic deficits, as
measured by sensory, motor, and reflex tests (Ren
et al., 2003). Lithium pretreatment in gerbils after
global cerebral ischemia was also found to suppress
most ischemia-induced changes in exploratory behav-
ioral and memory impairments (Bian et al., 2007).
These behavioral benefits in gerbils were associated

with an increased number of viable cells and a decrease
in apoptotic cells in the CA1 hippocampal ischemic
area.

b. Anti-excitotoxic and anti-apoptotic effects.

In
a rat model of global cerebral ischemia, lithium was
reported to inhibit ischemia-induced hyperactivation of
the NMDA receptor by inhibiting phosphorylation of
the NMDA subunit 2A tyrosine and its interactions
with Src and Fyn through PSD-95 in the rat hippo-
campus (Ma and Zhang, 2003). In a tMCAO model,
postischemic lithium treatment (presumably through
GSK-3 inhibition) upregulated heat shock responses,
including activation of HSF-1 and induction of HSP70
in the cortical penumbra (Ren et al., 2003). In addition,
in organotypic cultures of rat hippocampus subjected to
oxygen and glucose deprivation, lithium was neuro-
protective in conjunction with HSP27 activation
(Cimarosti et al., 2001). In the mouse brain, lithium
also attenuated hypoxia-induced serine dephosphoryla-
tion of GSK-3a and b (Roh et al., 2005). These findings
suggest that lithium protection against ischemia-
induced injury involves multiple mechanisms, including
GSK-3 inhibition. In addition to inducing anti-apoptotic
HSP70, lithium-induced neuroprotection was also ac-
companied by downregulation of proapoptotic p53 in the
CA1 but upregulation of anti-apoptotic Bcl-2 in the
global ischemic brain of gerbils (Bian et al., 2007).

c. Anti-inflammation.

It is now generally acknowl-
edged that ischemia-induced brain injury results at
least in part from neuroinflammation mediated by
microglia, monocytes, or macrophages. To date, lith-
ium’s anti-inflammatory effects have been demon-
strated in rat models of neonatal hypoxia-ischemia
and hemorrhagic stroke, but not in ischemic stroke.
Under neonatal hypoxia-ischemia conditions, postin-
sult treatment with lithium suppressed microglial
activation and attenuated overexpression of proinflam-
matory cytokines and chemokines (Li et al., 2011).
Pretreatment of intracerebral hemorrhagic rats with
lithium for three days suppressed the expression
of cyclooxygenase-2 (COX-2) and reactive microglia
in the perihematomal regions (Kang et al., 2012),
and this was associated with decreased cell death
and improved sensorimotor recovery, underscoring
lithium’s anti-inflammatory effects. Because GSK-3
inhibition is known to reduce neutrophil infiltration
and decrease the expression of proinflammatory
factors in a rat tMCAO model (Koh et al., 2008),
inhibition of this kinase may also be involved in
mediating lithium’s anti-inflammatory effects in the
context of stroke.

d. Angiogenesis. One key component of poststroke
neurovascular remodeling is angiogenesis, a process in
which new capillaries are formed on existing blood
vessels through directed proliferation and the migra-
tion of endothelial progenitor cells. Poststroke angio-
genesis increases collateral circulation and restores

118

Chiu et al.

Preclinical studies supporting the repurposing of lithium as a modulator of neuroprotection in various animal models of CNS diseases.

TABLE 1
Beneficial effects of the mood stabilizer lithium in multiple models of CNS disorders

Disease

Ischemic stroke

Rat and mouse MCAO models; gerbil and rat global
ischemia model; hippocampal organotypic cultures

Experimental models

References

Hemorrhagic stroke
TBI

Rat intracerebral hemorrhagic model
Rat and mouse models of controlled cortical impact

Rat excitotoxic model; rat corticostriatal slices;

Wei et al., 2001; Carmichael et al., 2002; Wood and

HD

AD

ALS

FXS

PD

transgenic mice; neuroblastoma cells

Cultured cells and hippocampal slices; rabbits and rats;

transgenic mice; Drosophila

Transgenic mice

Transgenic Drosophila and mouse models

Cellular, rat and mouse MPTP models; 6-

hydroxydopamine models

Retinal degeneration

Retinal ganglion cells in vivo and in vitro; retinal

neurocytes in vitro

Multiple sclerosis
Spinal cord injury

Mouse experimental autoimmune encephalomyelitis
Adult rats

Alcohol-induced degeneration Cultured neurons; neural stem cells; infant mice and

Drosophila

Down syndrome
Transgenic mice
Transgenic mice
Spinocerebellar ataxia-1
HIV-associated neurotoxicity Mouse model of encephalitis; cultured neurons

Nonaka and Chuang, 1998; Cimarosti et al., 2001; Ma
and Zhang, 2003; Ren et al., 2003; Xu et al., 2003; Roh
et al., 2005; Bian et al., 2007; Yan et al., 2007; Kim
et al., 2008; Li et al., 2010a, 2011; Tsai et al., 2011;

Kang et al., 2012
Shapira et al., 2007; Zhu et al., 2010; Dash et al., 2011;

Yu et al., 2012a,b

Morton, 2003; Senatorov et al., 2004; Berger et al.,
2005; Senatorov and Chuang, 2007; Sarkar et al.,
2008; Crespo-Biel et al., 2009; Chiu et al., 2011

Hong et al., 1997; Munoz-Montano et al., 1997; Alvarez
et al., 1999, 2002; Inestrosa et al., 2000; Wei et al.,
2000; Sang et al., 2001; Sun et al., 2002; De Ferrari
et al., 2003; Ghribi et al., 2003; Perez et al., 2003;
Phiel et al., 2003; Tsuji et al., 2003; Mudher et al.,
2004; Rametti et al., 2004, 2008; Su et al., 2004;
Nakashima et al., 2005; Noble et al., 2005; Scali et al.,
2006; Rockenstein et al., 2007; Martin et al., 2009;
Leroy et al., 2010; Sofola et al., 2010; Sy et al., 2011;
Zhang et al., 2011a

Shin et al., 2007; Feng et al., 2008; Fornai et al., 2008;

Ferrucci et al., 2010; Fulceri et al., 2011;

McBride et al., 2005; Min et al., 2009; Choi et al., 2010;
Mines et al., 2010; Mines and Jope, 2011; Liu et al.,
2011, 2012b

King et al., 2001; Chen et al., 2004; Youdim and Arraf,
2004; Koh et al., 2008; Duka et al., 2009; Kim et al.,
2011; Arraf et al., 2012; Castro et al., 2012

Huang et al., 2003; Huang and Klein, 2006; Schuettauf
et al., 2006; Cho and Chen, 2008; Zhuang et al., 2009

De Sarno et al., 2008
Shimizu et al., 2000; Yick et al., 2004; Su et al., 2007;

Dill et al., 2008

Zhong et al., 2006; Chakraborty et al., 2008; Ishii et al.,
2008; French and Heberlein, 2009; Liu et al., 2009;
Luo, 2010; Saito et al., 2010

Huang et al., 2000; Dou et al., 2005; Bianchi et al., 2010;
Watase et al., 2007
Maggirwar et al., 1999; Everall et al., 2002;

blood flow to injured tissue. These new vessels also
provide neurotrophic support for concurrent neuro-
genesis and synaptogenesis, ultimately leading to
functional recovery (Beck and Plate, 2009). For these
reasons, enhancing angiogenesis after stroke may hold
great promise for the treatment. Neurovascular remod-
eling in the chronic phase of stroke determines the
ultimate extent of recovery. A functional MRI study in
tMCAO rats demonstrated the neurohemodynamic
aspects of lithium-induced recovery from ischemia. In
this study, a delayed lithium injection (12 hours after
ischemic onset), followed by daily injections, signifi-
cantly enhanced the ratios of mean activated volume
and total activation of magnitude for both blood oxygen
level dependence and functional cerebral blood volume
on day 15 (Kim et al., 2008). Lithium elevated levels of
CD31 staining, a marker of microvasculature, and
functional cerebral blood volume in the peri-infarct
regions, suggesting possible vascular transformation
(Kim et al., 2008). An increase in MMP-9 staining and
its colocalization with CD31 further suggest that
neurovascular remodeling depends on MMP-9 in the

recovering brain area. Treatment of rat brain endothe-
lial cells with lithium was also found to increase
protein levels of VEGF, apparently through the PI3K
and GSK-3 signaling pathways (Guo et al., 2009).
Because VEGF has been linked to angiogenesis,
neurogenesis, and neuroprotection (Fan and Yang,
2007), VEGF overexpression may contribute to lith-
ium’s ability to promote neurovascular remodeling and
functional recovery after ischemic stroke.

e. Neurogenesis. Neurogenesis, which includes cell
proliferation, migration, and differentiation,
is the
process of forming integrated neurons from progenitor
cells (Kornack and Rakic, 2001). In the adult brain,
neurogenesis usually occurs in the subventricular zone
(SVZ) and hippocampal dentate gyrus (DG). The neural
stem cells in the SVZ migrate into the olfactory bulb
and then differentiate into interneurons, and new
neurons in the subgranular zone migrate into the
adjacent DG granule cell
layer. It is known that
cerebral ischemia enhances neurogenesis in regions
that are traditionally neurogenic and nonneurogenic,
perhaps as part of the self-repair system of ischemic

Therapeutic Potential of Mood Stabilizers

119

Preclinical studies supporting the repurposing of VPA as a modulator of neuroprotection in various animal models of CNS diseases.

TABLE 2
Beneficial effects of the mood stabilizer VPA in multiple models of CNS disorders

Disease

Experimental models

References

Ischemic stroke

Rat and mouse MCAO models; rat global ischemia

model

Hemorrhagic stroke
TBI
HD
AD

ALS
FXS
PD

Rat intracerebral hemorrhagic model
Rat model of controlled cortical impact
Transgenic mice
Cultured cells and hippocampal slices; transgenic mice;

Drosophila
Transgenic mice
FXS lymphoblastoid cell lines
LPS-treated midbrain neuron-glia co-cultures; cellular,
rat and mouse MPTP models; rotenone-challenged
cellular and rat models

Ren et al., 2004; Kim et al., 2007; Qian et al., 2010; Tsai
et al., 2011; Wang et al., 2011a, 2012; Xuan et al.,
2012

Sinn et al., 2007
Dash et al., 2010
Zadori et al., 2009; Chiu et al., 2011;
Su et al., 2004; Qing et al., 2008; Smith et al., 2010; Hu

et al., 2011

Sugai et al., 2004; Rouaux et al., 2007; Feng et al., 2008
Tabolacci et al., 2005, 2008
Peng et al., 2005; Chen et al., 2006, 2007; Wu et al.,

2008; Castro et al., 2012; Kidd and Schneider, 2010,
2011; Monti et al., 2010; Xiong et al., 2011

Retinal degeneration

Rat retinal ganglion cells; rat retinal ischemia model;

Biermann et al., 2010, 2011; Zhang et al., 2011b, 2012b

optic nerve crush; mice

Spinal cord injury

Adult rats and mice; organotypic culture of spinal cord Abematsu et al., 2010; Lv et al., 2011, 2012; Penas et al.,

Spinal muscular atrophy

SMA fibroblast cell lines; transgenic mice

Sumner et al., 2003; Tsai et al., 2006, 2008; Harahap

HIV-associated neurotoxicity Mouse model of encephalitis; cultured neurons

et al., 2012
Dou et al., 2005

2011; Lee et al., 2012b

injury (Arvidsson et al., 2002). In a rat model of
transient global ischemia with four-vessel occlusion,
chronic lithium treatment improved spatial learning
and memory deficits and increased the survival and
generation of newborn cells in the DG,
thereby
potentiating hippocampal neurogenesis (Yan et al.,
2007). It has been suggested that postischemic neuro-
genesis involves growth factor–induced activation of
receptor tyrosine kinases and subsequent stimulation
of PI3K/Akt and ERK signaling pathways (Shioda
et al., 2009). Consistently, lithium treatment enhanced
ERK phosphorylation after ischemia, whereas the ERK
inhibitor U0126 abolished the effects of lithium on
neurogenesis and behavioral improvement (Yan et al.,
2007).

f. Effects on MSC migration after transplantation.
Lithium- or VPA-primed MSCs transplanted by tail
vein injection into tMCAO rats 24 hours after ischemic
onset significantly increased the number of MSCs
homing to brain infarct regions, such as the cortex
and striatum, as measured two weeks after trans-
plantation (Tsai et al., 2011). For a more detailed
discussion of how priming with lithium and/or VPA
affects MSC migration, see section II.F. MCAO rats
receiving lithium- and/or VPA-primed MSCs exhibited
improved functional recovery, reduced infarct volume,
and enhanced angiogenesis in the penumbra regions.
Of note, MSCs that have been coprimed with lithium
and VPA showed further improvement in homing
ability, angiogenesis, and functional recovery after
transplantation into ischemic rats. Of significance,
pharmacological inhibition of MMP-9 reversed these
beneficial effects of lithium priming, and inhibition of
CXCR4 reversed the benefits of VPA priming, suggest-
ing that the mechanisms underlying these benefits
likely involve lithium-induced MMP-9 upregulation

and VPA-induced CXCR4 overexpression. These find-
ings indicate a potential for enhancing MSC migration
and homing capacity after transplantation into stroke
victims by priming them with GSK-3 and HDAC
inhibitors.

2. VPA-Induced Effects in Experimental Stroke

Models.

a. Neuroprotective effects and behavioral benefits.
VPA’s protective effects against brain ischemic injury
are well established. Initial studies using tMCAO found
that subcutaneous injection with VPA (300 mg/kg)
immediately after the onset of tMCAO, followed by
twice-daily injections thereafter, markedly decreased
infarct size, suppressed ischemia-induced apoptosis,
and reduced neurologic deficits (Ren et al., 2004). VPA
treatment in MCAO rats increased histone H3 acetyla-
tion and HSP70 upregulation in both ipsilateral and
contralateral brain hemispheres, suggesting the in-
volvement of HDAC inhibition and HSP70 induction
in mediating VPA-induced neuroprotection. Postinsult
treatment with VPA or other HDAC inhibitors (such as
SB or TSA) within at least three hours of ischemic onset
in a rat pMCAO model also significantly decreased
infarct volume and induced long-term improvement in
neurologic performance (Kim et al., 2007). Of note, it
has been recently shown that treatment with 100 mg/kg
VPA for seven days starting 24 hours after pMCAO in
rats significantly improved neurologic performance of
foot fault test, adhesive test, and neurologic severity
score measured 7–28 days after ischemia, although this
treatment did not reduce infarct volume (Liu et al.,
2012a). These findings suggest that the beneficial effects
of VPA on neurologic outcomes may be independent of
the infarct volume reduction.

b. Anti-inflammation.

In a rat pMCAO model, VPA
treatment markedly reduced the number of both

120

Chiu et al.

activated microglia and infiltrating monocytes/macro-
phages and suppressed ischemia-induced upregulation
of proinflammatory factors,
inducible nitric oxide
synthase, and COX-2 (Kim et al., 2007). The anti-
inflammatory effects of VPA have also been demon-
strated in vitro. In rat midbrain neuron-glia cocultures,
for example, the neuroprotection of VPA against LPS-
induced dopaminergic neurotoxicity was, at least in
part, found to be attributable to a decrease in levels of
released from activated
proinflammatory factors
microglia (Peng et al., 2005). Specifically, pretreating
cocultures with VPA markedly reduced LPS-induced
increases in the release of tumor necrosis factor-a
(TNF-a), nitric oxide, and intracellular ROS. These
anti-inflammatory effects correlate with a decrease in
the number of microglia. Treatment of rat microglia-
enriched cultures with VPA induced microglial death
with multiple hallmarks of apoptosis (Chen et al.,
2007). VPA-induced microglial apoptosis was also
accompanied by disrupted mitochondrial membrane
potential and hyperacetylation of histone H3—effects
mimicked by treatment with other HDAC inhibitors.
This HDAC inhibition-dependent microglial apoptosis
induced by VPA provides a novel mechanism of
protection against neuroinflammation.

Experiments with animal models of brain ischemia
have further shown that HDAC inhibitors other than
VPA (such as vorinostat, SB, and TSA) also super-
induced HSP70 (Ren et al., 2004; Faraco et al., 2006;
Kim et al., 2007). In a mouse tMCAO model, HSP70
overexpression inactivated the key inflammatory tran-
scription factor NF-kB and prevented nuclear trans-
location of activated NF-kB subunits (Zheng et al.,
2008). In addition, postinsult VPA treatment in a rat
model of intracerebral hemorrhagic stroke was found to
reduce the number of terminal deoxynucleotidyl trans-
ferase
(TdT)-mediated dUTP nick end labeling
(TUNEL)-positive cells, upregulate Bcl-2/Bcl-Xl, down-
regulate Bax, and inhibit caspase activity (Sinn et al.,
2007). VPA further mitigated cerebral inflammation by
inhibiting neutrophil infiltration, suppressing micro-
glial activation, and downregulating proinflammatory
factors. Thus, suppression of neuroinflammation and
apoptosis appears to be mediated by HDAC inhibition
and comprises multiple mechanisms that contribute to
the neuroprotective effects induced by VPA. Accord-
ingly, VPA-induced inhibition of HDACs has been
shown to suppress microglial activation, reduce levels
of proinflammatory factors, and induce HSP70—anti-
inflammatory effects that may mediate neuroprotection
against hippocampal neuronal loss and cognitive defi-
cits in rat models of transient global ischemia (Xuan
et al., 2012).

c. BBB protection. Disruption of the BBB is critical
to the pathogenesis of brain ischemia and other
neurologic disorders, allowing intravascular proteins
and fluid to penetrate into the cerebral parenchymal

extracellular space, followed by leukocyte infiltration,
vasogenic edema, and hemorrhage. One study found
that postinsult treatment with VPA (200 and 300 mg/kg
i.p.) robustly attenuated tMCAO-induced BBB dis-
ruption and brain edema (Wang et al., 2011a). Of note,
VPA-induced BBB protection was dose-dependent
and persisted for at least 72 hours after transient
ischemia.

The BBB can be disrupted by abnormal activity of
MMPs, a family of zinc-dependent endopeptidases
known to perform multiphasic roles in ischemic stroke
(Rosell and Lo, 2008). The abnormal upregulation of
both MMP-2 and -9 induced by ischemia, for instance, is
linked to BBB disruption by degrading tight junctions
and basal lamina proteins and disrupting cell-matrix
homeostasis. VPA strongly reduced MCAO-induced
MMP-9 activity and protein elevation and concomi-
tantly restored protein levels of tight junctions, claudin-
5 and ZO-1, which are degraded 24 hours after MCAO
(Wang et al., 2011a). MMP-9 expression has been shown
to be regulated by NF-kB (Van den Steen et al., 2002), in
which activation may be inhibited by VPA through
upregulation of HSP70, as mentioned above. Consistent
with this notion, treatment with VPA or SB completely
blocked MCAO-induced nuclear translocation of the NF-
kB p65 subunit (Wang et al., 2011a). Taken together,
the evidence suggests that VPA’s ability to protect the
BBB likely involves the initial inhibition of HDACs,
followed by suppression of MCAO-induced NF-kB
activation, MMP-9 overexpression, and tight junction
degradation.

d. Angiogenesis. As measured on day 14 after
tMCAO, long-term postinsult administration of VPA
(200 mg/kg i.p.) markedly reduced infarct volume and
improved functional recovery (Wang et al., 2012).
Concurrently, VPA treatment enhanced postischemic
angiogenesis by increasing microvessel density, facili-
tating endothelial cell proliferation and upregulating
regional cerebral blood flow in the ipsilateral cortex. In
addition, ischemia is followed by an increase in levels of
three key proangiogenic factors: VEGF, MMP-2, and
MMP-9. These molecules are regulated by HIF-1,
a transcription factor responsible for gene transcription
that facilitates adaptation and survival after hypoxia or
ischemia (Ke and Costa, 2006). As measured on days 7
and 14 after MCAO, VPA treatment was shown to
potentiate MCAO-induced HIF-1a accumulation and to
upregulate downstream levels of VEGF and MMP-2/9
activity in the ipsilateral cortex. Inhibition of HIF-1a,
moreover, reversed the elevated postischemic angiogen-
esis and functional recovery induced by VPA.

Taken together, these findings indicate that long-
term VPA treatment enhances postischemic angiogen-
esis and promotes long-term functional recovery in an
experimental model of ischemic stroke. The findings
are further supported by reports from an in vitro
study that the HDAC inhibitors VPA and vorinostat

Therapeutic Potential of Mood Stabilizers

121

enhanced VEGF-induced spheroid sprout formation in
human umbilical vein endothelial cells and that VPA
displayed a trend toward increasing endothelial cell
migration (Jin et al., 2011). Of note, VPA appeared to
play a dual role in preserving postischemic endothelial
cell function: it limited cell damage by inhibiting
MMP-9 and VEGF in the acute phase but enhanced
angiogenesis by upregulating VEGF and MMP-2/9 in
the later recovery phase (Wang et al., 2012). To date,
little is known about the mechanisms underlying this
time-dependent switch in VPA-induced activity after
MCAO. Further investigation is certainly warranted.

conditions of

e. Neurogenesis. When studied in vitro and in vivo,
VPA has been shown to promote hippocampal neuro-
genesis (Hsieh et al., 2004; Yu et al., 2009). In addition,
even under
favored lineage-specific
differentiation, VPA was also found to inhibit the
differentiation of astrocytes and oligodendrocytes
(Hsieh et al., 2004). In fact, VPA-induced inhibition of
HDAC has been shown to upregulate several regula-
tory factors favoring neurogenic transcription (such as
NeuroD, Ngn1, Math1, and p15). Chromatin immuno-
precipitation analysis further showed that, in neuronal
differentiation of both hippocampal neural progenitor
cells and adult hippocampal neurogenesis, acetylated
histone H4 was associated with the promoter of Ngn1
(Yu et al., 2009). In a rat pMCAO model, delayed VPA
treatment promoted white matter repair by increasing
survival of oligodendrocytes and differentiation of
oligodendrocyte progenitor cells and enhanced neuro-
genesis by increasing the number of newly formed
neuroblasts in the ischemic boundary zone 28 days
after ischemia (Liu et al., 2012a). In addition, VPA
increased acetylated histone H4 levels in neuroblasts
and neural progenitor cells, suggesting the involve-
ment of HDAC inhibition in VPA’s proneurogenic
effects. The HDAC inhibitors SB and TSA, which are
structurally similar and dissimilar to VPA, respec-
tively, were also found to exert postischemic proneuro-
genic effects in a rat pMCAO model (Kim et al., 2009).
In addition, postinsult treatment with SB of rats
undergoing pMCAO was shown to stimulate BrdU
incorporation in the SVZ, DG, striatum, and frontal
cortex; post-MCAO treatment with SB or TSA was also
shown to increase the population of cells expressing
nestin, GFAP, CREB, BDNF, and polysialic acid-
neural cell adhesion molecule (PSA-NCAM), a neuro-
blast marker with important neurobiological functions.
After treatment with HDAC inhibitors, moreover,
extensive colocalization of BrdU and PSA-NCAM was
noted in multiple brain regions. BDNF and phospho-
CREB, which are known to regulate neurogenesis,
were robustly upregulated by treatment with SB or
TSA. It is noteworthy that intraventricular injection of
the TrkB antagonist K252a markedly suppressed SB-
induced cell proliferation detected by BrdU and Ki67 in
the ipsilateral SVZ, DG, and other brain regions. It also

blocked nestin expression and CREB activation and
attenuated the long-lasting behavioral benefits of SB.
Together, these results suggest that proliferation, mi-
gration, and differentiation induced by HDAC inhibition
require BDNF-TrkB signaling, which therefore, contrib-
utes to long-term behavioral improvement after stroke.
Overall, these findings highlight the ability of lithium
and VPA to improve functional outcomes, suppress cell
death, attenuate neuroinflammation, enhance migra-
tion of transplanted MSCs, and promote angiogenesis
and neurogenesis in diverse animal models of cerebral
ischemia. Figure 2 is a proposed model of how these two
mood stabilizers induce multiple neurobiological effects
in the MCAO ischemic model. These beneficial effects
further confirm the considerable therapeutic potential of
these mood-stabilizing drugs in the treatment of certain
conditions of human stroke. Nevertheless, caution is
warranted because of the limited therapeutic window of
both lithium and VPA dosing, because adverse effects
arise rapidly at toxic doses. These adverse effects can
significantly negate the beneficial outcomes of long-term
treatment. Therefore, appropriate dosing for both of
these drugs is essential for their therapeutic potential to
be realized, particularly because effective dosing for
stroke and other neurodegenerative diseases is cur-
rently lacking. We anticipate that combining treatment
of lithium and VPA may also provide unique advantages
toward reducing harmful adverse effects by requiring
lower doses for clinical benefit.

B. TBI

TBI is characterized by initial injury to neurons, glia,
and vascular structures, followed by secondary injury
from excitotoxicity, BBB breakdown, brain edema,
neuroinflammation, and neurodegeneration. Secondary
injury is often accompanied by behavioral and cognitive
deficits and neuropsychiatric disturbances (such as
depression, anxiety, and posttraumatic stress disorder)
(for a review, see Ursano et al., 2010). Since 2001, more
than 200,000 military personnel in the United States
have sustained TBI, which is increasingly considered to
be a signature wound of
the wars in Iraq and
Afghanistan. In addition, in developed countries, TBI
is one of the leading causes of mortality and disability
among young persons, and its incidence is rapidly
increasing. Moreover, despite extensive research aimed
at developing therapies for TBI, no FDA-approved drug
yet exists for its treatment. Because of TBI’s complex
pathology, any effective therapy will need drugs that
can act on multiple cell survival and death pathways,
either alone or in combination (Margulies et al., 2009);
in this regard, accumulating evidence indicates that
lithium and VPA are both strong candidates.

1. Lithium-Induced Effects on Neurodegeneration,
Neuroinflammation, Behavioral Improvement, and Ab
In cases of mild TBI
Accumulation in Models of TBI.
in mice, pretreatment with lithium (or another GSK-3

122

Chiu et al.

Fig. 2. A proposed model to demonstrate the molecular actions of lithium and VPA in preclinical models of cerebral ischemia. By inhibiting GSK-3 and
HDACs, respectively, lithium and VPA induce transcriptional activation of diverse neuroprotective and neurotrophic genes in the ischemic brain.
HSP70 expression is enhanced by mechanisms involving lithium-induced HSF-1 activation and VPA-induced Sp1 activation by acetylation. HSP70 is
neuroprotective and anti-inflammatory, presumably because it inhibits NF-kB, in which activity is inhibited by VPA and, possibly, by lithium. NF-kB
inhibition also contributes to protection against BBB breakdown by downregulating MMP-9 shortly after ischemia. VEGF and MMP-9 are induced by
long-term lithium or VPA treatment and are key protein molecules involved in potentiating angiogenesis. In addition, BDNF is transcriptionally
activated by lithium and VPA, and BDNF-TrkB signaling is essential for enhancing neurogenesis. BDNF and VEGF also contribute to neuroprotection
and the behavioral benefits of mood stabilizers. Furthermore, ischemia-induced NMDA receptor overstimulation and calcium overflow in the ischemic
brain are inhibited by lithium treatment through inhibition of NR2 subunit tyrosine phosphorylation. This could suppress excitotoxicity-induced p38
and Jun N-terminal kinase (JNK) and subsequent activator protein 1 (AP-1) activation to block neuronal apoptosis. Lines with solid arrows represent
stimulatory connections; lines with flattened ends represent inhibitory connections. Dashed lines represent pathways with reduced activity as a result
of lithium or VPA treatment.

inhibitor) 30 minutes before injury alleviated depressive
behavior 24 hours after mild TBI (Shapira et al., 2007).
In the hippocampus, mild TBI increased phosphoryla-
tion of Akt, phosphorylation of GSK-3b at Ser9, and
accumulation of downstream b-catenin, suggesting the
activation of this prosurvival cascade. The evidence thus
suggests that inhibiting GSK-3b may be beneficial in
TBI. In a mouse model of moderate TBI produced by
controlled cortical impact, a method widely used for the
accurate control of mechanical input, chronic lithium
pretreatment for 14 days attenuated the loss of hemi-
spheric tissue, brain edema, IL-1b expression, and
hippocampal neuronal degeneration. In addition, these
effects of lithium pretreatment in moderate TBI mice
were associated with improved spatial learning and
memory (Zhu et al., 2010).

Postinsult treatment with lithium also exerts robust
neuroprotective effects in TBI. With a therapeutic
window of 3–6 hours after injury, lithium treatment
was recently reported to reduce controlled cortical
impact–induced lesion volume in a TBI mouse model,
when assessed at three days and three weeks after
injury (Yu et al., 2012a). This postinsult lithium
treatment attenuated TBI-induced neuronal death,
microglial activation, COX-2 induction, and MMP-9
expression and preserved the integrity of the BBB, in
addition to normalizing TBI-induced hyperlocomotor
activity, anxiety-like behavior, and motor coordination.

Under these experimental conditions,
lithium also
robustly increased GSK-3b phosphorylation at Ser9,
suggesting that inhibition of this kinase is involved in
mediating the drug’s beneficial effects. In another
study, controlled cortical impact–induced TBI was also
found to cause a delayed increase in GSK-3b Ser9
phosphorylation. In contrast, postinsult (30 minutes
after injury) lithium administration for five days was
associated with elevated phosphorylation of this kinase
and subsequent b-catenin accumulation with reduced
hippocampal CA3 neuron loss and with lower deficits
in hippocampus-dependent learning and memory, as
measured at 14–28 days after injury (Dash et al.,
2011). That lithium’s behavioral benefits are partially
mimicked by the GSK-3 selective inhibitor SB-216763
supports the theory that lithium’s protective effects
against TBI involve GSK-3 inhibition. Of note, how-
ever, lithium treatment may well have other targets
that contribute to its beneficial effects.

Of note, TBI has been identified as a major risk
factor for developing AD. Memory impairments are
frequent in both patients with TBI and animal models
(Spikman et al., 2012), and Ab levels were found to be
elevated in CSF and postmortem brain samples from
patient with TBI (Uryu et al., 2007). Hyperactivity of
GSK-3 has been implicated in the pathogenesis of AD
(Hooper et al., 2008), an idea supported by the fact that
lithium treatment produces many benefits in various

Therapeutic Potential of Mood Stabilizers

123

models of this disease (see section III.D). In recent
findings from our laboratory, lithium treatment in the
corpus callosum and hippocampus robustly reduced
a number of molecules and processes induced by TBI,
including Ab load, amyloid precursor protein (APP), tau
hyperphosphorylation, and overexpression of b-APP–-
cleaving enzyme-1 (Yu et al., 2012b). Of importance,
lithium also ameliorated TBI-induced deficits in spatial
learning and memory, as assessed by the Morris water-
maze and Y-maze tests; these effects were associated
with increased hippocampal preservation. Together,
these findings demonstrate multiple beneficial effects
of lithium in TBI and underscore the continued need for
its clinical investigation.

2. VPA-Induced Effects on Neurodegeneration,
Neuroinflammation, and Functional Recovery in Mod-
els of TBI. Although less is known about the thera-
peutic potential of VPA in TBI, preclinical animal
studies have similarly revealed beneficial effects. In
a rat model of TBI, postinjury systemic VPA adminis-
tration reduced cortical contusion volume, decreased
BBB permeability, and, of most importance, improved
motor function and spatial memory (Dash et al., 2010).
VPA also dose-dependently increased histone acetyla-
tion and reduced GSK-3 activity in the hippocampus.
Similar results were observed in a previous study from
the same group using another HDAC inhibitor, SB, in
combination with behavioral training (Dash et al.,
2009). In addition, HDAC inhibition also reduced TBI-
induced microglial
inflammatory response in rats
(Zhang et al., 2008). In a mouse model of closed head
injury, a single dose of the HDAC inhibitor ITF2357
given 24 hours after injury significantly increased
levels of acetylated histone H3, HSP70, and phosphor-
ylated Akt (Shein et al., 2009). Other benefits included
reduced neurologic deficits, attenuated neuronal de-
generation, and reduced lesion volume. These results
confirm the hypothesis that VPA’s effects are mediated
through HDAC inhibition and that VPA merits further
investigation as a potential treatment of TBI.

3. Clinical Trials of VPA Treatment in TBI.

In
a two-year randomized double-blind trial, VPA treat-
ment began within 24 hours after injury and lasted for
one or six months. VPA substantially reduced the rate of
early seizure, although this benefit was not significant,
compared with short-term (one week) treatment with
phenytoin; neither drug prevented late seizures (Temkin
et al., 1999). In addition, no significant adverse or
beneficial effects were associated with VPA in another
clinical study, as assessed by a battery of neuro-
psychological measurements administered 1, 6, and 12
months after TBI (Dikmen et al., 2000). On the basis of
this trial, it was suggested that VPA should not be used
for prophylaxis of posttraumatic seizures. Although
VPA showed no benefit over phenytoin, it is possible
that treatment could be optimized by shortening the
treatment time window, controlling the dropout rate,

and including a placebo group. Because these two
clinical trials were conducted over a decade ago and
evidence is accumulating for VPA’s robust benefits in
preclinical TBI models, there is a need to re-examine
the clinical effects of VPA and other HDAC inhibitors
in patients with TBI. A recent study showed that VPA
treatment caused an acute ischemic stroke in a patient
with a mutation of methylenetetrahydrofolate reduc-
tase (Varoglu, 2009). Mutation of this enzyme results
in a decrease in its activity and induces hyperhomo-
cysteinemia, a possible risk factor for epilepsy and
occlusive vascular disease. The use of VPA could
exacerbate hyperhomocysteinemia by reducing folic
acid and vitamin B12 levels. Therefore, genetic
examination or the determination of plasma levels of
homocysteine may prevent these risks associated with
VPA treatment.

C. HD

HD is a devastating inherited neurodegenerative
disease. It is estimated by the World Health Organi-
zation (WHO) that HD affects 180,000 Americans,
30,000 of whom currently have the disease and 150,000
of whom have a 50% chance of developing it. A member
of the polyglutamine (polyQ) family of disorders, HD is
caused by a trinucleotide CAG-repeat in the gene that
encodes a polyQ stretch to an unnaturally high number
($35) of glutamines in the N terminus of the disease-
causing huntingtin (Htt) protein (Macdonald, 1993).
This abnormally expanded mutant Htt (mHtt) causes
neurotoxicity, possibly through both a toxic gain of
function and a loss of wild-type Htt protein (Zuccato
et al., 2001). The presence of mHtt ultimately results in
the selective loss of neurons in the brain that
particularly affects medium-sized spiny neurons in
the striatum and, to a lesser extent, neurons in the
cortex (Friedlander, 2003; Hickey and Chesselet,
2003). Clinically, patients with HD experience various
cognitive, psychiatric, and physical symptoms, such as
memory loss, changes in personality, emotional de-
terioration, and uncontrollable jerky movements. HD
is lethal, with death occurring ;15 years after the
initial symptoms (Martin and Gusella, 1986; Vonsattel
and DiFiglia, 1998; Ross and Tabrizi, 2011). No cure for
HD presently exists, nor are there effective treatments
to halt disease progression. The search for neuro-
protective agents to combat this dreaded disease is
therefore of critical importance.

1. Lithium-Induced Effects on Apoptosis, Cell Pro-
liferation, and Neuroprotection in Excitotoxic Models of
HD. Both preclinical and clinical studies have impli-
cated excitotoxicity, a mechanism of neuronal death
caused by supersensitivity to (or hyperactivation of)
excitatory amino acid receptors, in the neuropathology
of HD (Taylor-Robinson et al., 1996; Levine et al.,
1999; Zeron et al., 2001, 2002). The development of an
excitotoxic animal model of HD was based on the fact

124

Chiu et al.

that intrastriatal injection with kainic or quinolinic
acid (QA), both glutamate receptor agonists, mimicked
the loss of medium-sized spiny neurons and produced
many of the neuroanatomical changes found in the
brain of patients with HD (Coyle and Schwarcz, 1976;
Schwarcz and Whetsell, 1982; Foster et al., 1983; Beal
et al., 1986). QA is also endogenously produced, among
other toxic substances, by activated microglia and
macrophages. Infusion of this compound into the
striatum has been reported to downregulate cytopro-
tective Bcl-2 and upregulate proapoptotic p53 and c-
Myc (Liang et al., 2005). Furthermore, it has been
hypothesized that QA-induced striatal neuronal apo-
ptosis may be the result, at least in part, of a failed cell
cycle attempt (Liang et al., 2007). Administration of
the succinate dehydrogenase inhibitor 3-nitropropionic
acid (3-NP) also mimics striatal HD pathology (Brouillet
et al., 1999). The excitotoxic features of HD suggest that
lithium and VPA could be useful for its treatment.

Initial research in the rat excitotoxic model of HD
found that lithium pretreatment, at doses within the
therapeutic range, markedly reduced the size of QA-
lesions and the loss of striatal
induced striatal
medium-sized neurons (Senatorov et al., 2004). Lith-
ium’s protective effects correlated with upregulation of
Bcl-2, downregulation of Bax, and suppression of
caspase-3 activation. In addition, the ability of lithium
to protect against QA-induced excitotoxicity was
further confirmed in mature rat corticostriatal organo-
typic cultures (Senatorov and Chuang, 2007). This
preparation has the advantages of both in vivo and in
vitro approaches, because it preserves organotypic
organization and interneuronal connections. Lithium
pretreatment stimulated the proliferation of striatal
cells near the site of QA-induced injuries, and some of
these replicating cells had the phenotype of neurons or
astroglia (Senatorov et al., 2004). These observations
were corroborated by reports that lithium increased
neurogenesis in the rat hippocampus in vivo (Chen
et al., 2000). In rat cortical neuronal cultures, lithium
stimulated the proliferation of neuroblasts and antag-
onized glutamate or corticosterone-induced loss of
neuroblast proliferation (Hashimoto et al., 2003b).
These studies demonstrate lithium’s anti-apoptotic,
cell-proliferating, and neuroprotective effects in differ-
ent models of HD.

2. Investigating Mood Stabilizers in Transgenic
Models of HD. HD pathogenesis is frequently modeled
through the transgenic expression of mHtt, which
causes aggregate formation and toxicity in cell models
and in vivo (Carmichael et al., 2002). In the brains of
N171-82Q and YAC128 transgenic mouse models of HD,
GSK-3 and HDAC hyperactivity has been associated
with the onset of behavioral symptoms of the disease
(Chiu et al., 2011). As discussed above, GSK-3 dysfunc-
tion has been implicated in many neuropsychiatric
disorders, and activation of this kinase has been linked

to apoptotic cell death induced by multiple insults. In
a neuroblastoma cellular model of HD, the protective
effects of lithium in reducing mHtt aggregates and cell
death were mimicked either by treatment with a GSK-
3b inhibitor or overexpression of a dominant-negative
GSK-3b mutant (Carmichael et al., 2002). In Drosoph-
ila, lithium-induced protection against the toxicity of
aggregate-prone proteins was mimicked by AR-
A014418, a GSK-3b inhibitor (Berger et al., 2005).
HDACs, on the other hand, play a key role in the
homeostasis of histone acetylation of chromatin and
regulation of
Imbalances in protein
acetylation and transcription are associated with a wide
variety of brain disorders, as discussed above. In HD,
moreover, mHtt has been shown to affect diverse
transcriptional regulatory pathways (Cha, 2007). Tran-
scriptional dysregulation is in fact an early and pro-
gressive event in HD and is an important causative
factor in the disease (Sugars and Rubinsztein, 2003;
Hodges et al., 2006).

transcription.

Wild-type Htt has been shown to activate transcrip-
tion of the BDNF gene (Zuccato et al., 2001), whereas
mHtt represses it (Zuccato et al., 2003, 2007); of note,
BDNF is a neurotrophin essential for striatal neuron
survival (Nakao et al., 1995; Ventimiglia et al., 1995).
BDNF plays a central role in cortical development and
synaptic plasticity. Accordingly, in HD, loss of this
trophic support from the cortex is considered to be one
of the causal factors of striatal death, and decreased
BDNF has been reported both in animal models of HD
(Duan et al., 2003, 2008) and in the striatum of
patients with HD (Ferrer et al., 2000; Zuccato et al.,
2001). In contrast, enhanced BDNF expression has
been shown to protect neurons from neurochemical
insults associated with HD, both in cultured cells
(Saudou et al., 1998) and in rodents (Bemelmans et al.,
1999; Canals et al., 2004; Kells et al., 2004). Emerging
evidence indicates that treatment with lithium and
VPA affects both transcriptional activity and gene
expression. Long-term treatment with either of these
two drugs increased BDNF expression in the rat brain
(Fukumoto et al., 2001). As reported above, moreover,
both lithium inhibition of GSK-3b and VPA inhibi-
tion of HDACs activate BDNF promoter IV in cortical
neurons (Yasuda et al., 2009). In various in vitro
and in vivo models of HD, however, treatment with
lithium or VPA has had mixed results in protecting
against mHtt toxicity (Wei et al., 2001; Carmichael
et al., 2002; Wood and Morton, 2003; Zadori et al.,
2009).

3. Effects of Mood Stabilizers on Clearance of mHtt.
Abnormal proteolytic processing of mHtt is believed to
be another critical step in the onset of HD. This
cleavage of mHtt in human HD tissue was found to be
partially mediated by calpain, a calcium-activated
neutral protease in which activity is elevated in the
caudate of human HD tissues (Gafni and Ellerby,

Therapeutic Potential of Mood Stabilizers

125

2002). In both cultured primary brain neurons and
a rat 3-NP model of HD, pretreatment with lithium
attenuated 3-NP–induced cellular death and striatal
neurodegeneration by preventing calpain and sub-
sequent activation of
cyclin-dependent kinase 5
(Cdk5) (Crespo-Biel et al., 2009). Eliminating mHtt
expression, moreover, not only halted symptom pro-
gression but also led to a regression of disease-like
symptoms (Yamamoto et al., 2000). These results
suggest that improved clearance of the mutant protein
can prevent cellular dysfunction and neurodegenera-
tion in HD.

As described in section II.E, the UPS and autophagy
are two major intracellular mechanisms for the clear-
ance of abnormal protein accumulation. These mecha-
nism are therefore believed to be particularly beneficial
in those neurodegenerative disorders (such as HD)
characterized by the accumulation of misfolded, dis-
ease-causing proteins (Luo and Le, 2010; Hegde and
Upadhya, 2011; Li and Li, 2011; Nijholt et al., 2011).
Because both lithium and VPA induce autophagy
independent of mTOR activation, lithium in combina-
tion with rapamycin has been proposed as a rational HD
therapy and has been tested in various models of the
disease (Sarkar et al., 2008). This autophagy-inducing
property has also been hypothesized to contribute to
lithium’s protective effects in ALS (Fornai et al., 2008).
In HD models, overexpression of HSPs, molecular
chaperones that promote the degradation of abnor-
mally folded proteins, has been shown to reduce the
formation of Htt aggregates and to suppress the
neurodegeneration and toxicity associated with this
disease (Chan et al., 2000; Jana et al., 2000; Fujimoto
et al., 2005). The brains of HD animal models, however,
show a decrease in HSP70 and its cochaperone HSP40
(Hay et al., 2004; Chiang et al., 2007; Duan et al., 2008;
Yamanaka et al., 2008), which have been found to
colocalize with Htt aggregates (Jana et al., 2000). Of
significance, in cultured neurons and rats subjected to
cerebral ischemia, after treatment with either lithium
or VPA, expression of HSP70 was found to increase
(Ren et al., 2003, 2004; Kim et al., 2007; Marinova
et al., 2009, 2011).

4. Effects of Combined Lithium and VPA Treatment
on Behavior in Transgenic Models of HD. The most
frequently studied transgenic mouse model of HD is
the R6/2, which carries a 145 CAG repeat expansion
and shows behavioral motor deficits as early as 5–6
weeks of age. In this model, postsymptomatic lithium
treatment significantly improved rotarod performance
but had no overall effect on survival
(Wood and
Morton, 2003). However, because cotreatment with
lithium and VPA synergistically protected cultured
brain neurons from glutamate excitotoxicity (Leng
et al., 2008), combination therapy is expected to provide
additional benefits in neurodegenerative conditions.
Figure 3 shows a hypothetical working model of

the molecular actions of combined lithium and VPA
treatment in preclinical models of HD.

The therapeutic potential of combined treatment
with lithium and VPA was recently assessed (Chiu
et al., 2011) in two transgenic mouse models of HD
with distinct genetic backgrounds and disease pro-
gressions: N171-82Q and YAC128 (Schilling et al.,
1999; Slow et al., 2003). Although neither additive nor
synergistic in every aspect of this disease, combined
lithium and VPA treatment produced overall reliable
behavioral benefits in both models. This combined
treatment alleviated impaired locomotion and depres-
sive-like behaviors more strongly than treatment with
either drug alone. Combination therapy was also more
improving
than single-drug therapy at
successful
motor skill learning and coordination in N171-82Q
mice and at suppressing anxiety-like behaviors in
YAC128 mice.

In addition to motor and cognitive impairments,
patients with HD frequently experience psychiatric
disturbances, such as anxiety and depression (Di Maio
et al., 1993), that severely reduce their daily function-
ing and quality of life (Hamilton et al., 2003; Wheelock
et al., 2003). In the brains of HD mice treated with
lithium and VPA together, the activity of GSK-3b and
HDACs was consistently decreased, and expression of
BDNF and HSP70 was rapidly elevated and sustained
(Chiu et al., 2011). Because BDNF is considered a key
mediator of the clinical efficacy of antidepressants and
anxiolytic drugs (Woo and Lu, 2006), these actions
have particular relevance for the drugs’ behavioral
effects. Perhaps of more importance,
in N171-82Q
mice, cotreatment markedly prolonged survival. Taken
together, the data suggest that combined lithium and
VPA treatment could be even more effective against
HD if administered early in the course of the disease
(Chiu et al., 2011). Potential patients with HD can be
identified by genetic testing before the onset of
symptoms; thus, these data provide a strong rationale
for using a combination of lithium and VPA to treat
HD.

5. Clinical Trials of Lithium and VPA Treatment in
HD. Before their neuroprotective properties were
lithium or VPA in
discovered, the clinical use of
patients with HD was explored decades ago. In
patients with HD, lithium strikingly reduced chorea
and markedly improved voluntary movements (Anden
et al., 1973) and motor function (Mattsson, 1973). One
study found that patients in the early stages of the
disease were more likely to benefit from lithium
treatment (Foerster and Regli, 1977); in that study,
lithium conferred beneficial mood- and temper-stabilizing
effects. Combined therapy with lithium and neuro-
leptics has also proven to be beneficial in several
patients with HD (Anden et al., 1973; Manyam and
Bravo-Fernandez, 1973; Leonard et al., 1974, 1975;
Schenk and Leijnse-Ybema, 1974). On the other hand,

126

Chiu et al.

Fig. 3. A hypothetical working model to demonstrate molecular actions of combined lithium and VPA treatment in preclinical models of HD. In HD,
the expression of mHtt affects a diverse set of transcriptional regulatory pathways and produces aggregates and toxicity in the striatal neurons.
Transcriptional dysregulation, an early and progressive event in HD, is an important causative factor in this disease. Combined lithium and VPA
treatment, by more consistently inhibiting both GSK-3 and HDACs, disinhibits several transcription factors, and subsequently elevates the expression
of cytoprotective proteins, such as BDNF, HSP70, and Bcl-2. Suppressed GSK-3 activity further reduces the activity of the proapoptotic protein p53 and
its negative regulatory effect on Bcl-2. Superinduction of HSP70 together with upregulated Bcl-2 and downregulated p53 attenuate apoptosis. As
a molecular chaperone, HSP70 can also facilitate degradation of misfolded proteins via the ubiquitin-proteasome system (UPS). On the other hand, by
decreasing inositol 1,4,5-trisphosphate (IP3) levels, lithium and VPA induce autophagy, a key physiologic process for the bulk degradation of
cytoplasmic proteins that has recently been recognized as one of the important regulators of neuronal survival and function. Induction of these
intracellular protein quality control mechanisms enhances the clearance of mHtt and, thus, reduces mHtt-induced transcriptional dysregulation and
toxicity. Moreover, increased expression of BDNF, an important neurotrophic support for striatal neurons, further protects against neurochemical
insults associated with HD and promotes neurogenesis. These neuroprotective effects after lithium and VPA coadministration contribute to behavioral
improvement and prolong the lifespan of transgenic HD mice. Lines with solid arrows represent stimulatory connections; lines with flattened ends
represent inhibitory connections. Dashed lines represent pathways with reduced activity as a result of combined treatment.

VPA has been suggested as a rational choice as
a neuroleptic therapy in HD treatment (Tremolizzo
et al., 2007). A case study showed that VPA dose-
dependently improved myoclonic hyperkinesia in eight
patients with HD (Saft et al., 2006). When given in
combination with olanzapine, VPA at the lowest effective
dose (60–80 mg/ml
in plasma) also appeared to be
beneficial for relieving both psychosis and movement
symptoms in patients with HD (Grove et al., 2000).

Other reports showed that lithium had no beneficial
effects in patients with HD (Aminoff and Marshall,
1974; Vestergaard et al., 1977). In some instances,
lithium treatment, particularly when used as the sole
therapeutic agent, even worsened motor and cognitive
performance (Carman et al., 1974; Leonard et al.,
1974). VPA has also been reported to have no beneficial
effects (Symington et al., 1978) or to lead to a state of
tolerance (Tan et al., 1976) on involuntary movements
in patients with HD. In these ancient trials reporting
no effect, however, the patient samples were small and
the duration of drug treatment was short. Large-scale
new clinical trials with long treatment duration are
necessary to resolve these discrepancies and assess the
potential benefits of using mood-stabilizing drugs to
treat HD. Lithium and VPA are already FDA-approved
medications with a long history of safe use in humans,
and in light of results from recent promising preclinical
studies, combined treatment with lithium and VPA or
other neuroprotective drugs is recommended for future

clinical investigation. Because the symptoms of this
disease are devastating and worsen progressively
without remission until death, the potential effects on
behaviors may significantly improve quality of life for
individuals with HD and their caregivers.

D. AD

In 2011, AD affected an estimated 5.4 million
Americans and was the sixth leading cause of death.
Clinically, it is characterized by progressive memory
loss, personality changes, and ultimately, dementia.
There is essentially no treatment available to arrest or
reverse the deterioration of neurons in AD, although the
FDA has approved five drugs that can temporarily slow
disease progression (Tariot et al., 2011). The pathogen-
the
esis of AD is not well understood; however,
accumulation of Ab in the brain is believed to be the
primary cause (Hardy and Selkoe, 2002). This neuro-
pathological hallmark of AD presumably results from
an imbalance between Ab production and clearance.
The hyperphosphorylation of tau, a microtubule-binding
protein (Selkoe, 2001), has also been implicated in the
early development of neurofibrillary pathology (tauopa-
thies) associated with AD and other neurodegenerative
diseases (Lee et al., 2001; Planel et al., 2001).

Therefore, in the treatment of AD, Ab accumulation
and tau hyperphosphorylation are the primary treat-
ment targets. It is well-established that GSK-3 acts as
an Ab production regulator (Phiel et al., 2003; Su et al.,

Therapeutic Potential of Mood Stabilizers

127

2004; Rockenstein et al., 2007) and a tau kinase
(Hanger et al., 1992; Lovestone et al., 1994; Brownlees
et al., 1997). Because abnormal increases in GSK-3
levels and activity are associated with pathogenesis
and neuronal death in the brain of individuals with AD
(Munoz-Montano et al., 1999; Bhat et al., 2004), the
mood stabilizers lithium and VPA, which have been
shown to inhibit GSK-3, could have potential thera-
peutic use in treating this disorder.

1. Effects of Mood Stabilizers on GSK-3 Inhibition in
AD Models. Ab peptide is derived from APP by
sequential secretase-dependent proteolytic processing.
Through GSK-3 inhibition, chronic treatment with
lithium or VPA has been reported to block Ab
production. For example, chronic lithium treatment
was found to block Ab accumulation in the brains of
mice overproducing APP (Phiel et al., 2003), pre-
sumably by interfering with the reaction of g-secretase.
lithium could also
As discussed in section III.B.1,
decrease Ab burden by inhibiting APP processing
through BACE-1 inhibition in the brain of TBI mice
(Yu et al., 2012b). Although this effect of lithium in
vitro was mimicked by transfection with siRNA of
GSK-3a but not GSK-3b (Phiel et al., 2003), other in
vitro and in vivo studies found that GSK-3b inhibition
also mimicked the ability of lithium or VPA to suppress
the process of Ab formation from APP (Su et al., 2002,
2004; Qing et al., 2008). A recent study in an adult-
onset Drosophila model of AD demonstrated a novel
mechanism, whereby GSK-3 directly regulated Ab42
levels in the absence of any effects on APP processing
(Sofola et al., 2010).

By inhibiting GSK-3, moreover, lithium has been
demonstrated, both in vivo and in vitro, to reduce tau
phosphorylation (Hong et al., 1997; Munoz-Montano
et al., 1997; Sang et al., 2001). In transgenic mouse
models of AD, chronic lithium treatment decreased
mutant tau protein aggregation (Perez et al., 2003) and
arrested the development of neurofibrillary tangles
(Leroy et al., 2010). In mouse models of tauopathies,
chronic lithium treatment not only inhibited tau
phosphorylation and neuronal degeneration mediated
by GSK-3 (Noble et al., 2005), but also promoted
ubiquitination, thereby decreasing tau-induced lesions
(Nakashima et al., 2005). In addition to GSK-3, tau
phosphorylation was also regulated by PP2A (Tanaka
et al., 1998). It has been reported that the activity of
PP2A is reduced in the brain of individuals with AD
(Trojanowski and Lee, 1995). PP2A inhibition pre-
vented tau dephosphorylation, a process that precedes
and is required for tau cleavage and degradation
(Rametti et al., 2004). In cultured cortical neurons,
lithium was found to down-regulate tau transcription
(Rametti et al., 2008). In the rat brain,
lithium
treatment not only increased PP2A activity (Tsuji
et al., 2003), but also decreased tau phosphorylation,
which in turn, facilitated tau destruction (Rametti

et al., 2004). Finally, the fact that blockade of PP2A
activity in cultured neurons reversed lithium-induced
down-regulation of total tau proteins mediated by
GSK-3b inhibition (Martin et al., 2009) suggests that
PP2A is involved in lithium’s action.

2. Effects of Mood Stabilizers on Other Molecular
Targets in AD Models.
In addition to inhibiting GSK-
3, lithium and VPA have other protective effects re-
levant to the pathogenesis of AD. In hippocampal slices,
lithium treatment prevents acetylcholinesterase-
promoted Ab toxicity and associated loss of func-
tion of Wnt signaling components (Inestrosa et al.,
2000). By rescuing b-catenin levels in rat brains,
long-term lithium treatment was found to be neuro-
protective against Ab-induced hippocampal neurode-
generation (De Ferrari et al., 2003). It was also found
that induction of Dickkopf protein 1 (DKK1), a Wnt
pathway inhibitor (Krupnik et al., 1999), was associ-
ated with neurodegeneration in the brains of individ-
uals with AD (Caricasole et al., 2004). Researchers
demonstrated that,
in the CA1 region of the rat
hippocampus, systemic administration of lithium re-
versed local infusion of DKK1-induced neuronal cell
death and astrocytosis (Scali et al., 2006). Lithium has
further been shown to protect against Ab-induced ER
stress and the subsequent activation of caspases and
NF-kB in the hippocampus of rabbits (Ghribi et al.,
2003). This effect presumably comes from the induction
of the chaperone protein GRP78 (Hiroi et al., 2005), as
discussed in section II.E.2.

VPA, on the other hand, has been shown to enhance
microglial phagocytosis of Ab in vitro (Smith et al.,
2010). In human astrocytes, moreover, VPA (but not
lithium) has been shown to act as a potent inducer of
clusterin expression and secretion (Nuutinen et al.,
2010). Clusterin is a small, HSP-like molecular
chaperone, in which secretion is induced by stress.
Expression of clusterin is increased in AD (May et al.,
1990); it is present in neuritic plaques and binds to and
enhances the clearance of Ab in the brain (Nuutinen
et al., 2009). VPA’s ability to induce clusterin expres-
sion and secretion is therefore a distinct protective
mechanism. Chronic lithium treatment also largely
suppressed exogenous Ab-induced downregulation of
Bcl-2 and neuronal death in vitro (Hong et al., 1997;
Alvarez et al., 1999, 2002; Wei et al., 2000). Of note,
Bcl-2 protein levels in the brains of a mouse model of
AD were inversely correlated with miR-34a expression
(Guan et al., 2009), a miRNA that has recently
emerged as a common target for lithium and VPA
(Zhou et al., 2009). These findings suggest that miRNA
regulation may be a novel mechanism for the pro-
tective effects of these mood stabilizers in AD.

3. Effects of Mood Stabilizers on Recovery of
Cognitive Function in AD Models.
In Drosophila
models of tauopathies, lithium is known to reverse
axonal transport and locomotor deficits by inhibiting

128

Chiu et al.

GSK-3b (Mudher et al., 2004). In normal healthy rats,
long-term lithium treatment improved learning and
memory (Nocjar et al., 2007), and it ameliorated spatial
learning deficits in rats injected with preformed Ab
fibrils (De Ferrari et al., 2003). By inhibiting GSK-3b
signaling, lithium treatment of 3 months also reduced
Ab burden and tau hyperphosphorylation, prevented
neurodegeneration in the cortex and hippocampus, and
normalized memory deficits in transgenic mice over-
expressing human APP (Rockenstein et al., 2007).

Because dysregulation of histone acetylation is also
implicated in the memory impairment and pathogen-
esis of neurodegenerative diseases, using HDAC
inhibitors to control the elevation of histone acetylation
could be another novel approach for the treatment of
memory deficits in AD. HDAC2 is known to negatively
regulate memory formation and synaptic plasticity
(Guan et al., 2009), and its expression has been found
to be increased in experimental AD models and
patients (Graff et al., 2012). In a mouse model of
neurodegeneration,
shRNA-induced knockdown of
HDAC2 restored structural and synaptic plasticity
and abolished memory impairments (Graff et al.,
2012). In transgenic AD mice, relatively low doses of
the HDAC inhibitor VPA significantly reduced the
formation of neuritic plaques and improved memory
deficits (Qing et al., 2008). In animal models of this
disease, moreover, injections of other HDAC inhibitors
(such as SB, phenylbutyrate, or vorinostat) completely
restored contextual memory (Kilgore et al., 2010;
Ricobaraza et al., 2012). A recent study using SB in
AD mice indicated, in fact, that HDAC inhibitors may
be therapeutically beneficial even when administered
at an advanced stage of the disease (Govindarajan
et al., 2011). In contrast, another preclinical animal
study showed that, although administering a low dose
of VPA (30 mg/kg) at a later stage could affect
neuropathological changes, cognitive deficits could only
be reduced by early intervention; this effect was
attributed to GSK-3 inhibition (Qing et al., 2008).
The role of HDAC inhibition in this low-dose VPA-
induced effect requires further investigation.

4. Clinical Trials of Lithium and VPA Treatment in
AD. The use of lithium and VPA in the treatment of
AD has already been investigated clinically. Studies of
individuals with BD found that patients with a history
of lithium treatment had significantly better cognition
and memory scores than did patients receiving other
treatments (Terao et al., 2006). Long-term lithium
treatment was also found to reduce the prevalence of
AD in older patients with BD (Nunes et al., 2007). A
10-year Danish study reported that patients receiving
continued lithium treatment had a reduced rate of
dementia, compared with those who received only one
prescription of lithium, and this rate was equal to that
in the general population (Kessing et al., 2008); it
should be noted, however, that the study did not

specify the indication for the lithium prespcription.
In addition, a recent study showed that long-term
treatment (12 months) with lithium (0.2520.5 mM)
decreased phospho-tau levels in CSF and improved
cognitive performance on the AD Assessment Scale
(Forlenza et al., 2011). Moreover, lithium tolerability
was excellent, with a 91% adherence rate. In contrast,
a trial in which 33 patients with AD received 10 weeks
of
lithium treatment reported no effect on GSK-3
activity or cognitive performance (Hampel et al., 2009),
and other studies with small samples and short
duration have similarly reported no therapeutic effect
of lithium treatment in patients with AD (Brinkman
et al., 1984; Macdonald et al., 2008).

As with lithium, VPA clinical trials conducted on
patients with AD have produced mixed results. A
recent case study suggested that low-dose divalproex
may reduce the risk of adverse effects and led to
improvement in patients with AD with
behavioral
agitation (Dolder and McKinsey, 2010). A 10-week
safety and tolerability study with a sample of 20
outpatients with probable AD revealed that
the
maximum tolerated dosage of divalproex sodium was
,1000 mg/day, whereas the most common adverse
effects were sleepiness and tiredness (Profenno et al.,
2005). In patients with mild to moderate AD, dival-
proex treatment (10–12 mg/kg/day) did not delay the
emergence of agitation and cognitive impairment and,
more alarmingly, was found to accelerate brain volume
loss with significant toxic effects (Tariot et al., 2011).
VPA treatment was also found to be ineffective for the
management of agitation and aggression in older
patients with moderate to severe AD (Herrmann
et al., 2007). Of note, most of these reports used fixed
doses and had few data on VPA’s effects on the
pathogenesis or neuropathology of AD. Taken together,
these preliminary results suggest that studies with
longer treatment phases and larger groups of patient
with AD are needed to observe the potential benefits of
improvement of
lithium. With regard to potential
pathologic and cognitive impairments, VPA treatment
should be administered with flexible dosing and in the
early stages of AD.

E. ALS

ALS is an adult-onset neurodegenerative disease
characterized by progressive loss of motor neurons in
the motor cortex and spinal cord, resulting in gener-
alized weakness, muscle atrophy, paralysis, and death
within five years after disease onset (Rowland, 1994).
Damage to surrounding glial cells, muscle cells,
interneurons, and Renshaw inhibitory neurons have
also been reported, in addition to the loss of motor
neurons (Boillee et al., 2006; Dobrowolny et al., 2008;
Fornai et al., 2008). Most ALS cases occur sporadically,
with no family history of the disease (Boillee et al.,
2006; Wijesekera and Leigh, 2009). Sporadic and

Therapeutic Potential of Mood Stabilizers

129

autosomal-dominant familial forms of ALS are, how-
ever, clinically similar. Approximately 20% of familial
ALS is attributed to gain-of-function mutations in the
gene encoding Cu/Zn superoxide dismutase 1 (SOD1),
a key antioxidant enzyme (Rosen et al., 1993; Andersen
and Al-Chalabi, 2011). Mice expressing mutant Cu/Zn
SOD1 exhibit ALS-like phenotypes, including prema-
ture death, behavioral abnormalities, and the forma-
tion of intracellular aggregates of SOD1 in the brain
and spinal cord.

1. Effects of Lithium Treatment in ALS. Lithium’s
neuroprotective mechanisms have been suggested as a
possible treatment of ALS, particularly because upregu-
lation of GSK-3b, hyperphosphorylation of b-catenin
(Yang et al., 2008) and downregulation of VEGF and its
receptors (Brockington et al., 2006) have all been
identified in postmortem tissue samples from patients
with ALS. As described above, lithium treatment in-
creased the expression of VEGF, a growth factor that
has been shown to prolong survival in ALS mice (Wang
et al., 2007), and to protect motor neurons against
excitotoxicity (Tolosa et al., 2008). In organotypic slice
cultures of spinal cord, long-term treatment with lithium
dose-dependently inhibited the GSK-3b signaling path-
way and, thereby, prevented excitotoxic cell death of motor
neurons (Caldero et al., 2010). Treatment with lithium
alone or in conjunction with an antioxidant also improved
motor function and slowed disease progression in a mouse
model of ALS (Shin et al., 2007; Fornai et al., 2008;
Ferrucci et al., 2010). Because defective autophagy has
been found in diseased motor neurons (Venkatachalam
et al., 2008), the autophagy-inducing properties of
lithium are also believed to contribute to its protective
effects in ALS (Fornai et al., 2008; Fulceri et al., 2011).
However, one recent study in a female mouse ALS model
found that lithium had no beneficial or neuroprotective
effects (Pizzasegola et al., 2009). Although differences in
sex and the genetic background of the mice cannot be
excluded, the remarkably low serum steady-state lithium
level (0.05–0.07 mM) found in these female mice from the
latter study may account for this discrepancy.

2. Effects of VPA Treatment in ALS. Alteration in
the gene that encodes the survival motor neuron (SMN)
protein is responsible for spinal muscular atrophy
(SMA) (Lefebvre et al., 1995). This gene is present as
two homologous copies in the human genome: the
telomeric SMN1 and the centromeric SMN2. Homozy-
gous deletion or point mutation of SMN1 causes SMA,
whereas differential copy numbers of SMN2 modulate
the phenotype of this disease (Rochette et al., 1997;
Gavrilov et al., 1998). Of interest, abnormal copy numbers
of SMN1 (single and triple) have been implicated as a risk
factor in sporadic ALS (Corcia et al., 2002, 2006, 2009;
Blauw et al., 2012).

Although the roles of SMN2 were reported to be
inconclusive (Veldink et al., 2001; Blauw et al., 2012;
Corcia et al., 2012), genetic studies suggest that SMN

expression helps to modify disease severity in both
SOD1 mouse models (Kunst et al., 2000) and patients
with sporadic ALS (Veldink et al., 2001). Lower SMN2
copy numbers and lower SMN protein levels were
found to be associated with an increased susceptibility
to and severity of ALS (Turner et al., 2009; Veldink
et al., 2005). In SMA fibroblast cultures, VPA admin-
istration activated SMN2 transcription, modulated the
expression of splicing factors (Harahap et al., 2012),
and increased the expression of SMN protein (Sumner
et al., 2003). The upregulated level of SMN protein has
also been shown to depend on the number of SMN2
copies (Brichta et al., 2003). Although further explora-
tion is required, these results suggest that VPA may
have therapeutic potential in the treatment of ALS.

found that

In ALS mice, CREB-binding protein, a transcrip-
tional coactivator with histone acetyltransferase activ-
ity, was specifically reduced in motor neurons of the
lumbar spinal cord. Consistently, decreased histone
acetylation levels were observed in degenerating motor
neurons (Rouaux et al., 2003). Numerous studies have
reported the beneficial effects of HDAC inhibitors on
different aspects of neurodegeneration (Guo et al.,
2009). Although results are inconsistent in ALS mice,
treatment with VPA maintained histone acetylation in
the spinal cord, restored CREB-binding protein levels
in motor neurons, and slowed the degeneration of
motor neurons (Rouaux et al., 2007; Crochemore et al.,
2009). Although treatment with VPA was found to
protect motor neurons against glutamate toxicity in an
organotypic culture of spinal cord and, in one study,
prolonged lifespan in a G93A mouse model of ALS
(Sugai et al., 2004), another study using the same
mouse model
long-term dietary VPA
administration protected motor neurons but did not
significantly affect lifespan (Crochemore et al., 2009).
3. Clinical Trials of Lithium and VPA Treatment in
ALS. Although results from the aforementioned pre-
clinical studies raise the possibility that lithium and
VPA have putative utility for the treatment of ALS,
clinical trials of these mood stabilizers have, to date,
provided controversial results. A 15-month pilot clin-
ical trial in randomized patients with ALS found that,
when compared with matched control patients treated
with riluzole alone, cotreatment with riluzole and
lithium markedly reduced mortality (Fornai et al.,
2008). However, another randomized, double-blind,
this combined
controlled clinical
treatment did not slow the progression of sporadic
ALS more than riluzole plus placebo (Aggarwal et al.,
2010). In a sibling-matched, sex-balanced, investigator-
blinded trial, long-term lithium treatment was found to
be ineffective on any treatment measure (Gill et al.,
2009). Three of the latest trials also refute any
beneficial effect of lithium treatment in patients with
ALS (Chio et al., 2010; Miller et al., 2011; Verstraete
et al., 2012), and a randomized sequential trial using

found that

trial

130

Chiu et al.

a fixed dose of VPA found it to be equally ineffective in
patients with ALS (Piepers et al., 2009).

Because of these disappointing results, future in-
dependent and competitive trials may not be conducted
(de Carvalho and Pinto, 2011). Nevertheless, pre-
clinical studies in ALS mice suggest that combined
treatment with lithium and VPA produces a greater
and more consistent effect in delaying the onset of
disease symptoms, decreasing neurologic deficit scores
and prolonging lifespan, compared with monotherapy
with either drug (Feng et al., 2008). As with HD, this
preclinical evidence encourages future clinical trials
using this combined treatment, which may lead to
potential additive or synergistic protective effects that
may also reduce the required dosages of both drugs,
thereby minimizing their adverse effects. We suggest
that future trials be conducted with a larger number of
subjects early in the disease course, longer duration of
treatment, and various doses of drug to clarify
treatment discrepancies and the efficacy of these mood
stabilizers in ALS.

F. FXS

FXS is caused by a full mutation of the fragile X
mental retardation-1 (FMR1) gene with an abnormal
expansion of more than 200 CGG repeats within the
gene promoter (Verkerk et al., 1991). This expan-
sion triggers hypermethylation of cytosines in the
CpGs of the gene and hypoacetylation of associated
histones, resulting in transcriptional silencing of FMR1
(Verkerk et al., 1991; Sutcliffe et al., 1992; Hornstra et al.,
1993). This gene encodes the fragile X mental re-
tardation protein (FMRP), an RNA-binding protein that
negatively regulates translation at synapses (Garber
et al., 2006).

FXS is the most common inherited single-gene
disorder associated with mental retardation. Patients
with FXS exhibit cognitive impairments, seizures,
hyperactivity, and autistic behaviors. Another signifi-
cant problem for many affected young individuals is
symptomatic attention deficit hyperactivity disorder
(Baumgardner et al., 1995). The discovery of this
autism-related gene led to the development of FMRP
knockout animals, which not only serve as animal
models of FXS but have also improved our understand-
ing of the pathophysiological mechanisms of autism
(Hagerman et al., 2005). No cure presently exists for
treatments are focused on
FXS; current medical
behavioral improvement.

1. Therapeutic Potential of Lithium Treatment in
FXS.
It has been suggested that the absence of FMRP
in the brain of individuals with FXS enhances the
activation of the metabotropic glutamate receptor
(mGluR), which results in long-term depression (Bear
et al., 2004; Dolen et al., 2007). If so, the use of mGluR
antagonists may prove to be effective for treating this
disorder. In a Drosophila model of FXS that measured

naive and conditioned courtship behaviors after treat-
ment, mGluR antagonists were found to rescue both
behavioral and cognitive deficits (McBride et al., 2005).
Lithium treatment, which modulates signaling in a
manner similar to mGluR antagonists, also increased
naive courtship and restored short-term memory in FXS
flies (McBride et al., 2005). A later study further found
that treatment with mGluR antagonists or lithium
effectively prevented age-related cognitive impairments
in this Drosophila model of FXS (Choi et al., 2010).

In the brain of FXS mice, the inhibitory serine-
phosphorylation of GSK-3 was found to be impaired
(Min et al., 2009, 2010). Although levels of this GSK-3
phosphorylation can be increased by 2-methyl-6-
phenylethynyl-pyridine (MPEP), an mGluR5 antag-
onist (Min et al., 2009; Mines et al., 2010), the
combination of an mGluR5 antagonist with a GSK-3
inhibitor did not produce additive therapeutic effects
in FXS mice (Min et al., 2009). These findings
suggest that GSK-3 is the fundamental component
of FXS pathology and indicate that GSK-3 is a
potential therapeutic target. In fact, recent studies
using mouse models of FXS demonstrated that lithium,
a potent GSK-3 inhibitor, may be therapeutically useful
for treating the disease (Mines and Jope, 2011). These
studies showed that, in FXS mouse models, lithium
treatment not only corrected hypophosphorylation of
GSK-3 but also ameliorated aberrant dendritic spine
morphology, deficient social interactions, and impaired
learning ability (Min et al., 2009, 2010; Liu et al., 2011).
In addition, the increased rate of cerebral protein
synthesis observed in FXS mice, presumably a conse-
quence of FMRP deficiency, was also significantly
reversed by long-term lithium treatment (Liu et al.,
2012b). Consistent with preclinical
lithium
treatment in a pilot clinical study showed positive effects
on behavior, adaptive skills, and cognitive measures in
15 FXS patients aged 6–23 years (Berry-Kravis et al.,
2008).

findings,

2. Therapeutic Potential of VPA Treatment in FXS.
Increasing histone acetylation has been identified as an
epigenetic alteration to facilitate gene transcription. In
cells from normal individuals, FMR1 was associated
with acetylated histone H3 and H4, whereas in the cells
of patients with FXS, reduced acetylation was observed
(Coffee et al., 1999). Because the loss of transcriptional
activity of FMR1 appears to be the major cause of FXS,
pharmacological reactivation of this gene may serve as a
possible therapeutic approach. As both a mood stabilizer
and HDAC inhibitor, VPA may have dual beneficial
effects in FXS: ameliorating behavior and reactivating
FMR1.

Treatment of Fragile X cells with 5-aza-2-deoxycytidine,
a DNA demethylating agent, resulted in reassociation
of acetylated histone H3 and H4 with FMR1 promoter
and transcriptional reactivation (Tabolacci et al.,
In addition, a clinical study found that
2005).

Therapeutic Potential of Mood Stabilizers

131

treatment with L-acetylcarnitine, which regulates
FMR1 activity (possibly via increased histone acetyla-
tion; Tabolacci et al., 2005), effectively ameliorated the
symptoms of attention deficit hyperactivity disorder
in children with FXS (Torrioli et al., 2008). VPA
alone was found to produce only modest reactivation
of FMR1 in different FXS lymphoblastoid cell lines
(Tabolacci et al., 2008) and had no effect on DNA
demethylation. Of note, the effect of VPA on reac-
tivation of the FMR1 gene in other types of tissue
may be varied and still remains unclear. In addition,
VPA has already been proven to be an effective
treatment of behavioral and psychiatric symptoms
in patients with autism or FXS (Sovner, 1989;
Hagerman et al., 1999; Torrioli et al., 2010). For these
reasons, using VPA to treat FXS cannot be excluded,
although further research on its basic mechanisms is
needed.

IV. Limitations for Lithium and VPA Treatment

As the aforementioned evidence suggests, lithium and
VPA have tremendous potential for the treatment of
a variety of CNS and neurodegenerative disorders.
Nevertheless, their use is associated with numerous
concerns relating to toxicity, teratogenicity, dosing,
patient age, comorbidites, and patient stability, and
these must be addressed.

The toxicity of lithium was recently and systemati-
cally reviewed by McKnight and colleagues (2012).
This review examined 385 studies (from the 1950s to
the present) and included 33 studies examining renal
function, 77 studies examining thyroid function, 60
studies examining parathyroid function, 24 studies
examining hair, 77 studies examining skin, 55 studies
examining weight, and 62 studies examining teratoge-
nicity (McKnight et al., 2012). The main conclusions
drawn from this comprehensive meta-analysis were
that lithium increased the risk of polyuria, hypothy-
roidism, hyperparathyroidism, and weight gain; of
surprise, little clinical support was found for the notion
that lithium significantly impaired renal function in
most patients (0.53% in patients treated with lithium,
compared with 0.2% in the general population). The
review also concluded that the risk of teratogenicity in
infants exposed to lithium was not significantly
different when compared with control subjects; however,
there is still some uncertainty of risk to women who
wish to become pregnant, suggesting that patients, in
conjunction with their doctors, must balance these risks
between harm to the infant and maternal mental health
before continuing or discontinuing lithium treatment.

The review also noted that acute lithium toxicity
(doses above 1.2 mM) did occur, particularly in patients
made susceptible after surgery, renal
failure, heart
failure, or even severe illness resulting in diarrhea and
vomiting. Therefore, to avoid lithium toxicity, monitoring

serum lithium levels every three months is recommen-
ded, along with daily dosing rather than multiple daily
dosing (Malhi and Tanious, 2011). Among the potential
limitations of this exhaustive review are as follows: 1)
lack of many long-term randomized or controlled cohort
studies, 2) relatively small sample sizes, 3) lithium doses
considered to be mainly in therapeutic range (0.4–1.0
mM) rather than at concentrations of toxicity (above 1.2
mM), 4)
incomplete dosing information reported, 5)
exclusion of patients with a history of lithium toxicity
or sparse information to monitor these individuals and
evaluate their clinical response to lithium treatment,
and 6) tendency for a high dropout rate in important
cohort studies, with little information regarding the
from the study. Even with these
cause of removal
limitations, the authors provide an extensive systematic
quantification of the potential risks associated with
lithium treatment.

For current recommendations on optimal plasma
lithium levels (0.4–1.0 mM) in treating BD and the
risks associated with lithium treatment, the interested
reader is referred to a practical guide (Malhi et al.,
2011). These authors developed a lithiumeter, a visual
scale for optimal lithium plasma levels for the treat-
ment of BD. Future investigations may develop this
scale further to assess optimal lithium plasma levels in
combination therapies with VPA and also for dosing
considerations based on factors, such as patients’
comorbidities, age, and sex. Although a careful study
showing efficacy, tolerability, and safety of lithium in
older patients with BD is currently unavailable, a recent
review reported that lithium use in late-life BD was not
only effective in treating manic and depressive symp-
toms, it also provided the benefit of reducing cognitive
impairment and suicide rates (D’Souza et al., 2011).
However, caution is warranted when monitoring dosing
in older patients, because lithium plasma and brain
levels do not correlate in older patients in the same
manner as in younger patients (Forester et al., 2009).
Moreover, higher brain lithium levels were found to
correlate with both frontal lobe dysfunction and in-
creased depressive symptoms in older adults with BD.
VPA toxicity was also recently reviewed (Chateauvieux
et al., 2010). Adverse effects after treatment included
weight gain (Grosso et al., 2009; Wirrell, 2003), de-
creased reproductive potential (Isojarvi, 2008; Verrotti
et al., 2011), and a three-fold increase in birth de-
fects (spina bifida, anencephaly, cardiac defects,
dysmorphic features, valproate syndrome, and cra-
niofacial, skeletal, or limb defects) (Clayton-Smith
and Donnai, 1995; Genton et al., 2006; Ornoy, 2009).
In a recent review surveying drug treatments for
mood disorders during pregnancy, it was reported that
the use of VPA, in addition to chlorimipramine, par-
oxetine, and atypical antipsychotics, should be avoided
lithium was associ-
(Gentile, 2011);
ated with no significant teratogenic risks, making it

in contrast,

132

Chiu et al.

potentially appropriate for treating pregnant patients
(Gentile, 2012).

Additional adverse effects from VPA treatment
include decreasing IQ in children after fetal exposure
(Bromley et al., 2009; Meador et al., 2009) and some
neurologic adverse effects (inducing ischemic stroke
and exacerbating epilepsy) (Buechler and Buchhalter,
2007; Varoglu, 2009). The studies correlating VPA
treatment with neurologic adverse effects were case
reports and require additional randomized and con-
trolled studies to substantiate these potential risks in
a larger sample size. There have also been reports of
hepatotoxicity and hematopoietic damage (thrombocy-
topenia, platelet dysfunction, factor XIII deficiency,
hypofibrinogenemia, and vitamin K-dependent factor
deficiency) after VPA treatment (Koenig et al., 2006;
McFarland et al., 2008). Of
lithium was
suggested to be used in treating hematopoietic deficits
via increasing colony-stimulating factor (reviewed in
Focosi et al., 2009). VPA was also reported to increase
prevalence of von Wilbrant disease (Serdaroglu et al.,
2002; Koenig et al., 2008), a coagulation abnormality
presenting with increased bleeding tendency in the
form of easy bruising, nosebleeds, and bleeding gums,
and a nine-fold increase in aplastic anemia (Handoko
et al., 2006), a condition in which a patient has lower
red blood cells, white blood cells, and platelets because
of bone marrow not producing sufficient new cells.
Clearly, precautions are warranted with both lithium
and VPA treatments, and the risks must be weighed
against the benefits.

interest,

A final consideration of the limitations on these two
drugs to develop them into successful clinical treatments
beyond BD is the lack of financial incentive for un-
patentable drugs. This is based on problems with the
current patent-based drug development process. Cur-
rently, market demand and novelty are rewarded over
the reduction in global disease burden. A revised disease
burden incentive system would reward actual perfor-
mance of a new drug based on reducing the number of
patients with a specific disease or improving quality of
life (Barton and Emanuel, 2005). Without imposing
monetary incentives to favor such a prize-based system
that focuses on the social value of health benefits to
inspire drug innovation (Gandjour and Chernyak, 2011),
developing these unpatentable therapies will prove to be
difficult where large-scale randomized trials are re-
quired to determine efficacy and tolerability.

V. Conclusions and Future Directions

The past decade has seen remarkable growth in our
understanding of the mechanisms of action of lithium
and VPA. In vitro studies have revealed that both of
these mood-stabilizing drugs have robust neuroprotective
effects against glutamate-induced excitotoxicity and
a number of other insults in experimental settings. In

diverse preclinical animal models of CNS disorders
(including stroke, HD, AD, ALS, and others), lithium and
VPA have also been shown to improve behavioral and
cognitive performance, suppress neurodegeneration
and neuroinflammation, enhance neurogenesis and an-
giogenesis, and prolong cell survival. When considering
these drugs’ therapeutic potential, it is advisable to
address common mechanisms that may underlie these
benefits and thwart disease pathology.

Characterizing the unifying mechanisms that are
common to different diseases will provide clear targets
for facilitating beneficial effects across diverse CNS
disorders. This review focused on GSK-3 and HDAC,
two primary targets of lithium and VPA, respectively,
in which dysregulation has been implicated in diverse
neuropathological conditions. Although both drugs
induce neuroprotective and neurotrophic effects, they
use different molecular signaling pathways to regulate
transcriptional activation of cell survival signaling
cascades, oxidative stress pathways, protein quality
control mechanisms, and numerous other beneficial
effects. In promoting cell survival, lithium and VPA
appear to affect many different downstream molecules
(such as the neurotrophins BDNF and GDNF and
angiogenic VEGF) and anti-apoptotic proteins (such as
HSP70, Bcl-2, and Bcl-Xl).
In promoting cellular
lithium and VPA affect
plasticity and resiliency,
similar downstream molecules, such as BDNF and
Bcl-2; however, the associated changes in physiologic
function are different from that of promoting cell
survival mechanisms. These differences may provide
critical distinctions between impaired cellular plastic-
ity and different phases of neurodegeneration and cell
death when treating diverse CNS indications.

Further investigation is clearly warranted to estab-
lish the core cellular and molecular disturbances that
characterize the degree of impaired cellular plasticity
and neurodegeneration and ultimately determine the
associated changes in physiologic function (e.g., pre-
symptomatic, early, and late symptoms) that lead to
disease. This type of careful characterization will allow
for personalized treatments to be timed for specific
disease stages to slow or halt the progression from
impaired cellular resilience to a breakdown in the
maintenance of cellular integrity. In addition to timing
treatment, combing the use of effective and specific
risk biomarkers (genetic, molecular, cellular, and
for
neuroimaging based) may prove to be helpful
paving the way for personalize medicine by targeting
at-risk individuals before symptoms arise. Additional
considerations may include targeting specific cell types
and CNS regions. Keeping in mind these numerous
considerations and the limitations associated with both
agents, long-term clinical trials on a large scale are
now warranted to repurpose lithium and VPA for
therapeutic use in diverse new indications, ranging
from stroke to neurodegenerative diseases.

Therapeutic Potential of Mood Stabilizers

133

In this respect, it is important to reiterate that in
some experimental conditions in which treatment with
lithium or VPA alone was either ineffective or only
marginally beneficial, enhanced neuroprotection was
observed as a result of cotreatment with both agents.
This augmented neuroprotection was associated with
potentiating GSK-3 inhibition and may involve partic-
ular miRNA mechanisms currently under investiga-
tion, although understanding the precise underlying
mechanisms in detail will require future study. The
benefits of cotreatment also extend to enhancing MSC
migration via the upregulation of MMP-9 and CXCR4
by lithium and VPA, respectively. In addition,
in
transgenic mouse models of ALS and HD, cotreatment
with lithium and VPA more robustly and consistently
delayed disease syndrome progression, decreased
behavioral deficits, and increased lifespan. These
preclinical studies confirmed that using lithium and
VPA together is a rational strategy with significant
potential for treating neurodegenerative and neuro-
logic diseases; indeed, we speculate that combination
treatment may more effectively enhance neurotrophic
and neuroprotective mechanisms. Future studies are
required to confirm this hypothesis and to identify
common targets to discover new treatment opportuni-
ties. Furthermore, despite their long history of safe
clinical use, both lithium and VPA have adverse
effects, especially at high doses. However,
future
clinical investigations that combine treatment with
VPA and lithium could thus use lower doses of both
drugs, which would reduce undesirable adverse effects
and still achieve enhanced therapeutic actions.

In view of the many recent findings summarized
above, we expect that future studies will shed consider-
able new light on how to more effectively target the
mechanisms contributing to neurologic and neurode-
generative pathologies. New avenues of research into
mechanisms mediated by miRNAs, for instance, are
expected to reveal another layer of regulatory control
and identify network nodes capable of modulating
multiple signaling cascades. Validating miRNAs in-
volved in fundamental disease processes (neuroinflam-
mation, BBB integrity, and apoptosis) may also lead to
the development of novel and more efficacious treat-
ments capable of regulating multiple signaling net-
works. Finally, we predict
identifying the
mechanisms regulated by lithium and VPA will steer
genetic studies to identify susceptibility and protective
genes for both neurologic and neurodegenerative
diseases in which miRNA-mediated mechanisms may
provide one of the unifying links among patient
treatment response, therapeutic targets, and genetics.

that

Acknowledgments

The authors thank Ioline Henter, Elizabeth J. Sherman, Peter
Leeds, and Fairouz Chibane for critical review and editorial
assistance with this manuscript and the many collaborators involved
in the studies discussed in this report.

Authorship contributions

Wrote or contributed to the writing of the manuscript: Chiu, Wang,

Hunsberger, Chuang.

References

Abel T and Zukin RS (2008) Epigenetic targets of HDAC inhibition in neurodegen-

erative and psychiatric disorders. Curr Opin Pharmacol 8:57–64.

Abematsu M, Tsujimura K, Yamano M, Saito M, Kohno K, Kohyama J, Namihira M,
Komiya S, and Nakashima K (2010) Neurons derived from transplanted neural
stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord
injury. J Clin Invest 120:3255–3266.

Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P,
Conwit RA, Schoenfeld D, and Shefner J, et al.; Northeast and Canadian Amyo-
trophic Lateral Sclerosis consortia (2010) Safety and efficacy of lithium in combi-
nation with riluzole for treatment of amyotrophic lateral sclerosis: a randomised,
double-blind, placebo-controlled trial. Lancet Neurol 9:481–488.

Alessi DR and Cohen P (1998) Mechanism of activation and function of protein kinase

B. Curr Opin Genet Dev 8:55–62.

Alvarez G, Muñoz-Montaño JR, Satrústegui J, Avila J, Bogónez E, and Díaz-Nido
J (1999) Lithium protects cultured neurons against beta-amyloid-induced neuro-
degeneration. FEBS Lett 453:260–264.

Alvarez G, Muñoz-Montaño JR, Satrústegui J, Avila J, Bogónez E, and Díaz-Nido
J (2002) Regulation of tau phosphorylation and protection against beta-amyloid-
induced neurodegeneration by lithium. Possible implications for Alzheimer’s dis-
ease. Bipolar Disord 4:153–165.

Aminoff MJ and Marshall J (1974) Treatment of Huntington’s chorea with lithium

carbonate. A double-blind trial. Lancet 1:107–109.

Andén NE, Dalén P, and Johansson B (1973) Baclofen and lithium in Huntington’s

chorea. Lancet 2:93.

Andersen PM and Al-Chalabi A (2011) Clinical genetics of amyotrophic lateral

sclerosis: what do we really know? Nat Rev Neurol 7:603–615.

Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, Walz JC, Bond DJ, Goncalves CA,
Young LT, and Yatham LN (2009) 3-Nitrotyrosine and glutathione antioxidant
system in patients in the early and late stages of bipolar disorder. J Psychiatry
Neurosci 34:263–271.

Andreazza AC, Kauer-Sant’anna M, Frey BN, Bond DJ, Kapczinski F, Young LT,
and Yatham LN (2008) Oxidative stress markers in bipolar disorder: a meta-
analysis. J Affect Disord 111:135–144.

Andreopoulos S, Wasserman M, Woo K, Li PP, and Warsh JJ (2004) Chronic lithium
treatment of B lymphoblasts from bipolar disorder patients reduces transient re-
ceptor potential channel 3 levels. Pharmacogenomics J 4:365–373.

Angelucci F, Aloe L, Jiménez-Vasquez P, and Mathé AA (2003) Lithium treatment
alters brain concentrations of nerve growth factor, brain-derived neurotrophic
factor and glial cell line-derived neurotrophic factor in a rat model of depression.
Int J Neuropsychopharmacol 6:225–231.

Ansari MA, Roberts KN, and Scheff SW (2008) Oxidative stress and modification of
synaptic proteins in hippocampus after traumatic brain injury. Free Radic Biol
Med 45:443–452.

Aoki T, Koike T, Nakano T, Shibahara K, Kondo S, Kikuchi H, and Honjo T (1997)
Induction of Bip mRNA upon programmed cell death of differentiated PC12 cells as
well as rat sympathetic neurons. J Biochem 121:122–127.

Arraf Z, Amit T, Youdim MB, and Farah R (2012) Lithium and oxidative stress
lessons from the MPTP model of Parkinson’s disease. Neurosci Lett 516:57–61.
Arvidsson A, Collin T, Kirik D, Kokaia Z, and Lindvall O (2002) Neuronal re-
placement from endogenous precursors in the adult brain after stroke. Nat Med 8:
963–970.

Autry AE and Monteggia LM (2012) Brain-derived neurotrophic factor and neuro-

psychiatric disorders. Pharmacol Rev 64:238–258.

Barber PA, Zhang J, Demchuk AM, Hill MD, and Buchan AM (2001) Why are stroke
patients excluded from TPA therapy? An analysis of patient eligibility. Neurology
56:1015–1020.

Barber SC and Shaw PJ (2010) Oxidative stress in ALS: key role in motor neuron

injury and therapeutic target. Free Radic Biol Med 48:629–641.

Barton JH and Emanuel EJ (2005) The patents-based pharmaceutical development

process: rationale, problems, and potential reforms. JAMA 294:2075–2082.

Bauer S, Kerr BJ, and Patterson PH (2007) The neuropoietic cytokine family in

development, plasticity, disease and injury. Nat Rev Neurosci 8:221–232.

Baumgardner TL, Reiss AL, Freund LS, and Abrams MT (1995) Specification of the
neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 95:
744–752.

Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, and Martin JB (1986)
Replication of the neurochemical characteristics of Huntington’s disease by qui-
nolinic acid. Nature 321:168–171.

Bear MF, Huber KM, and Warren ST (2004) The mGluR theory of fragile X mental

retardation. Trends Neurosci 27:370–377.

Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M,
Trakhtenbroit M, Glahn DC, Brambilla P, and Sassi RB, et al. (2007) Greater
cortical gray matter density in lithium-treated patients with bipolar disorder. Biol
Psychiatry 62:7–16.

Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti M, Dierschke
N, Hayashi KM, Klunder AD, and Glahn DC, et al. (2008) Three-dimensional
mapping of hippocampal anatomy in unmedicated and lithium-treated patients
with bipolar disorder. Neuropsychopharmacology 33:1229–1238.

Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel
WC, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2008) A beta-arrestin 2 sig-
naling complex mediates lithium action on behavior. Cell 132:125–136.

Beck H and Plate KH (2009) Angiogenesis after cerebral ischemia. Acta Neuropathol

117:481–496.

134

Chiu et al.

Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto
RI, Cohen GM, and Green DR (2000) Heat-shock protein 70 inhibits apoptosis by
preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2:
469–475.

Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, and Mallet J (1999) Brain-
derived neurotrophic factor-mediated protection of striatal neurons in an excito-
toxic rat model of Huntington’s disease, as demonstrated by adenoviral gene
transfer. Hum Gene Ther 10:2987–2997.

Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN,
Schmitt I, Wullner U, Evert BO, and O’Kane CJ, et al. (2006) Rapamycin alleviates
toxicity of different aggregate-prone proteins. Hum Mol Genet 15:433–442.

Berger Z, Ttofi EK, Michel CH, Pasco MY, Tenant S, Rubinsztein DC, and O’Kane CJ
(2005) Lithium rescues toxicity of aggregate-prone proteins in Drosophila by per-
turbing Wnt pathway. Hum Mol Genet 14:3003–3011.

Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ,
and Greenough WT (2008) Open-label treatment trial of lithium to target the
underlying defect in fragile X syndrome. J Dev Behav Pediatr 29:293–302.

Bhat RV, Budd Haeberlein SL, and Avila J (2004) Glycogen synthase kinase 3: a drug

target for CNS therapies. J Neurochem 89:1313–1317.

Bian Q, Shi T, Chuang DM, and Qian Y (2007) Lithium reduces ischemia-induced hip-
pocampal CA1 damage and behavioral deficits in gerbils. Brain Res 1184:270–276.
Bianchi P, Ciani E, Contestabile A, Guidi S, and Bartesaghi R (2010) Lithium
restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for
Down syndrome. Brain Pathol 20:106–118.

Biermann J, Boyle J, Pielen A, and Lagrèze WA (2011) Histone deacetylase inhibitors
sodium butyrate and valproic acid delay spontaneous cell death in purified rat
retinal ganglion cells. Mol Vis 17:395–403.

Biermann J, Grieshaber P, Goebel U, Martin G, Thanos S, Di Giovanni S,
and Lagrèze WA (2010) Valproic acid-mediated neuroprotection and regeneration
in injured retinal ganglion cells. Invest Ophthalmol Vis Sci 51:526–534.

Bijur GN and Jope RS (2000) Opposing actions of phosphatidylinositol 3-kinase and
glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem
75:2401–2408.

Blauw HM, Barnes CP, van Vught PW, van Rheenen W, Verheul M, Cuppen E,
Veldink JH, and van den Berg LH (2012) SMN1 gene duplications are associated
with sporadic ALS. Neurology 78:776–780.

Boillée S, Vande Velde C, and Cleveland DW (2006) ALS: a disease of motor neurons

and their nonneuronal neighbors. Neuron 52:39–59.

Bown CD, Wang JF, and Young LT (2000) Increased expression of endoplasmic re-
ticulum stress proteins following chronic valproate treatment of rat C6 glioma
cells. Neuropharmacology 39:2162–2169.

Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu
IY, and Wirth B (2003) Valproic acid increases the SMN2 protein level: a well-
known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12:
2481–2489.

Brinkman SD, Pomara N, Barnett N, Block R, Domino EF, and Gershon S (1984)
Lithium-induced increases in red blood cell choline and memory performance in
Alzheimer-type dementia. Biol Psychiatry 19:157–164.

Brockington A, Wharton SB, Fernando M, Gelsthorpe CH, Baxter L, Ince PG, Lewis
CE, and Shaw PJ (2006) Expression of vascular endothelial growth factor and its
receptors in the central nervous system in amyotrophic lateral sclerosis. J Neu-
ropathol Exp Neurol 65:26–36.

Bromley RL, Baker GA, and Meador KJ (2009) Cognitive abilities and behaviour of
children exposed to antiepileptic drugs in utero. Curr Opin Neurol 22:162–166.
Brouillet E, Condé F, Beal MF, and Hantraye P (1999) Replicating Huntington’s

disease phenotype in experimental animals. Prog Neurobiol 59:427–468.

Brownlees J, Irving NG, Brion JP, Gibb BJ, Wagner U, Woodgett J, and Miller CC
(1997) Tau phosphorylation in transgenic mice expressing glycogen synthase ki-
nase-3beta transgenes. Neuroreport 8:3251–3255.

Buechler RD and Buchhalter JR (2007) Juvenile absence epilepsy exacerbated by

valproic acid. Pediatr Neurol 36:121–124.

Calderó J, Brunet N, Tarabal O, Piedrafita L, Hereu M, Ayala V, and Esquerda JE
(2010) Lithium prevents excitotoxic cell death of motoneurons in organotypic slice
cultures of spinal cord. Neuroscience 165:1353–1369.

Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín-Ibañez R, Muñoz MT,
Mengod G, Ernfors P, and Alberch J (2004) Brain-derived neurotrophic factor
regulates the onset and severity of motor dysfunction associated with enkephali-
nergic neuronal degeneration in Huntington’s disease. J Neurosci 24:7727–7739.
Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M,
Gaviraghi G, Terstappen GC, and Nicoletti F (2004) Induction of Dickkopf-1,
a negative modulator of the Wnt pathway,
is associated with neuronal de-
generation in Alzheimer’s brain. J Neurosci 24:6021–6027.

Carman JS, Shoulson I, and Chase TN (1974) Letter: Huntington’s chorea treated

with lithium carbonate. Lancet 1:811.

Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660.
Carmichael J, Sugars KL, Bao YP, and Rubinsztein DC (2002) Glycogen synthase
kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the
Huntington’s disease mutation. J Biol Chem 277:33791–33798.

Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, and Prediger RD (2012)
Lithium and valproate prevent olfactory discrimination and short-term memory
impairments
in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) rat model of Parkinson’s disease. Behav Brain Res 229:208–215.

Cha JH (2007) Transcriptional signatures in Huntington’s disease. Prog Neurobiol

83:228–248.

Chakraborty G, Saito M, Mao RF, Wang R, Vadasz C, and Saito M (2008) Lithium
blocks ethanol-induced modulation of protein kinases in the developing brain.
Biochem Biophys Res Commun 367:597–602.

Chalecka-Franaszek E and Chuang DM (1999) Lithium activates the serine/threo-
nine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in
neurons. Proc Natl Acad Sci USA 96:8745–8750.

Chan HY, Warrick JM, Gray-Board GL, Paulson HL, and Bonini NM (2000) Mech-
anisms of chaperone suppression of polyglutamine disease: selectivity, synergy and
modulation of protein solubility in Drosophila. Hum Mol Genet 9:2811–2820.

Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R,
and McCubrey JA (2003) Regulation of cell cycle progression and apoptosis by the
Ras/Raf/MEK/ERK pathway (Review). Review Int J Oncol 22:469–480.

Chateauvieux S, Morceau F, Dicato M, and Diederich M (2010) Molecular and
therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010:2010.
Chen G, Bower KA, Ma C, Fang S, Thiele CJ, and Luo J (2004) Glycogen synthase
kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death.
FASEB J 18:1162–1164.

Chen G, Huang LD, Jiang YM, and Manji HK (1999a) The mood-stabilizing agent val-
proate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72:1327–1330.
Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, and Manji HK (2000) Enhancement

of hippocampal neurogenesis by lithium. J Neurochem 75:1729–1734.

Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, and Manji HK (1999b)
The mood-stabilizing agents lithium and valproate robustly increase the levels of
the neuroprotective protein bcl-2 in the CNS. J Neurochem 72:879–882.

Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, Maier CM, Narasimhan
P, Goeders CE, and Chan PH (2011) Oxidative stress in ischemic brain damage:
mechanisms of cell death and potential molecular targets for neuroprotection.
Antioxid Redox Signal 14:1505–1517.

Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW,
and Chuang DM, et al. (2006) Valproate protects dopaminergic neurons in mid-
brain neuron/glia cultures by stimulating the release of neurotrophic factors from
astrocytes. Mol Psychiatry 11:1116–1125.

Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H, Lu RB, Gean PW, Chuang
DM, and Hong JS (2007) Valproic acid and other histone deacetylase inhibitors
induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminer-
gic neurotoxicity. Neuroscience 149:203–212.

Chen RW and Chuang DM (1999) Long term lithium treatment suppresses p53 and
Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection
against excitotoxicity. J Biol Chem 274:6039–6042.

Chiang MC, Chen HM, Lee YH, Chang HH, Wu YC, Soong BW, Chen CM, Wu YR,
Liu CS, and Niu DM, et al. (2007) Dysregulation of C/EBPalpha by mutant Hun-
tingtin causes the urea cycle deficiency in Huntington’s disease. Hum Mol Genet
16:483–498.

Chiò A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, Giannini F,
Logroscino G, Mandrioli J, and Marcello N, et al.; LITALS Study Group (2010)
Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-
finding trial. Neurology 75:619–625.

Chiu CT and Chuang DM (2010) Molecular actions and therapeutic potential of
lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128:
281–304.

Chiu CT, Liu G, Leeds P, and Chuang DM (2011) Combined treatment with the mood
stabilizers lithium and valproate produces multiple beneficial effects in transgenic
mouse models of Huntington’s disease. Neuropsychopharmacology 36:2406–2421.
Cho KS and Chen DF (2008) Promoting optic nerve regeneration in adult mice with

pharmaceutical approach. Neurochem Res 33:2126–2133.

Choi CH, McBride SM, Schoenfeld BP, Liebelt DA, Ferreiro D, Ferrick NJ, Hinchey
P, Kollaros M, Rudominer RL, and Terlizzi AM, et al. (2010) Age-dependent cog-
nitive impairment in a Drosophila fragile X model and its pharmacological rescue.
Biogerontology 11:347–362.

Chuang DM, Leng Y, Marinova Z, Kim HJ, and Chiu CT (2009) Multiple roles of
HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32:591–601.
Chuang DM, Wang Z and Chiu CT (2011) GSK-3 as a Target for Lithium-Induced
Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models
of Ischemic Stroke. Frontiers in Molecular Neuroscience 4:15.

Ciani L and Salinas PC (2005) WNTs in the vertebrate nervous system: from pat-

terning to neuronal connectivity. Nat Rev Neurosci 6:351–362.

Cimarosti H, Rodnight R, Tavares A, Paiva R, Valentim L, Rocha E, and Salbego C
(2001) An investigation of the neuroprotective effect of lithium in organotypic slice
cultures of rat hippocampus exposed to oxygen and glucose deprivation. Neurosci
Lett 315:33–36.

Cipriani A, Pretty H, Hawton K, and Geddes JR (2005) Lithium in the prevention of
suicidal behavior and all-cause mortality in patients with mood disorders: a sys-
tematic review of randomized trials. Am J Psychiatry 162:1805–1819.

Clayton-Smith J and Donnai D (1995) Fetal valproate syndrome. J Med Genet 32:

724–727.

Coffee B, Zhang F, Warren ST, and Reines D (1999) Acetylated histones are associ-
ated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 22:98–101.
Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA, and Scott
EW (2004) Bone marrow transdifferentiation in brain after transplantation: a ret-
rospective study. Lancet 363:1432–1437.

Corcia P, Camu W, Halimi JM, Vourc’h P, Antar C, Vedrine S, Giraudeau B, de Toffol
B, and Andres CR; French ALS Study Group (2006) SMN1 gene, but not SMN2, is
a risk factor for sporadic ALS. Neurology 67:1147–1150.

Corcia P, Camu W, Praline J, Gordon PH, Vourch P, and Andres C (2009) The
importance of the SMN genes in the genetics of sporadic ALS. Amyotroph Lateral
Scler 10:436–440.

Corcia P, Ingre C, Blasco H, Press R, Praline J, Antar C, Veyrat-Durebex C, Guettard
YO, Camu W, Andersen PM, and Vourc’h P, et al. (2012) Homozygous SMN2 de-
letion is a protective factor in the Swedish ALS population. Eur J Hum Genet 20:
588–591.

Corcia P, Mayeux-Portas V, Khoris J, de Toffol B, Autret A, Müh JP, Camu W,
and Andres C; French ALS Research Group. Amyotrophic Lateral Sclerosis (2002)
Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lat-
eral sclerosis. Ann Neurol 51:243–246.

Coyle JT and Schwarcz R (1976) Lesion of striatal neurones with kainic acid provides

a model for Huntington’s chorea. Nature 263:244–246.

Therapeutic Potential of Mood Stabilizers

135

Creson TK, Austin DR, Shaltiel G, McCammon J, Wess J, Manji HK, and Chen G
(2011) Lithium treatment attenuates muscarinic M(1) receptor dysfunction. Bi-
polar Disord 13:238–249.

Crespo-Biel N, Camins A, Pallàs M, and Canudas AM (2009) Evidence of calpain/
cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in
vitro. Neuropharmacology 56:422–428.

Crochemore C, Virgili M, Bonamassa B, Canistro D, Pena-Altamira E, Paolini M,
and Contestabile A (2009) Long-term dietary administration of valproic acid does
not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for
amyotrophic lateral sclerosis. Muscle Nerve 39:548–552.

Crossley NA and Bauer M (2007) Acceleration and augmentation of antidepressants
with lithium for depressive disorders: two meta-analyses of randomized, placebo-
controlled trials. J Clin Psychiatry 68:935–940.

Cuervo AM (2004) Autophagy: many paths to the same end. Mol Cell Biochem 263:

55–72.

D’Souza R, Rajji TK, Mulsant BH, and Pollock BG (2011) Use of lithium in the

treatment of bipolar disorder in late-life. Curr Psychiatry Rep 13:488–492.

Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN,
and Pati S (2011) Involvement of the glycogen synthase kinase-3 signaling path-
way in TBI pathology and neurocognitive outcome. PLoS ONE 6:e24648.

Dash PK, Orsi SA, and Moore AN (2009) Histone deactylase inhibition combined with
behavioral therapy enhances learning and memory following traumatic brain in-
jury. Neuroscience 163:1–8.

Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, Zhao J, and Moore AN (2010) Valproate
administered after traumatic brain injury provides neuroprotection and improves
cognitive function in rats. PLoS ONE 5:e11383.

de Carvalho M and Pinto S (2011) Lithium treatment in amyotrophic lateral scle-

rosis: do we have enough trials? Expert Rev Neurother 11:1693–1698.

De Ferrari GV, Chacón MA, Barría MI, Garrido JL, Godoy JA, Olivares G, Reyes AE,
Alvarez A, Bronfman M, and Inestrosa NC (2003) Activation of Wnt signaling
rescues neurodegeneration and behavioral impairments induced by beta-amyloid
fibrils. Mol Psychiatry 8:195–208.

De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, and Jope RS (2008) Lithium
prevents and ameliorates experimental autoimmune encephalomyelitis. J Immu-
nol 181:338–345.

De Sarno P, Li X, and Jope RS (2002) Regulation of Akt and glycogen synthase
kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharma-
cology 43:1158–1164.

de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, Forlenza
OV, Gattaz WF, and Machado-Vieira R (2011) Lithium increases plasma brain-
derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study.
Neurosci Lett 494:54–56.

Di Daniel E, Mudge AW, and Maycox PR (2005) Comparative analysis of the effects of
four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord 7:
33–41.

Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, and Conneally PM

(1993) Suicide risk in Huntington’s disease. J Med Genet 30:293–295.

Dikmen SS, Machamer JE, Winn HR, Anderson GD, and Temkin NR (2000) Neu-
ropsychological effects of valproate in traumatic brain injury: a randomized trial.
Neurology 54:895–902.

Dill J, Wang H, Zhou F, and Li S (2008) Inactivation of glycogen synthase kinase 3

promotes axonal growth and recovery in the CNS. J Neurosci 28:8914–8928.

Dinan TG (2010) MicroRNAs as a target for novel antipsychotics: a systematic review

of an emerging field. Int J Neuropsychopharmacol 13:395–404.

Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, Boncompagni S,
Belia S, Wannenes F, Nicoletti C, and Del PZ, et al. (2008) Skeletal muscle is
a primary target of SOD1G93A-mediated toxicity. Cell Metab 8:425–436.

Dolder C and McKinsey J (2010) Low-dose divalproex in agitated patients with

Alzheimer’s disease. J Psychiatr Pract 16:63–67.

Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, and Bear MF

(2007) Correction of fragile X syndrome in mice. Neuron 56:955–962.

Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S,
Dewhurst S, Gelbard HA, and Gendelman HE (2005) Neuroprotective mechanisms
of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 25:
8375–8385.

Dröge W (2002) Free radicals in the physiological control of cell function. Physiol Rev

82:47–95.

Duan W, Guo Z, Jiang H, Ware M, Li XJ, and Mattson MP (2003) Dietary restriction
normalizes glucose metabolism and BDNF levels, slows disease progression, and
increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 100:
2911–2916.

Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL,
Wong J, and Ross CA (2008) Sertraline slows disease progression and increases
neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis 30:
312–322.

Duka T, Duka V, Joyce JN, and Sidhu A (2009) Alpha-Synuclein contributes to GSK-
3beta-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J 23:
2820–2830.

Dweep H, Sticht C, Pandey P, and Gretz N (2011) miRWalk—database: prediction of
possible miRNA binding sites by “walking” the genes of three genomes. J Biomed
Inform 44:839–847.

Eacker SM, Dawson TM, and Dawson VL (2009) Understanding microRNAs in

neurodegeneration. Nat Rev Neurosci 10:837–841.

Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockestein E, and Masliah E
(2002) Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci
21:493–501.

Fan Y and Yang GY (2007) Therapeutic angiogenesis for brain ischemia: a brief re-

view. J Neuroimmune Pharmacol 2:284–289.

Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, Moroni F,
and Chiarugi A (2006) Pharmacological inhibition of histone deacetylases by

suberoylanilide hydroxamic acid specifically alters gene expression and reduces
ischemic injury in the mouse brain. Mol Pharmacol 70:1876–1884.

Fass DM, Shah R, Ghosh B, Hennig K, Norton S, Zhao WN, Reis SA, Klein PS,
Mazitschek R, et al. (2010) Effect of inhibiting histone deacetylase with short-chain
carboxylic acids and their hydroxamic acid analogs on vertebrate development and
neuronal chromatin. ACS Med Chem Lett 2:39–42.

Fei W, Aixi Y, Danmou X, Wusheng K, Zhengren P, and Ting R (2011) The mood
stabilizer valproic acid induces proliferation and myelination of rat Schwann cells.
Neurosci Res 70:383–390.

Feinstein DL, Galea E, Aquino DA, Li GC, Xu H, and Reis DJ (1996) Heat shock
protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by de-
creasing NFkappaB activation. J Biol Chem 271:17724–17732.

Feng HL, Leng Y, Ma CH, Zhang J, Ren M, and Chuang DM (2008) Combined
lithium and valproate treatment delays disease onset, reduces neurological deficits
and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neurosci-
ence 155:567–572.

Feng YT (1979) The necessity for a collection development policy statement. Libr

Resour Tech Serv 23:39–44.

Ferrara N, Gerber HP, and LeCouter J (2003) The biology of VEGF and its receptors.

Nat Med 9:669–676.

Ferrer I, Goutan E, Marín C, Rey MJ, and Ribalta T (2000) Brain-derived neuro-

trophic factor in Huntington disease. Brain Res 866:257–261.

Ferrucci M, Spalloni A, Bartalucci A, Cantafora E, Fulceri F, Nutini M, Longone P,
Paparelli A, and Fornai F (2010) A systematic study of brainstem motor nuclei in
a mouse model of ALS, the effects of lithium. Neurobiol Dis 37:370–383.
Fink AL (1999) Chaperone-mediated protein folding. Physiol Rev 79:425–449.
Finkbeiner S (2000) CREB couples neurotrophin signals to survival messages.

Neuron 25:11–14.

Focosi D, Azzarà A, Kast RE, Carulli G, and Petrini M (2009) Lithium and hema-

tology: established and proposed uses. J Leukoc Biol 85:20–28.

Foerster K and Regli F (1977) [Lithium therapy of extrapyramidal movement dis-

orders-an attempt (author’s transl)]. Nervenarzt 48:228–232.

Forester BP, Streeter CC, Berlow YA, Tian H, Wardrop M, Finn CT, Harper D,
Renshaw PF, and Moore CM (2009) Brain lithium levels and effects on cognition
and mood in geriatric bipolar disorder: a lithium-7 magnetic resonance spectros-
copy study. Am J Geriatr Psychiatry 17:13–23.

Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, and Gattaz WF (2011)
Disease-modifying properties of long-term lithium treatment for amnestic mild
cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351–356.
Forman JJ, Legesse-Miller A, and Coller HA (2008) A search for conserved sequences
in coding regions reveals that the let-7 microRNA targets Dicer within its coding
sequence. Proc Natl Acad Sci USA 105:14879–14884.

Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G,
Spalloni A, Bellio N, and Lenzi P, et al. (2008) Lithium delays progression of
amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 105:2052–2057.

Foster AC, Collins JF, and Schwarcz R (1983) On the excitotoxic properties of qui-
nolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds.
Neuropharmacology 22 (12A):1331–1342.

French RL and Heberlein U (2009) Glycogen synthase kinase-3/Shaggy mediates
ethanol-induced excitotoxic cell death of Drosophila olfactory neurons. Proc Natl
Acad Sci USA 106:20924–20929.

Friedlander RM (2003) Apoptosis and caspases in neurodegenerative diseases. N

Engl J Med 348:1365–1375.

Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, and Nakai A
(2005) Active HSF1 significantly suppresses polyglutamine aggregate formation in
cellular and mouse models. J Biol Chem 280:34908–34916.

Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, and Yamawaki S (2001) Chronic
lithium treatment increases the expression of brain-derived neurotrophic factor in
the rat brain. Psychopharmacology (Berl) 158:100–106.

Fulceri F, Ferrucci M, Lazzeri G, Paparelli S, Bartalucci A, Tamburini I, Paparelli A,
and Fornai F (2011) Autophagy activation in glutamate-induced motor neuron loss.
Arch Ital Biol 149:101–111.

Gafni J and Ellerby LM (2002) Calpain activation in Huntington’s disease. J Neurosci

22:4842–4849.

Gandjour A and Chernyak N (2011) A new prize system for drug innovation. Health

Policy 102:170–177.

Gao TY and Newton AC (2002) The turn motif is a phosphorylation switch that
regulates the binding of Hsp70 to protein kinase C. J Biol Chem 277:31585–31592.
Gao XM, Fukamauchi F, and Chuang DM (1993) Long-term biphasic effects of lith-
ium treatment on phospholipase C-coupled M3-muscarinic acetylcholine receptors
in cultured cerebellar granule cells. Neurochem Int 22:395–403.

Garber K, Smith KT, Reines D, and Warren ST (2006) Transcription, translation and

fragile X syndrome. Curr Opin Genet Dev 16:270–275.

Gavrilov DK, Shi X, Das K, Gilliam TC, and Wang CH (1998) Differential SMN2

expression associated with SMA severity. Nat Genet 20:230–231.

Geddes JR, Burgess S, Hawton K, Jamison K, and Goodwin GM (2004) Long-term
lithium therapy for bipolar disorder: systematic review and meta-analysis of ran-
domized controlled trials. Am J Psychiatry 161:217–222.

Gentile S (2011) Drug treatment for mood disorders in pregnancy. Curr Opin Psy-

chiatry 24:34–40.

Gentile S (2012) Lithium in pregnancy: the need to treat, the duty to ensure safety.

Expert Opin Drug Saf 11:425–437.

Genton P, Semah F, and Trinka E (2006) Valproic acid in epilepsy : pregnancy-

related issues. Drug Saf 29:1–21.

Ghribi O, Herman MM, and Savory J (2003) Lithium inhibits Abeta-induced stress in
endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative
damage and tau phosphorylation. J Neurosci Res 71:853–862.

Gill A, Kidd J, Vieira F, Thompson K, and Perrin S (2009) No benefit from chronic
lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial
using a standard mouse model of familial ALS. PLoS ONE 4:e6489.

136

Chiu et al.

Goldman S (2005) Stem and progenitor cell-based therapy of the human central

nervous system. Nat Biotechnol 23:862–871.

Goodwin FK and Jamison KR (2007) Manic-Depressive Illness: Bipolar Disorders and

Recurrent Depression, Oxford University Press, New York.

Gorbatyuk MS, Shabashvili A, Chen W, Meyers C, Sullivan LF, Salganik M, Lin JH,
Lewin AS, Muzyczka N, and Gorbatyuk OS (2012) Glucose regulated protein 78
diminishes a-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther
20:1327–1337.

Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo
Coco F, Nervi C, and Pelicci PG, et al. (2001) Valproic acid defines a novel class of
HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:
6969–6978.

Gould TD, Chen G, and Manji HK (2004a) In vivo evidence in the brain for lithium
inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29:32–38.
Gould TD, Einat H, Bhat R, and Manji HK (2004b) AR-A014418, a selective GSK-3
inhibitor, produces antidepressant-like effects in the forced swim test. Int J
Neuropsychopharmacol 7:387–390.

Gould TD, Einat H, O’Donnell KC, Picchini AM, Schloesser RJ, and Manji HK (2007)
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive
behaviors. Neuropsychopharmacology 32:2173–2183.

Gould TD and Manji HK (2005) Glycogen synthase kinase-3: a putative molecular

target for lithium mimetic drugs. Neuropsychopharmacology 30:1223–1237.

Gould TD, O’Donnell KC, Picchini AM, Dow ER, Chen G, and Manji HK (2008)
Generation and behavioral characterization of beta-catenin forebrain-specific
conditional knock-out mice. Behav Brain Res 189:117–125.

Gould TD, Quiroz JA, Singh J, Zarate CA, and Manji HK (2004c) Emerging experi-
mental therapeutics for bipolar disorder: insights from the molecular and cellular
actions of current mood stabilizers. Mol Psychiatry 9:734–755.

Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, and Fischer A (2011) Sodium
butyrate improves memory function in an Alzheimer’s disease mouse model when ad-
ministered at an advanced stage of disease progression. J Alzheimers Dis 26:187–197.
Gräff J, Rei D, Guan JS, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F,
Nervi C, and Pelicci PG, et al. (2012) An epigenetic blockade of cognitive functions
in the neurodegenerating brain. Nature 483:222–226.

Grosso S, Mostardini R, Piccini B, and Balestri P (2009) Body mass index and serum
lipid changes during treatment with valproic acid in children with epilepsy. Ann
Pharmacother 43:45–50.

Grove VE Jr, Quintanilla J, and DeVaney GT (2000) Improvement of Huntington’s

disease with olanzapine and valproate. N Engl J Med 343:973–974.

Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ,
Zhou Y, Wang X, and Mazitschek R, et al. (2009) HDAC2 negatively regulates
memory formation and synaptic plasticity. Nature 459:55–60.

Gul H, Marquez-Curtis LA, Jahroudi N, Lo J, Turner AR, and Janowska-Wieczorek A
(2009) Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor
cells by chromatin remodeling. Stem Cells Dev 18:831–838.

Guo S, Arai K, Stins MF, Chuang DM, and Lo EH (2009) Lithium upregulates vas-
cular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 40:
652–655.

Gupta A, Schulze TG, Nagarajan V, Akula N, Corona W, Jiang XY, Hunter N,
McMahon FJ, and Detera-Wadleigh SD (2012) Interaction networks of lithium and
valproate molecular targets reveal a striking enrichment of apoptosis functional
clusters and neurotrophin signaling. Pharmacogenomics J 12:328–341.

Gurvich N, Tsygankova OM, Meinkoth JL, and Klein PS (2004) Histone deacetylase
is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:
1079–1086.

Hagerman RJ, Hills J, Scharfenaker S, and Lewis H (1999) Fragile X syndrome and

selective mutism. Am J Med Genet 83:313–317.

Hagerman RJ, Ono MY, and Hagerman PJ (2005) Recent advances in fragile X:
a model for autism and neurodegeneration. Curr Opin Psychiatry 18:490–496.
Hajek T, Bauer M, Pfennig A, Cullis J, Ploch J, O’Donovan C, Bohner G, Klingebiel R,
Young LT, and Macqueen GM, et al. (2012) Large positive effect of lithium on
prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre
study. J Psychiatry Neurosci 37:185–192.

Hamilton JM, Salmon DP, Corey-Bloom J, Gamst A, Paulsen JS, Jerkins S, Jacobson
MW, and Peavy G (2003) Behavioural abnormalities contribute to functional de-
cline in Huntington’s disease. J Neurol Neurosurg Psychiatry 74:120–122.

Hampel H, Ewers M, Bürger K, Annas P, Mortberg A, Bogstedt A, Frolich L,
Schroder J, Schonknecht P, and Riepe MW, et al. (2009) Lithium trial in Alz-
heimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-
week study. J Clin Psychiatry 70:922–931.

Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC,
and van den Bemt PM (2006) Risk of aplastic anemia in patients using antiepi-
leptic drugs. Epilepsia 47:1232–1236.

Hanger DP, Hughes K, Woodgett JR, Brion JP, and Anderton BH (1992) Glycogen
synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: gen-
eration of paired helical filament epitopes and neuronal localisation of the kinase.
Neurosci Lett 147:58–62.

Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, Gould TD, Manji HK, and Chen G
(2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neu-
ronal growth and neurogenesis. J Neurosci 24:6590–6599.

Harahap IS, Saito T, San LP, Sasaki N, Gunadi, Nurputra DK, Yusoff S, Yamamoto
T, Morikawa S, and Nishimura N, et al. (2012) Valproic acid increases SMN2
expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast
cell lines. Brain Dev 34:213–222.

Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease:

progress and problems on the road to therapeutics. Science 297:353–356.

Hartl FU and Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from na-

scent chain to folded protein. Science 295:1852–1858.

Hashimoto R, Fujimaki K, Jeong MR, Christ L, and Chuang DM (2003a) Lithium-
induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in

neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity.
FEBS Lett 538:145–148.

Hashimoto R, Hough C, Nakazawa T, Yamamoto T, and Chuang DM (2002a) Lithium
protection against glutamate excitotoxicity in rat cerebral cortical neurons: in-
volvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine
phosphorylation. J Neurochem 80:589–597.

Hashimoto R, Senatorov V, Kanai H, Leeds P, and Chuang DM (2003b) Lithium
stimulates progenitor proliferation in cultured brain neurons. Neuroscience 117:
55–61.

Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, and Chuang DM (2002b) Lithium
induces brain-derived neurotrophic factor and activates TrkB in rodent cortical
neurons: an essential step for neuroprotection against glutamate excitotoxicity.
Neuropharmacology 43:1173–1179.

Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith
DL, Woodman B, and Bates GP (2004) Progressive decrease in chaperone protein
levels in a mouse model of Huntington’s disease and induction of stress proteins as
a therapeutic approach. Hum Mol Genet 13:1389–1405.

Hayashi A, Kasahara T, Kametani M, Toyota T, Yoshikawa T, and Kato T (2009)
Aberrant endoplasmic reticulum stress response in lymphoblastoid cells from
patients with bipolar disorder. Int J Neuropsychopharmacol 12:33–43.

He H, McColl K, and Distelhorst CW (2000) Involvement of c-Fos in signaling grp78

induction following ER calcium release. Oncogene 19:5936–5943.

Hébert SS and De Strooper B (2009) Alterations of the microRNA network cause

neurodegenerative disease. Trends Neurosci 32:199–206.

Hegde AN and Upadhya SC (2011) Role of ubiquitin-proteasome-mediated pro-

teolysis in nervous system disease. Biochim Biophys Acta 1809:128–140.

Heiseke A, Aguib Y, Riemer C, Baier M, and Schätzl HM (2009) Lithium induces
clearance of protease resistant prion protein in prion-infected cells by induction of
autophagy. J Neurochem 109:25–34.

Hendrick JP and Hartl FU (1993) Molecular chaperone functions of heat-shock

proteins. Annu Rev Biochem 62:349–384.

Herrmann N, Lanctôt KL, Rothenburg LS, and Eryavec G (2007) A placebo-controlled
trial of valproate for agitation and aggression in Alzheimer’s disease. Dement
Geriatr Cogn Disord 23:116–119.

Hickey MA and Chesselet MF (2003) Apoptosis in Huntington’s disease. Prog Neu-

ropsychopharmacol Biol Psychiatry 27:255–265.

Hiroi T, Wei H, Hough C, Leeds P, and Chuang DM (2005) Protracted lithium
treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells:
roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J 5:102–111.
Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA,
Hartog C, Goldstein DR, and Thu D, et al. (2006) Regional and cellular gene ex-
pression changes in human Huntington’s disease brain. Hum Mol Genet 15:
965–977.

Hong M, Chen DC, Klein PS, and Lee VM (1997) Lithium reduces tau phosphory-
lation by inhibition of glycogen synthase kinase-3. J Biol Chem 272:25326–25332.
Hooper C, Killick R, and Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s

disease. J Neurochem 104:1433–1439.

Hornstra IK, Nelson DL, Warren ST, and Yang TP (1993) High resolution methyl-
ation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome.
Hum Mol Genet 2:1659–1665.

Hough C, Lu SJ, Davis CL, Chuang DM, and Post RM (1999) Elevated basal and
thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from
bipolar affective disorder patients measured by a fluorometric microassay. Biol
Psychiatry 46:247–255.

Hsieh J, Nakashima K, Kuwabara T, Mejia E, and Gage FH (2004) Histone deace-
tylase inhibition-mediated neuronal differentiation of multipotent adult neural
progenitor cells. Proc Natl Acad Sci USA 101:16659–16664.

Hu JP, Xie JW, Wang CY, Wang T, Wang X, Wang SL, Teng WP, and Wang ZY (2011)
Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen
synthase kinase 3 signaling pathways. Brain Res Bull 85:194–200.

Huang EJ and Reichardt LF (2001) Neurotrophins: roles in neuronal development

and function. Annu Rev Neurosci 24:677–736.

Huang EJ and Reichardt LF (2003) Trk receptors: roles in neuronal signal trans-

duction. Annu Rev Biochem 72:609–642.

Huang HC and Klein PS (2006) Multiple roles for glycogen synthase kinase-3 as

a drug target in Alzheimer’s disease. Curr Drug Targets 7:1389–1397.

Huang W, Galdzicki Z, van Gelderen P, Balbo A, Chikhale EG, Schapiro MB,
and Rapoport SI (2000) Brain myo-inositol level is elevated in Ts65Dn mouse and
reduced after lithium treatment. Neuroreport 11:445–448.

Huang X, Wu DY, Chen G, Manji H, and Chen DF (2003) Support of retinal ganglion
cell survival and axon regeneration by lithium through a Bcl-2-dependent mech-
anism. Invest Ophthalmol Vis Sci 44:347–354.

Huelsken J and Behrens J (2002) The Wnt signalling pathway. J Cell Sci 115:

3977–3978.

Hunsberger JG, Austin DR, Chen G, and Manji HK (2009) Cellular mechanisms
underlying affective resiliency: the role of glucocorticoid receptor- and mito-
chondrially-mediated plasticity. Brain Res 1293:76–84.

Hunsberger JG, Fessler EB, Wang Z, Elkahloun AG, and Chuang DM (2012) Post-
insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia.
Am J Transl Res 4:316–332.

Inestrosa NC, Alvarez A, Godoy J, Reyes A, and De Ferrari GV (2000) Acetylcho-
linesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in
Abeta neurotoxicity. Acta Neurol Scand Suppl 176:53–59.

Inui M, Martello G, and Piccolo S (2010) MicroRNA control of signal transduction.

Nat Rev Mol Cell Biol 11:252–263.

Ishii T, Hashimoto E, Ukai W, Tateno M, Yoshinaga T, Saito S, Sohma H, and Saito T
(2008) Lithium-induced suppression of transcription repressor NRSF/REST: effects on
the dysfunction of neuronal differentiation by ethanol. Eur J Pharmacol 593:36–43.
Isojärvi J (2008) Disorders of reproduction in patients with epilepsy: antiepileptic

drug related mechanisms. Seizure 17:111–119.

Therapeutic Potential of Mood Stabilizers

137

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, and Su B
(2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt
phosphorylation and substrate specificity. Cell 127:125–137.

Jana NR, Tanaka M, Wang GH, and Nukina N (2000) Polyglutamine length-
dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-
terminal huntingtin: their role in suppression of aggregation and cellular toxicity.
Hum Mol Genet 9:2009–2018.

Jiang Y, Lv H, Liao M, Xu X, Huang S, Tan H, Peng T, Zhang Y, and Li H (2012)
GRP78 counteracts cell death and protein aggregation caused by mutant hun-
tingtin proteins. Neurosci Lett 516:182–187.

Jin G, Bausch D, Knightly T, Liu Z, Li Y, Liu B, Lu J, Chong W, Velmahos GC,
and Alam HB (2011) Histone deacetylase inhibitors enhance endothelial cell
sprouting angiogenesis in vitro. Surgery 150:429–435.

Jin K, Zhu Y, Sun Y, Mao XO, Xie L, and Greenberg DA (2002) Vascular endothelial
growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad
Sci USA 99:11946–11950.

Jope RS (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry

4:117–128.

Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple

outcomes. Trends Pharmacol Sci 24:441–443.

Jope RS (2011) Glycogen synthase kinase-3 in the etiology and treatment of mood

disorders. Fron Mol Neurosci 4:16.

Jope RS and Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-

3. Trends Biochem Sci 29:95–102.

Jope RS and Roh MS (2006) Glycogen synthase kinase-3 (GSK3) in psychiatric dis-

eases and therapeutic interventions. Curr Drug Targets 7:1421–1434.

Jope RS, Yuskaitis CJ, and Beurel E (2007) Glycogen synthase kinase-3 (GSK3):

inflammation, diseases, and therapeutics. Neurochem Res 32:577–595.

Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, and Nolta JA (2010) Mesenchymal
stem cells for the treatment of neurodegenerative disease. Regen Med 5:933–946.
Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberte C, Khan
M, Okamoto K, Chambers JW, and Fletcher PJ, et al. (2009) Abnormalities in brain
structure and behavior in GSK-3alpha mutant mice. Mol Brain 2:35.

Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, and Eldar-Finkelman H (2004)
Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and
its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55:781–784.

Kalasapudi VD, Sheftel G, Divish MM, Papolos DF, and Lachman HM (1990) Lith-
ium augments fos protoonocogene expression in PC12 pheochromocytoma cells:
implications for therapeutic action of lithium. Brain Res 521:47–54.

Kang K, Kim YJ, Kim YH, Roh JN, Nam JM, Kim PY, Ryu WS, Lee SH, and Yoon
BW (2012) Lithium pretreatment reduces brain injury after intracerebral hemor-
rhage in rats. Neurol Res 34:447–454.

Karege F, Perroud N, Burkhardt S, Fernandez R, Ballmann E, La Harpe R,
and Malafosse A (2011) Alterations in phosphatidylinositol 3-kinase activity and
PTEN phosphatase in the prefrontal cortex of depressed suicide victims. Neuro-
psychobiology 63:224–231.

Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R,
and Malafosse A (2007) Alteration in kinase activity but not in protein levels of
protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of
depressed suicide victims. Biol Psychiatry 61:240–245.

Karp JM and Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the

details. Cell Stem Cell 4:206–216.

Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, Morihara T, Yoneda
T, Gomi F, and Mori Y, et al. (1999) Presenilin-1 mutations downregulate the
signalling pathway of the unfolded-protein response. Nat Cell Biol 1:479–485.
Kaufman RJ (1999) Stress signaling from the lumen of the endoplasmic reticulum:
coordination of gene transcriptional and translational controls. Genes Dev 13:
1211–1233.

Ke Q and Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70:

1469–1480.

Kells AP, Fong DM, Dragunow M, During MJ, Young D, and Connor B (2004) AAV-
mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Hun-
tington disease. Mol Ther 9:682–688.

Kessing LV, Søndergård L, Forman JL, and Andersen PK (2008) Lithium treatment

and risk of dementia. Arch Gen Psychiatry 65:1331–1335.

Khairova R, Pawar R, Salvadore G, Juruena MF, de Sousa RT, Soeiro-de-Souza MG,
Salvador M, Zarate CA, Gattaz WF, and Machado-Vieira R (2012) Effects of lith-
ium on oxidative stress parameters in healthy subjects. Mol Med Report 5:680–682.
Kidd SK and Schneider JS (2010) Protection of dopaminergic cells from MPP+-me-

diated toxicity by histone deacetylase inhibition. Brain Res 1354:172–178.

Kidd SK and Schneider JS (2011) Protective effects of valproic acid on the nigros-
triatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse
model of Parkinson’s disease. Neuroscience 194:189–194.

Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD,
and Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse con-
textual memory deficits in a mouse model of Alzheimer’s disease. Neuro-
psychopharmacology 35:870–880.

Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, van den
Oord EJ, Riley BP, Kendler KS, and Vladimirov VI (2010) MicroRNA expression
profiling in the prefrontal cortex of individuals affected with schizophrenia and
bipolar disorders. Schizophr Res 124:183–191.

Kim HJ, Leeds P, and Chuang DM (2009) The HDAC inhibitor, sodium butyrate,

stimulates neurogenesis in the ischemic brain. J Neurochem 110:1226–1240.

Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, and Chuang DM (2007) Histone
deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in
a rat permanent ischemic model of stroke: multiple mechanisms of action. J
Pharmacol Exp Ther 321:892–901.

Kim YH, Rane A, Lussier S, and Andersen JK (2011) Lithium protects against oxi-
dative stress-mediated cell death in a-synuclein-overexpressing in vitro and in vivo
models of Parkinson’s disease. J Neurosci Res 89:1666–1675.

Kim YR, van Meer MP, Tejima E, Murata Y, Mandeville JB, Dai G, Chuang DM,
Rosen BR, and Lo EH (2008) Functional MRI of delayed chronic lithium treatment
in rat focal cerebral ischemia. Stroke 39:439–447.

King TD, Bijur GN, and Jope RS (2001) Caspase-3 activation induced by inhibition of
mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and at-
tenuated by lithium. Brain Res 919:106–114.

Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, and Eldar-Finkelman
H (2004) Lithium-mediated phosphorylation of glycogen synthase kinase-3beta
involves PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosc
24:237–245.

Klein PS and Melton DA (1996) A molecular mechanism for the effect of lithium on

development. Proc Natl Acad Sci USA 93:8455–8459.

Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, and Broderick JP (2008) National
US estimates of recombinant tissue plasminogen activator use: ICD-9 codes sub-
stantially underestimate. Stroke 39:924–928.

Klepac N, Relja M, Klepac R, He(cid:1)cimovi(cid:1)c S, Babi(cid:1)c T, and Trkulja V (2007) Oxidative
stress parameters in plasma of Huntington’s disease patients, asymptomatic
Huntington’s disease gene carriers and healthy subjects : a cross-sectional study. J
Neurol 254:1676–1683.

Klionsky DJ and Emr SD (2000) Autophagy as a regulated pathway of cellular

degradation. Science 290:1717–1721.

Koenig S, Gerstner T, Keller A, Teich M, Longin E, and Dempfle CE (2008) High
incidence of vaproate-induced coagulation disorders in children receiving valproic
acid: a prospective study. Blood Coagul Fibrinolysis 19:375–382.

Koenig SA, Buesing D, Longin E,, Oehring R, Haussermann P, Kluger G, Lindmayer
F, Hanusch R, Degen I, and Kuhn H, et al. (2006) Valproic acid-induced hepat-
opathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027–2031.
Koh SH, Yoo AR, Chang DI, Hwang SJ, and Kim SH (2008) Inhibition of GSK-3
reduces infarct volume and improves neurobehavioral functions. Biochem Biophys
Res Commun 371:894–899.

Kornack DR and Rakic P (2001) The generation, migration, and differentiation of
olfactory neurons in the adult primate brain. Proc Natl Acad Sci USA 98:
4752–4757.

Kostrouchová M, Kostrouch Z, and Kostrouchová M (2007) Valproic acid, a molecular

lead to multiple regulatory pathways. Folia Biol (Praha) 53:37–49.

Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, Amaravadi L, Brown
DE, Guyot D, Mays G, and Leiby K, et al. (1999) Functional and structural di-
versity of the human Dickkopf gene family. Gene 238:301–313.

Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, and Cinkilinc N (2002)
Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia
and bipolar disorder. Cell Biochem Funct 20:171–175.

Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, and Al-Harthi L (2008) Active
beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus
replication in peripheral blood mononuclear cells. J Virol 82:2813–2820.

Kunst CB, Messer L, Gordon J, Haines J, and Patterson D (2000) Genetic mapping of

a mouse modifier gene that can prevent ALS onset. Genomics 70:181–189.

Laeng P, Pitts RL, Lemire AL, Drabik CE, Weiner A, Tang H, Thyagarajan R, Mallon
BS, and Altar CA (2004) The mood stabilizer valproic acid stimulates GABA
neurogenesis from rat forebrain stem cells. J Neurochem 91:238–251.

Lai EC (2002) Micro RNAs are complementary to 39 UTR sequence motifs that me-

diate negative post-transcriptional regulation. Nat Genet 30:363–364.

Lai JS, Zhao C, Warsh JJ, and Li PP (2006) Cytoprotection by lithium and valproate

varies between cell types and cellular stresses. Eur J Pharmacol 539:18–26.

Lee J, Giordano S, and Zhang J (2012a) Autophagy, mitochondria and oxidative

stress: cross-talk and redox signalling. Biochem J 441:523–540.

Lee JY, Kim HS, Choi HY, Oh TH, Ju BG, and Yune TY (2012b) Valproic acid
attenuates blood-spinal cord barrier disruption by inhibiting matrix metal-
loprotease-9 activity and improves functional recovery after spinal cord injury. J
Neurochem 121:818–829.

Lee VM, Goedert M, and Trojanowski JQ (2001) Neurodegenerative tauopathies.

Annu Rev Neurosci 24:1121–1159.

Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B,
Cruaud C, Millasseau P, and Zeviani M, et al. (1995) Identification and charac-
terization of a spinal muscular atrophy-determining gene. Cell 80:155–165.

Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, and Chuang DM (2008) Synergistic
neuroprotective effects of lithium and valproic acid or other histone deacetylase
inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28:
2576–2588.

Leonard DP, Kidson MA, Brown JG, Shannon PJ, and Taryan S (1975) A double blind
trial of lithium carbonate and haloperidol in Huntington’s chorea. Aust N Z J
Psychiatry 9:115–118.

Leonard DP, Kidson MA, Shannon PJ, and Brown J (1974) Letter: Double-blind trial
of lithium carbonate and haloperidol in Huntington’s chorea. Lancet 2:1208–1209.
Leroy K, Ando K, Héraud C, Yilmaz Z, Authelet M, Boeynaems JM, Buée L, De
Decker R, and Brion JP (2010) Lithium treatment arrests the development of
neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibril-
lary pathology. J Alzheimers Dis 19:705–719.

Levine B and Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132:

27–42.

Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES,
Carpenter EM, Zanjani H, and Hurst RS, et al. (1999) Enhanced sensitivity to N-
methyl-D-aspartate receptor activation in transgenic and knockin mouse models of
Huntington’s disease. J Neurosci Res 58:515–532.

Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, and Laske C
(2009) Increase of BDNF serum concentration in lithium treated patients with
early Alzheimer’s disease. J Alzheimers Dis 16:649–656.

Li H, Li Q, Du X, Sun Y, Wang X, Kroemer G, Blomgren K, and Zhu C (2011)
Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is
associated with antiinflammatory effects and enhanced proliferation and survival
of neural stem/progenitor cells. J Cereb Blood Flow Metab 31:2106–2115.

138

Chiu et al.

Li Q, Li H, Roughton K, Wang X, Kroemer G, Blomgren K and Zhu C (2010a) Lithium
reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell death &
disease 1:e56.

Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS, Davis LL, and Jope RS
(2007) Lithium regulates glycogen synthase kinase-3beta in human peripheral
blood mononuclear cells: implication in the treatment of bipolar disorder. Biol
Psychiatry 61:216–222.

Li X and Jope RS (2010) Is glycogen synthase kinase-3 a central modulator in mood

regulation? Neuropsychopharmacology 35:2143–2154.

Li X, Liu M, Cai Z, Wang G, and Li X (2010b) Regulation of glycogen synthase kinase-

3 during bipolar mania treatment. Bipolar Disord 12:741–752.

Li XJ and Li S (2011) Proteasomal dysfunction in aging and Huntington disease.

Neurobiol Dis 43:4–8.

Liang ZQ, Wang X, Li LY, Wang Y, Chen RW, Chuang DM, Chase TN, and Qin ZH
(2007) Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication
associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat stria-
tum. J Neurosci Res 85:1295–1309.

Liang ZQ, Wang XX, Wang Y, Chuang DM, DiFiglia M, Chase TN, and Qin ZH (2005)
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of
Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiol Dis 20:
562–573.

Liu XS, Chopp M, Kassis H, Jia LF, Hozeska-Solgot A, Zhang RL, Chen C, Cui YS,
and Zhang ZG (2012a) Valproic acid increases white matter repair and neuro-
genesis after stroke. Neuroscience 220:313–321.

Liu Y, Chen G, Ma C, Bower KA, Xu M, Fan Z, Shi X, Ke ZJ, and Luo J (2009)
Overexpression of glycogen synthase kinase 3beta sensitizes neuronal cells to
ethanol toxicity. J Neurosci Res 87:2793–2802.

Liu ZH, Chuang DM, and Smith CB (2011) Lithium ameliorates phenotypic deficits
in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 14:618–630.
Liu ZH, Huang T, and Smith CB (2012b) Lithium reverses increased rates of cerebral
protein synthesis in a mouse model of fragile X syndrome. Neurobiol Dis 45:1145–1152.
Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D,
Mulot S, Marquardt B, and Stabel S, et al. (1994) Alzheimer’s disease-like phos-
phorylation of the microtubule-associated protein tau by glycogen synthase kinase-
3 in transfected mammalian cells. Curr Biol 4:1077–1086.

Lunn JS, Sakowski SA, Hur J, and Feldman EL (2011) Stem cell technology for

neurodegenerative diseases. Ann Neurol 70:353–361.

Luo GR and Le WD (2010) Collective roles of molecular chaperones in protein deg-
radation pathways associated with neurodegenerative diseases. Curr Pharm Bio-
technol 11:180–187.

Luo J (2010) Lithium-mediated protection against ethanol neurotoxicity. Front

Neurosci 4:41.

Lv L, Han X, Sun Y, Wang X, and Dong Q (2012) Valproic acid improves locomotion in
vivo after SCI and axonal growth of neurons in vitro. Exp Neurol 233:783–790.
Lv L, Sun Y, Han X, Xu CC, Tang YP, and Dong Q (2011) Valproic acid improves
outcome after rodent spinal cord injury: potential roles of histone deacetylase in-
hibition. Brain Res 1396:60–68.

Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, and Renshaw PF
(2010) Lithium-induced gray matter volume increase as a neural correlate of
treatment response in bipolar disorder: a longitudinal brain imaging study. Neu-
ropsychopharmacology 35:1743–1750.

Ma J and Zhang GY (2003) Lithium reduced N-methyl-D-aspartate receptor subunit
2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by
PSD-95 in rat hippocampus following cerebral
ischemia. Neurosci Lett 348:
185–189.

Ma Y and Hendershot LM (2001) The unfolding tale of the unfolded protein response.

Cell 107:827–830.

Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, and Lovestone S (2008)
A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr
Psychiatry 23:704–711.

Macdonald M; The Huntington’s Disease Collaborative Research Group (1993) A
novel gene containing a trinucleotide repeat that is expanded and unstable on
Huntington’s disease chromosomes. Cell 72:971–983.

Macdonald RL and Kelly KM (1995) Antiepileptic drug mechanisms of action. Epi-

lepsia 36 (Suppl 2):S2–S12.

Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V Jr, da Silva Vargas
R, Kapczinski F, Portela LV, Souza DO, and Salvador M, et al. (2007) Oxidative
stress parameters in unmedicated and treated bipolar subjects during initial manic
episode: a possible role for lithium antioxidant effects. Neurosci Lett 421:33–36.
Maggirwar SB, Tong N, Ramirez S, Gelbard HA, and Dewhurst S (1999) HIV-1 Tat-
mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated
neurotoxicity. J Neurochem 73:578–586.

Maler JM, Spitzer P, Lewczuk P, Kornhuber J, Herrmann M, and Wiltfang J (2006)
Decreased circulating CD34+ stem cells in early Alzheimer’s disease: Evidence for
a deficient hematopoietic brain support? Mol Psychiatry 11:1113–1115.

Malhi GS and Tanious M (2011) Optimal frequency of lithium administration in the
treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 25:
289–298.

Malhi GS, Tanious M, and Gershon S (2011) The lithiumeter: a measured approach.

Bipolar Disord 13:219–226.

Manyam NV and Bravo-Fernandez E (1973) Lithium carbonate in Huntington’s

chorea. Lancet 1:1010.

Margulies S and Hicks R; Combination Therapies for Traumatic Brain Injury
Workshop Leaders (2009) Combination therapies for traumatic brain injury: pro-
spective considerations. J Neurotrauma 26:925–939.

Marinova Z, Leng Y, Leeds P, and Chuang DM (2011) Histone deacetylase inhibition
alters histone methylation associated with heat shock protein 70 promoter mod-
ifications in astrocytes and neurons. Neuropharmacology 60:1109–1115.

Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S, Leeds P,
and Chuang DM (2009) Valproic acid induces functional heat-shock protein 70 via

Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1
acetylation. J Neurochem 111:976–987.

Marmol F (2008) Lithium: bipolar disorder and neurodegenerative diseases Possible
lithium. Prog Neuro-

the therapeutic effects of

cellular mechanisms of
psychopharmacol Biol Psychiatry 32:1761–1771.

Martin JB and Gusella JF (1986) Huntington’s disease. Pathogenesis and manage-

ment. N Engl J Med 315:1267–1276.

Martin L, Magnaudeix A, Esclaire F, Yardin C, and Terro F (2009) Inhibition of
glycogen synthase kinase-3beta downregulates total tau proteins in cultured
neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res
1252:66–75.

Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, and Geiger JD (2000)
Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative
disorders. Trends Neurosci 23:222–229.

Mattsson B (1973) Huntington’s chorea and lithium therapy. Lancet 1:718–719.
May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, and Finch CE
(1990) Dynamics of gene expression for a hippocampal glycoprotein elevated in
Alzheimer’s disease and in response to experimental lesions in rat. Neuron 5:
831–839.

McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A,
Siwicki KK, Dockendorff TC, and Nguyen HT, et al. (2005) Pharmacological rescue
of synaptic plasticity, courtship behavior, and mushroom body defects in a Dro-
sophila model of fragile X syndrome. Neuron 45:753–764.

McClung CA and Nestler EJ (2008) Neuroplasticity mediated by altered gene ex-

pression. Neuropsychopharmacology 33:3–17.

McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, Chinnery
PF, and Ramesh V (2008) Reversible valproate hepatotoxicity due to mutations in
mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 93:151–153.
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, and Geddes JR (2012)
Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379:
721–728.

Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A, Liporace JD,
Sam M, Kalayjian LA, and Thurman DJ, et al.; NEAD Study Group (2009) Anti-
epileptic drug use in women of childbearing age. Epilepsy Behav 15:339–343.
Meijer L, Flajolet M, and Greengard P (2004) Pharmacological inhibitors of glycogen

synthase kinase 3. Trends Pharmacol Sci 25:471–480.

Mezey E, Chandross KJ, Harta G, Maki RA, and McKercher SR (2000) Turning blood
into brain: cells bearing neuronal antigens generated in vivo from bone marrow.
Science 290:1779–1782.

Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, Werz O, Eikel
D, Zornig M, and Nau H, et al. (2006) Valproic acid induces extracellular signal-
regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell
Death Differ 13:446–453.

Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB,
Goslin KL, Graves MC, and McCluskey LF, et al.; WALS Study Group (2011) Phase
II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining
a more efficient trial design. Neurology 77:973–979.

Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, and Bauchwitz RP
(2009) Elevated glycogen synthase kinase-3 activity in Fragile X mice: key meta-
bolic regulator with evidence for treatment potential. Neuropharmacology 56:
463–472.

Mines MA and Jope RS (2011) Glycogen synthase kinase-3: a promising therapeutic

target for fragile x syndrome. Frontiers in molecular neuroscience 4:35.

Mines MA, Yuskaitis CJ, King MK, Beurel E, and Jope RS (2010) GSK3 influences
interaction in

social preference and anxiety-related behaviors during social
a mouse model of fragile X syndrome and autism. PLoS ONE 5:e9706.

Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, and Contestabile A (2010) Val-
proic acid is neuroprotective in the rotenone rat model of Parkinson’s disease:
involvement of alpha-synuclein. Neurotox Res 17:130–141.

Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, Faulk
MW, Koch S, Glitz DA, and Jolkovsky L, et al. (2000a) Lithium increases N-acetyl-
aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic
effects? Biol Psychiatry 48:1–8.

Moore GJ, Bebchuk JM, Wilds IB, Chen G, and Manji HK (2000b) Lithium-induced

increase in human brain grey matter. Lancet 356:1241–1242.

Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, Drevets WC,
and Manji HK (2009) A longitudinal study of the effects of lithium treatment on
prefrontal and subgenual prefrontal gray matter volume in treatment-responsive
bipolar disorder patients. J Clin Psychiatry 70:699–705.

Moreau MP, Bruse SE, David-Rus R, Buyske S, and Brzustowicz LM (2011) Altered
microRNA expression profiles in postmortem brain samples from individuals with
schizophrenia and bipolar disorder. Biol Psychiatry 69:188–193.

Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A,
Drummond JA, Berg S, and MacKay D, et al. (2004) GSK-3beta inhibition reverses
axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychia-
try 9:522–530.

Muñoz-Montaño JR, Lim F, Moreno FJ, Avila J, and Díaz-Nido J (1999) Glycogen
Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible
Implications for Neurite Pathology in Alzheimer’s Disease. J Alzheimers Dis 1:
361–378.

Muñoz-Montaño JR, Moreno FJ, Avila J, and Diaz-Nido J (1997) Lithium inhibits
Alzheimer’s disease-like tau protein phosphorylation in neurons. FEBS Lett 411:
183–188.

Nakao N, Brundin P, Funa K, Lindvall O, and Odin P (1995) Trophic and protective
actions of brain-derived neurotrophic factor on striatal DARPP-32-containing
neurons in vitro. Brain Res Dev Brain Res 90:92–101.

Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S,
Hamamura T, Trojanowski JQ, and Lee VM, et al. (2005) Chronic lithium treat-
ment decreases tau lesions by promoting ubiquitination in a mouse model of
tauopathies. Acta Neuropathol 110:547–556.

Therapeutic Potential of Mood Stabilizers

139

Neri LM, Borgatti P, Capitani S, and Martelli AM (2002) The nuclear phosphoino-
sitide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys
Acta 1584:73–80.

Neth P, Ciccarella M, Egea V, Hoelters J, Jochum M, and Ries C (2006) Wnt signaling
regulates the invasion capacity of human mesenchymal stem cells. Stem Cells 24:
1892–1903.

Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E,
and Duman RS (2003) Gene profile of electroconvulsive seizures: induction of
neurotrophic and angiogenic factors. J Neurosci 23:10841–10851.

Newton SS and Duman RS (2004) Regulation of neurogenesis and angiogenesis in

depression. Curr Neurovasc Res 1:261–267.

Ni M, Zhang Y, and Lee AS (2011) Beyond the endoplasmic reticulum: atypical GRP78

in cell viability, signalling and therapeutic targeting. Biochem J 434:181–188.

Nicholson KM and Anderson NG (2002) The protein kinase B/Akt signalling pathway

in human malignancy. Cell Signal 14:381–395.

Nijholt DA, De Kimpe L, Elfrink HL, Hoozemans JJ, and Scheper W (2011) Removing
protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem
18:2459–2476.

Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L,
LaFrancois J, and Feinstein B, et al. (2005) Inhibition of glycogen synthase kinase-
3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl
Acad Sci USA 102:6990–6995.

Nocjar C, Hammonds MD, and Shim SS (2007) Chronic lithium treatment magnifies

learning in rats. Neuroscience 150:774–788.

Nonaka S and Chuang DM (1998) Neuroprotective effects of chronic lithium on focal

cerebral ischemia in rats. Neuroreport 9:2081–2084.

Nunes PV, Forlenza OV, and Gattaz WF (2007) Lithium and risk for Alzheimer’s
disease in elderly patients with bipolar disorder. Br J Psychiatry 190:359–360.
Nuutinen T, Suuronen T, Kauppinen A, and Salminen A (2009) Clusterin: a forgotten

player in Alzheimer’s disease. Brain Res Brain Res Rev 61:89–104.

Nuutinen T, Suuronen T, Kauppinen A, and Salminen A (2010) Valproic acid stim-
ulates clusterin expression in human astrocytes: Implications for Alzheimer’s
disease. Neurosci Lett 475:64–68.

O’Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S, and Klein PS
(2004) Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral
and molecular effects of lithium. J Neurosci 24:6791–6798.

Ohgami H, Terao T, Shiotsuki I, Ishii N, and Iwata N (2009) Lithium levels in
drinking water and risk of suicide. Br J Psychiatry 194:464–465, discussion 446.
Omata N, Chiu CT, Moya PR, Leng Y, Wang Z, Hunsberger JG, Leeds P, and Chuang
DM (2011) Lentivirally mediated GSK-3b silencing in the hippocampal dentate
gyrus induces antidepressant-like effects in stressed mice.
Int J Neuro-
psychopharmacol 14:711–717.

Omata N, Murata T, Takamatsu S, Maruoka N, Mitsuya H, Yonekura Y, Fujibayashi
Y, and Wada Y (2008) Neuroprotective effect of chronic lithium treatment against
hypoxia in specific brain regions with upregulation of cAMP response element
binding protein and brain-derived neurotrophic factor but not nerve growth factor:
comparison with acute lithium treatment. Bipolar Disord 10:360–368.

Ornoy A (2009) Valproic acid in pregnancy: how much are we endangering the em-

bryo and fetus? Reprod Toxicol 28:1–10.

Ozaki N and Chuang DM (1997) Lithium increases transcription factor binding
to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J
Neurochem 69:2336–2344.

Pan T, Li X, Xie W, Jankovic J, and Le W (2005) Valproic acid-mediated Hsp70
induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 579:
6716–6720.

Paratcha G and Ledda F (2008) GDNF and GFRalpha: a versatile molecular complex

for developing neurons. Trends Neurosci 31:384–391.

Pardo R, Andreolotti AG, Ramos B, Picatoste F, and Claro E (2003) Opposed effects of
lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and
stimulation in neurons by GSK3 independent mechanisms. J Neurochem 87:
417–426.

Park HJ, Kang WS, Paik JW, and Kim JW (2012) Effect of valproic acid through
regulation of NMDA receptor-ERK signaling in sleep deprivation rats. J Mol
Neurosci 47:554–558.

Penas C, Verdú E, Asensio-Pinilla E, Guzmán-Lenis MS, Herrando-Grabulosa M,
Navarro X, and Casas C (2011) Valproate reduces CHOP levels and preserves
oligodendrocytes and axons after spinal cord injury. Neuroscience 178:33–44.

Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, and Hong JS
(2005) Valproate pretreatment protects dopaminergic neurons from LPS-induced
neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol
Brain Res 134:162–169.

Pérez M, Hernández F, Lim F, Díaz-Nido J, and Avila J (2003) Chronic lithium
treatment decreases mutant tau protein aggregation in a transgenic mouse model.
J Alzheimers Dis 5:301–308.

Perova T, Wasserman MJ, Li PP, and Warsh JJ (2008) Hyperactive intracellular
calcium dynamics in B lymphoblasts from patients with bipolar I disorder. Int J
Neuropsychopharmacol 11:185–196.

Perry G, Cash AD, and Smith MA (2002) Alzheimer Disease and Oxidative Stress.

J Biomed Biotechnol 2:120–123.

Phiel CJ and Klein PS (2001) Molecular targets of lithium action. Annu Rev Phar-

macol Toxicol 41:789–813.

Phiel CJ, Wilson CA, Lee VM, and Klein PS (2003) GSK-3alpha regulates production

of Alzheimer’s disease amyloid-beta peptides. Nature 423:435–439.

Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, and Klein PS (2001) Histone
deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood sta-
bilizer, and teratogen. J Biol Chem 276:36734–36741.

Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV,
Schelhaas HJ, Scheffer H, de Visser M, and de Jong JM, et al. (2009) Randomized
sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 66:
227–234.

Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, Carrì MT, and Bendotti C
(2009) Treatment with lithium carbonate does not improve disease progression in
two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 10:221–228.
Planel E, Yasutake K, Fujita SC, and Ishiguro K (2001) Inhibition of protein phos-
phatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and
cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in
the hippocampus of starved mouse. J Biol Chem 276:34298–34306.

Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A, and Tariot PN (2005) A ran-
domized, double-blind, placebo-controlled pilot trial of safety and tolerability of two
doses of divalproex sodium in outpatients with probable Alzheimer’s disease. Curr
Alzheimer Res 2:553–558.

Qian YR, Lee MJ, Hwang S, Kook JH, Kim JK, and Bae CS (2010) Neuroprotection
by valproic Acid in mouse models of permanent and transient focal cerebral is-
chemia. Korean J Physiol Pharmacol 14:435–440.

Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, and Chen
CH, et al. (2008) Valproic acid inhibits Abeta production, neuritic plaque forma-
tion, and behavioral deficits in Alzheimer’s disease mouse models. J Exp Med 205:
2781–2789.

Quiroz JA, Gould TD, and Manji HK (2004) Molecular effects of lithium. Mol Interv 4:

259–272.

Quiroz JA, Machado-Vieira R, Zarate CA Jr, and Manji HK (2010) Novel insights into
lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuro-
psychobiology 62:50–60.

Rametti A, Esclaire F, Yardin C, Cogné N, and Terro F (2008) Lithium down-regu-
lates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Neurosci Lett 434:93–98.

Rametti A, Esclaire F, Yardin C, and Terro F (2004) Linking alterations in tau
phosphorylation and cleavage during neuronal apoptosis. J Biol Chem 279:
54518–54528.

Rao JS and Rapoport SI (2009) Mood-stabilizers target the brain arachidonic acid

cascade. Curr Mol Pharmacol 2:207–214.

Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T,
Jaattela M, Penninger JM, and Garrido C, et al. (2001) Heat-shock protein 70
antagonizes apoptosis-inducing factor. Nat Cell Biol 3:839–843.

Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton
DF, Duden R, and O’Kane CJ, et al. (2004) Inhibition of mTOR induces autophagy
and reduces toxicity of polyglutamine expansions in fly and mouse models of
Huntington disease. Nat Genet 36:585–595.

Ren M, Leng Y, Jeong M, Leeds PR, and Chuang DM (2004) Valproic acid reduces
brain damage induced by transient focal cerebral ischemia in rats: potential roles
of histone deacetylase inhibition and heat shock protein induction. J Neurochem
89:1358–1367.

Ren M, Senatorov VV, Chen RW, and Chuang DM (2003) Postinsult treatment with
lithium reduces brain damage and facilitates neurological recovery in a rat is-
chemia/reperfusion model. Proc Natl Acad Sci USA 100:6210–6215.

Ricobaraza A, Cuadrado-Tejedor M, Marco S, Pérez-Otaño I, and García-Osta A
(2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits
in a mouse model of Alzheimer disease. Hippocampus 22:1040–1050.

Rochette CF, Surh LC, Ray PN, McAndrew PE, Prior TW, Burghes AH, Vanasse M,
and Simard LR (1997) Molecular diagnosis of non-deletion SMA patients using
quantitative PCR of SMN exon 7. Neurogenetics 1:141–147.

Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L,
and Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase
kinase-3beta signaling pathway in a transgenic model of Alzheimer’s disease are
associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:
1981–1991.

Roedding AS, Gao AF, Au-Yeung W, Scarcelli T, Li PP, and Warsh JJ (2012) Effect of
oxidative stress on TRPM2 and TRPC3 channels in B lymphoblast cells in bipolar
disorder. Bipolar Disord 14:151–161.

Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai
S, de Simone G, and Ford ES, et al.; American Heart Association Statistics Committee
and Stroke Statistics Subcommittee (2011) Heart disease and stroke statistics—2011
update: a report from the American Heart Association. Circulation 123:e18–e209.
Roh MS, Eom TY, Zmijewska AA, De Sarno P, Roth KA, and Jope RS (2005) Hypoxia
activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood
stabilizers and imipramine. Biol Psychiatry 57:278–286.

Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, Hong F, Yang HZ, Wan F,
and Ye XY, et al. (2011) MicroRNA-134 plasma levels before and after treatment
for bipolar mania. J Psychiatr Res 45:92–95.

Rosa AO, Kaster MP, Binfare RW, Morales S, Martin-Aparicio E, Navarro-Rico ML,
Martinez A, Medina M, Garcia AG, and Lopez MG, et al. (2008) Antidepressant-
like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuro-
psychopharmacol Biol Psychiatry 32:1549–1556.

Rosell A and Lo EH (2008) Multiphasic roles for matrix metalloproteinases after

stroke. Curr Opin Pharmacol 8:82–89.

Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D,
Goto J, O’Regan JP, and Deng HX (1993) Mutations in Cu/Zn superoxide dismutase
gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62.
Ross CA and Poirier MA (2005) Opinion: What is the role of protein aggregation in

neurodegeneration? Nat Rev Mol Cell Biol 6:891–898.

Ross CA and Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to

clinical treatment. Lancet Neurol 10:83–98.

Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, and Boutillier AL (2003)
Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neuro-
degeneration. EMBO J 22:6537–6549.

Rouaux C, Panteleeva I, René F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis
L, Menger Y, Boutillier AL, and Loeffler JP (2007) Sodium valproate exerts neu-
roprotective effects in vivo through CREB-binding protein-dependent mechanisms
but does not improve survival in an amyotrophic lateral sclerosis mouse model.
J Neurosci 27:5535–5545.

140

Chiu et al.

Rowe MK and Chuang DM (2004) Lithium neuroprotection: molecular mechanisms

and clinical implications. Expert Rev Mol Med 6:1–18.

Rowe MK, Wiest C, and Chuang DM (2007) GSK-3 is a viable potential target for
therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31:920–931.

Rowland LP (1994) Amyotrophic lateral sclerosis. Curr Opin Neurol 7:310–315.
Rubinsztein DC, Gestwicki JE, Murphy LO, and Klionsky DJ (2007) Potential

therapeutic applications of autophagy. Nat Rev Drug Discov 6:304–312.

Saft C, Lauter T, Kraus PH, Przuntek H, and Andrich JE (2006) Dose-dependent
improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington’s
Disease patients: a case series. BMC Neurol 6:11.

Saito M, Chakraborty G, Mao RF, Paik SM, Vadasz C, and Saito M (2010) Tau
phosphorylation and cleavage in ethanol-induced neurodegeneration in the
developing mouse brain. Neurochem Res 35:651–659.

Salmena L, Poliseno L, Tay Y, Kats L, and Pandolfi PP (2011) A ceRNA hypothesis:

the Rosetta Stone of a hidden RNA language? Cell 146:353–358.

Sang H, Lu Z, Li Y, Ru B, Wang W, and Chen J (2001) Phosphorylation of tau by
glycogen synthase kinase 3beta in intact mammalian cells influences the stability
of microtubules. Neurosci Lett 312:141–144.

Santarelli DM, Beveridge NJ, Tooney PA, and Cairns MJ (2011) Upregulation of
dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann
area 46 in schizophrenia. Biol Psychiatry 69:180–187.

Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ,
and Rubinsztein DC (2005) Lithium induces autophagy by inhibiting inositol
monophosphatase. J Cell Biol 170:1101–1111.

Sarkar S, Krishna G, Imarisio S, Saiki S, O’Kane CJ, and Rubinsztein DC (2008) A
rational mechanism for combination treatment of Huntington’s disease using
lithium and rapamycin. Hum Mol Genet 17:170–178.

Sarkar S and Rubinsztein DC (2006) Inositol and IP3 levels regulate autophagy:

biology and therapeutic speculations. Autophagy 2:132–134.

Sassi RB, Brambilla P, Hatch JP, Nicoletti MA, Mallinger AG, Frank E, Kupfer DJ,
Keshavan MS, and Soares JC (2004) Reduced left anterior cingulate volumes in
untreated bipolar patients. Biol Psychiatry 56:467–475.

Sassi RB, Nicoletti M, Brambilla P, Mallinger AG, Frank E, Kupfer DJ, Keshavan
MS, and Soares JC (2002) Increased gray matter volume in lithium-treated bipolar
disorder patients. Neurosci Lett 329:243–245.

Saudou F, Finkbeiner S, Devys D, and Greenberg ME (1998) Huntingtin acts in the
nucleus to induce apoptosis but death does not correlate with the formation of
intranuclear inclusions. Cell 95:55–66.

Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, Selek S,
Tutkun H, Zoroglu SS, and Akyol O (2006) Elevated serum nitric oxide and su-
peroxide dismutase in euthymic bipolar patients: impact of past episodes. World J
Biol Psychiatry 7:51–55.

Savory J, Herman MM, and Ghribi O (2003) Intracellular mechanisms underlying

aluminum-induced apoptosis in rabbit brain. J Inorg Biochem 97:151–154.

Scali C, Caraci F, Gianfriddo M, Diodato E, Roncarati R, Pollio G, Gaviraghi G,
Copani A, Nicoletti F, and Terstappen GC, et al. (2006) Inhibition of Wnt signaling,
modulation of Tau phosphorylation and induction of neuronal cell death by DKK1.
Neurobiol Dis 24:254–265.

Schenk G and Leijnse-Ybema HJ (1974) Letter: Huntington’s chorea and levodopa.

Lancet 1:364.

Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH,
Ratovitski T, Cooper JK, and Jenkins NA, et al. (1999) Intranuclear inclusions and
neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of
huntingtin. Hum Mol Genet 8:397–407.

Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, and Greenberg
ME (2006) A brain-specific microRNA regulates dendritic spine development.
Nature 439:283–289.

Schuettauf F, Rejdak R, Thaler S, Bolz S, Lehaci C, Mankowska A, Zarnowski T, Junemann
A, Zagorski Z, and Zrenner E, et al. (2006) Citicoline and lithium rescue retinal
ganglion cells following partial optic nerve crush in the rat. Exp Eye Res 83:1128–1134.
Schwarcz R and Whetsell WO Jr (1982) Post-mortem high affinity glutamate uptake

in human brain. Neuroscience 7:1771–1778.

Seidensticker MJ and Behrens J (2000) Biochemical interactions in the wnt pathway.

Biochim Biophys Acta 1495:168–182.

Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:

741–766.

Senatorov VV and Chuang DM (2007) Lithium protects against quinolinic-acid
excitotoxicity in rat cortico-striatal organotypic culture. Int J Neuroprotect Neu-
roregen 3:122–132.

Senatorov VV, Ren M, Kanai H, Wei H, and Chuang DM (2004) Short-term lithium
treatment promotes neuronal survival and proliferation in rat striatum infused
with quinolinic acid, an excitotoxic model of Huntington’s disease. Mol Psychiatry
9:371–385.

Serdaroglu G, Tütüncüoglu S, Kavakli K, and Tekgül H (2002) Coagulation abnor-
malities and acquired von Willebrand’s disease type 1 in children receiving valproic
acid. J Child Neurol 17:41–43.

Shao L, Sun X, Xu L, Young LT, and Wang JF (2006) Mood stabilizing drug lithium
increases expression of endoplasmic reticulum stress proteins in primary cultured
rat cerebral cortical cells. Life Sci 78:1317–1323.

Shapira M, Licht A, Milman A, Pick CG, Shohami E, and Eldar-Finkelman H (2007)
Role of glycogen synthase kinase-3beta in early depressive behavior induced by
mild traumatic brain injury. Mol Cell Neurosci 34:571–577.

Shein NA, Grigoriadis N, Alexandrovich AG, Simeonidou C, Lourbopoulos A, Polyzoidou
E, Trembovler V, Mascagni P, Dinarello CA, and Shohami E (2009) Histone
deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery,
and induces glial apoptosis following experimental traumatic brain injury. FASEB
J 23:4266–4275.

Shimizu T, Shibata M, Wakisaka S, Inoue T, Mashimo T, and Yoshiya I (2000)
Intrathecal lithium reduces neuropathic pain responses in a rat model of periph-
eral neuropathy. Pain 85:59–64.

Shin JH, Cho SI, Lim HR, Lee JK, Lee YA, Noh JS, Joo IS, Kim KW, and Gwag BJ
(2007) Concurrent administration of Neu2000 and lithium produces marked im-
provement of motor neuron survival, motor function, and mortality in a mouse
model of amyotrophic lateral sclerosis. Mol Pharmacol 71:965–975.

Shioda N, Han F, and Fukunaga K (2009) Role of Akt and ERK signaling in the

neurogenesis following brain ischemia. Int Rev Neurobiol 85:375–387.

Shirayama Y, Chen AC, Nakagawa S, Russell DS, and Duman RS (2002) Brain-
derived neurotrophic factor produces antidepressant effects in behavioral models of
depression. J Neurosci 22:3251–3261.

Shyu WC, Lin SZ, Chiang MF, Su CY, and Li H (2006) Intracerebral peripheral blood
stem cell
implantation induces neuroplasticity by enhancing beta1
integrin-mediated angiogenesis in chronic stroke rats. J Neurosci 26:3444–3453.
Siegel G, Saba R, and Schratt G (2011) microRNAs in neurons: manifold regulatory

(CD34+)

roles at the synapse. Curr Opin Genet Dev 21:491–497.

Sigurjonsson OE, Perreault MC, Egeland T, and Glover JC (2005) Adult human
hematopoietic stem cells produce neurons efficiently in the regenerating chicken
embryo spinal cord. Proc Natl Acad Sci USA 102:5227–5232.

Silva R, Martins L, Longatto-Filho A, Almeida OF, and Sousa N (2007) Lithium
prevents stress-induced reduction of vascular endothelium growth factor levels.
Neurosci Lett 429:33–38.

Sinha D, Wang Z, Ruchalski KL, Levine JS, Krishnan S, Lieberthal W, Schwartz JH,
and Borkan SC (2005) Lithium activates the Wnt and phosphatidylinositol 3-ki-
nase Akt signaling pathways to promote cell survival in the absence of soluble
survival factors. Am J Physiol Renal Physiol 288:F703–F713.

Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, Kim JM, Park DK, Kun Lee S,,
et al. (2007) Valproic acid-mediated neuroprotection in intracerebral hemorrhage
via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 26:
464–472.

Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R,
Bissada N, Hossain SM, and Yang YZ, et al. (2003) Selective striatal neuronal loss
in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555–1567.
Smith AM, Gibbons HM, and Dragunow M (2010) Valproic acid enhances microglial

phagocytosis of amyloid-beta(1-42). Neuroscience 169:505–515.

Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, Allen MJ, Hardy J,
Lovestone S, and Partridge L (2010) Inhibition of GSK-3 ameliorates Abeta pa-
thology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet 6:6.
Sovner R (1989) The use of valproate in the treatment of mentally retarded persons
with typical and atypical bipolar disorders. J Clin Psychiatry 50 (Suppl):40–43.
Spikman JM, Timmerman ME, Milders MV, Veenstra WS, and van der Naalt J (2012)
Social cognition impairments in relation to general cognitive deficits, injury severity,
and prefrontal lesions in traumatic brain injury patients. J Neurotrauma 29:101–111.
Stambolic V, Ruel L, and Woodgett JR (1996) Lithium inhibits glycogen synthase ki-
nase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664–1668.
Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, and McCubrey JA
(2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle pro-
gression and leukemogenesis. Leukemia 18:189–218.

Su H, Chu TH, and Wu W (2007) Lithium enhances proliferation and neuronal dif-
ferentiation of neural progenitor cells in vitro and after transplantation into the
adult rat spinal cord. Exp Neurol 206:296–307.

Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou Y, and Liu F,
et al. (2004) Lithium, a common drug for bipolar disorder treatment, regulates
amyloid-beta precursor protein processing. Biochemistry 43:6899–6908.

Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, Hamasaki T, Goto M,
and Sakoda S (2004) Benefit of valproic acid in suppressing disease progression of
ALS model mice. Eur J Neurosci 20:3179–3183.

Sugars KL and Rubinsztein DC (2003) Transcriptional abnormalities in Huntington

disease. Trends Genet 19:233–238.

Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, Schussler K,
Chen X, Jarecki J, and Burghes AH, et al. (2003) Valproic acid increases SMN
levels in spinal muscular atrophy patient cells. Ann Neurol 54:647–654.

Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, and Takashima
A (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid
precursor protein C100. Neurosci Lett 321:61–64.

Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, and Warren ST
(1992) DNA methylation represses FMR-1 transcription in fragile X syndrome.
Hum Mol Genet 1:397–400.

Suwalska A, Sobieska M, and Rybakowski JK (2010) Serum brain-derived neuro-
trophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neu-
ropsychobiology 62:229–234.

Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, and Laferla FM
(2011) Inflammation induced by infection potentiates tau pathological features in
transgenic mice. Am J Pathol 178:2811–2822.

Symington GR, Leonard DP, Shannon PJ, and Vajda FJ (1978) Sodium valproate in

Huntington’s disease. Am J Psychiatry 135:352–354.

Tabolacci E, De Pascalis I, Accadia M, Terracciano A, Moscato U, Chiurazzi P,
and Neri G (2008) Modest reactivation of the mutant FMR1 gene by valproic acid is
accompanied by histone modifications but not DNA demethylation. Pharmacogenet
Genomics 18:738–741.

Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, and Neri G (2005)
Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome
after reactivating pharmacological treatments. Eur J Hum Genet 13:641–648.
Takahashi-Yanaga F and Sasaguri T (2007) The Wnt/beta-catenin signaling pathway

as a target in drug discovery. J Pharmacol Sci 104:293–302.

Takayama S, Reed JC, and Homma S (2003) Heat-shock proteins as regulators of

apoptosis. Oncogene 22:9041–9047.

Tan BK, Leijnse-Ybema HJ, and Zee MF (1976) Sodium valproate in Huntington’s

chorea. Clin Neurol Neurosurg 79:62–65.

Tanaka T, Zhong J, Iqbal K, Trenkner E, and Grundke-Iqbal I (1998) The regulation
of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phos-
phatases. FEBS Lett 426:248–254.

Therapeutic Potential of Mood Stabilizers

141

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R,
Bartocci B, and Fleisher AIsmail MS, et al.Alzheimer’s Disease Cooperative Study
Group (2011) Chronic divalproex sodium to attenuate agitation and clinical pro-
gression of Alzheimer disease. Arch Gen Psychiatry 68:853–861.

Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE,
and Brooks DJ (1996) Proton magnetic resonance spectroscopy in Huntington’s
disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 11:167-
173.

Temkin NR, Dikmen SS, Anderson GD, Wilensky AJ, Holmes MD, Cohen W, Newell
DW, Nelson P, Awan A, and Winn HR (1999) Valproate therapy for prevention of
posttraumatic seizures: a randomized trial. J Neurosurg 91:593–600.

Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, and Iwata N (2006) Lithium
and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry
30:1125–1128.

The BALANCE investigators and collaborators (2010) Lithium plus valproate com-
bination therapy versus monotherapy for relapse prevention in bipolar I disorder
(BALANCE): a randomised open-label trial. Lancet 375:385–395.

Tolosa L, Mir M, Asensio VJ, Olmos G, and Lladó J (2008) Vascular endothelial
growth factor protects spinal cord motoneurons against glutamate-induced exci-
totoxicity via phosphatidylinositol 3-kinase. J Neurochem 105:1080–1090.

Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, Hutchison
JA, Di Raimo FR, Tabolacci E, and Neri G (2010) Treatment with valproic acid
ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A 152A:
1420–1427.

Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S,
Ramos FJ, Frontera M, and Sorge G, et al. (2008) A double-blind, parallel, multi-
center comparison of L-acetylcarnitine with placebo on the attention deficit hy-
peractivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803–812.
Tremolizzo L, Rodriguez-Menendez V, DiFrancesco JC, Sala G, Galbussera A,
Appollonio I, and Ferrarese C (2007) Huntington’s disease and HDACi: would
sulpiride and valproate be of therapeutic value? Med Hypotheses 69:964–965.
Trojanowski JQ and Lee VM (1995) Phosphorylation of paired helical filament tau in
Alzheimer’s disease neurofibrillary lesions: focusing on phosphatases. FASEB J 9:
1570–1576.

Tsai LK, Leng Y, Wang Z, Leeds P, and Chuang DM (2010) The mood stabilizers
valproic acid and lithium enhance mesenchymal stem cell migration via distinct
mechanisms. Neuropsychopharmacology 35:2225–2237.

Tsai LK, Tsai MS, Lin TB, Hwu WL, and Li H (2006) Establishing a standardized
for spinal muscular atrophy. Neurobiol Dis 24:

therapeutic testing protocol
286–295.

Tsai LK, Tsai MS, Ting CH, Wang SH, and Li H (2008) Restoring Bcl-x(L) levels
benefits a mouse model of spinal muscular atrophy. Neurobiol Dis 31:361–367.
Tsai LK, Wang Z, Munasinghe J, Leng Y, Leeds P, and Chuang DM (2011) Mesen-
chymal stem cells primed with valproate and lithium robustly migrate to infarcted
regions and facilitate recovery in a stroke model. Stroke 42:2932–2939.

Tsuji S, Morinobu S, Tanaka K, Kawano K, and Yamawaki S (2003) Lithium, but not
valproate, induces the serine/threonine phosphatase activity of protein phosphatase
2A in the rat brain, without affecting its expression. J Neural Transm 110:413–425.
Turner BJ, Parkinson NJ, Davies KE, and Talbot K (2009) Survival motor neuron
deficiency enhances progression in an amyotrophic lateral sclerosis mouse model.
Neurobiol Dis 34:511–517.

Ursano RJ, Goldenberg M, Zhang L, Carlton J, Fullerton CS, Li H, Johnson L,
and Benedek D (2010) Posttraumatic stress disorder and traumatic stress: from
bench to bedside, from war to disaster. Ann N Y Acad Sci 1208:72–81.

Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM,
Trojanowski JQ, and Smith DH (2007) Multiple proteins implicated in neurode-
generative diseases accumulate in axons after brain trauma in humans. Exp
Neurol 208:185–192.

Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, and Opdenakker G
(2002) Biochemistry and molecular biology of gelatinase B or matrix metal-
loproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37:375–536.

Varoglu AO (2009) Na VPA-induced acute ischemic stroke in an epileptic patient with
methylenetetrahydrofolate reductase gene polymorphism. Epilepsy Res 86:232–236.
Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C,
Scheffer H, Wokke JH, and Van den Berg LH (2005) SMN genotypes producing less
SMN protein increase susceptibility to and severity of sporadic ALS. Neurology 65:
820–825.

Veldink JH, van den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F,
Wokke JH, and Scheffer H (2001) Homozygous deletion of the survival motor
neuron 2 gene is a prognostic factor in sporadic ALS. Neurology 56:749–752.

Venkatachalam K, Long AA, Elsaesser R, Nikolaeva D, Broadie K, and Montell C
(2008) Motor deficit in a Drosophila model of mucolipidosis type IV due to defective
clearance of apoptotic cells. Cell 135:838–851.

Ventimiglia R, Mather PE, Jones BE, and Lindsay RM (1995) The neurotrophins
BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical
differentiation of striatal neurons in vitro. Eur J Neurosci 7:213–222.

Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards
S, Victoria MF, and Zhang FP, et al. (1991) Identification of a gene (FMR-1) con-
taining a CGG repeat coincident with a breakpoint cluster region exhibiting length
variation in fragile X syndrome. Cell 65:905–914.

Verrotti A, Loiacono G, Laus M, Coppola G, Chiarelli F, and Tiboni GM (2011)
Hormonal and reproductive disturbances in epileptic male patients: emerging
issues. Reprod Toxicol 31:519–527.

Verstraete E, Veldink JH, Huisman MH, Draak T, Uijtendaal EV, van der Kooi AJ,
Schelhaas HJ, de Visser M, van der Tweel I, and van den Berg LH (2012) Lithium
lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised
sequential trial. J Neurol Neurosurg Psychiatry 83:557–564.

Vestergaard P, Baastrup PC, and Petersson H (1977) Lithium treatment of Hun-
tington’s chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 56:
183–188.

Vonsattel JP and DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol

57:369–384.

Walasek MA, Bystrykh L, van den Boom V, Olthof S, Ausema A, Ritsema M, Huls G,
de Haan G, and van Os R (2012) The combination of valproic acid and lithium
delays hematopoietic stem/progenitor cell differentiation. Blood 119:3050–3059.
Wang JF, Azzam JE, and Young LT (2003) Valproate inhibits oxidative damage to lipid
and protein in primary cultured rat cerebrocortical cells. Neuroscience 116:485–489.
Wang JF, Bown C, and Young LT (1999) Differential display PCR reveals novel
targets for the mood-stabilizing drug valproate including the molecular chaperone
GRP78. Mol Pharmacol 55:521–527.

Wang JF, Bown CD, Chen B, and Young LT (2001) Identification of mood stabilizer-
regulated genes by differential-display PCR. Int J Neuropsychopharmacol 4:65–74.
Wang Y, Deng Y, and Zhou GQ (2008) SDF-1alpha/CXCR4-mediated migration of
systemically transplanted bone marrow stromal cells towards ischemic brain lesion
in a rat model. Brain Res 1195:104–112.

Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, and Jin K (2007)
Vascular endothelial growth factor overexpression delays neurodegeneration and
prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 27:304–307.
Wang Z, Leng Y, Tsai LK, Leeds P, and Chuang DM (2011a) Valproic acid attenuates
blood-brain barrier disruption in a rat model of transient focal cerebral ischemia:
the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 31:52–57.
Wang Z, Tsai LK, Munasinghe J, Leng Y, Fessler EB, Chibane F, Leeds P,
and Chuang DM (2012) Chronic valproate treatment enhances postischemic an-
giogenesis and promotes functional recovery in a rat model of ischemic stroke.
Stroke 43:2430–2436.

Wang ZF, Fessler EB, and Chuang DM (2011b) Beneficial effects of mood stabilizers
lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol
Sin 32:1433–1445.

Warner-Schmidt JL and Duman RS (2007) VEGF is an essential mediator of the
neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA
104:4647–4652.

Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, Mizusawa H, Orr
HT, Shaw C, and Zoghbi HY (2007) Lithium therapy improves neurological func-
tion and hippocampal dendritic arborization in a spinocerebellar ataxia type 1
mouse model. PLoS Med 4:e182.

Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, and Chuang DM (2001)
Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Hun-
tington’s disease. Neuroscience 106:603–612.

Wei HF, Leeds PR, Qian YN, Wei WL, Chen RW, and Chuang DM (2000) beta-
amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is
inhibited by long-term lithium treatment. Eur J Pharmacol 392:117–123.

Wexler EM, Geschwind DH, and Palmer TD (2008) Lithium regulates adult hippo-
campal progenitor development through canonical Wnt pathway activation. Mol
Psychiatry 13:285–292.

Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme
C, and Shoulson I; Huntington Study Group (2003) Predictors of nursing home
placement in Huntington disease. Neurology 60:998–1001.

Wijesekera LC and Leigh PN (2009) Amyotrophic lateral sclerosis. Orphanet J Rare

Dis 4:3.

Wiltse J (2005) Mode of action: inhibition of histone deacetylase, altering WNT-
dependent gene expression, and regulation of beta-catenin—developmental effects
of valproic acid. Crit Rev Toxicol 35:727–738.

Wirrell EC (2003) Valproic acid-associated weight gain in older children and teens

with epilepsy. Pediatr Neurol 28:126–129.

Woo NH and Lu B (2006) Regulation of cortical interneurons by neurotrophins: from

development to cognitive disorders. Neuroscientist 12:43–56.

Wood NI and Morton AJ (2003) Chronic lithium chloride treatment has variable
effects on motor behaviour and survival of mice transgenic for the Huntington’s
disease mutation. Brain Res Bull 61:375–383.

Wu JB and Shih JC (2011) Valproic acid induces monoamine oxidase A via Akt/

forkhead box O1 activation. Mol Pharmacol 80:714–723.

Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X,
and Leng Y, et al. (2008) Histone deacetylase inhibitors up-regulate astrocyte
GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J
Neuropsychopharmacol 11:1123–1134.

Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, Hou L, Yang H, Cao X,
and Liang Z, et al. (2011) Potential autophagy enhancers attenuate rotenone-
induced toxicity in SH-SY5Y. Neuroscience 199:292–302.

Xu C, Li PP, Cooke RG, Parikh SV, Wang K, Kennedy JL, and Warsh JJ (2009)
TRPM2 variants and bipolar disorder risk: confirmation in a family-based associ-
ation study. Bipolar Disord 11:1–10.

Xu C, Macciardi F, Li PP, Yoon IS, Cooke RG, Hughes B, Parikh SV, McIntyre RS,
Kennedy JL, and Warsh JJ (2006) Association of the putative susceptibility gene,
transient receptor potential protein melastatin type 2, with bipolar disorder. Am J
Med Genet B Neuropsychiatr Genet 141B:36–43.

Xu J, Culman J, Blume A, Brecht S, and Gohlke P (2003) Chronic treatment with
a low dose of lithium protects the brain against ischemic injury by reducing apo-
ptotic death. Stroke 34:1287–1292.

Xuan A, Long D, Li J, Ji W, Hong L, Zhang M, and Zhang W (2012) Neuroprotective
effects of valproic acid following transient global ischemia in rats. Life Sci 90:
463–468.

Yamamoto A, Lucas JJ, and Hen R (2000) Reversal of neuropathology and motor

dysfunction in a conditional model of Huntington’s disease. Cell 101:57–66.

Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H, and Nukina N
(2008) Mutant Huntingtin reduces HSP70 expression through the sequestration of
NF-Y transcription factor. EMBO J 27:827–839.

Yan XB, Hou HL, Wu LM, Liu J, and Zhou JN (2007) Lithium regulates hippocampal
neurogenesis by ERK pathway and facilitates recovery of spatial learning and
memory in rats after transient global cerebral ischemia. Neuropharmacology 53:
487–495.

142

Chiu et al.

Yang W, Leystra-Lantz C, and Strong MJ (2008) Upregulation of GSK3beta ex-
pression in frontal and temporal cortex in ALS with cognitive impairment (ALSci).
Brain Res 1196:131–139.

Yasuda S, Liang MH, Marinova Z, Yahyavi A, and Chuang DM (2009) The mood
stabilizers lithium and valproate selectively activate the promoter IV of brain-
derived neurotrophic factor in neurons. Mol Psychiatry 14:51–59.

Yatham LN (2004) Newer anticonvulsants in the treatment of bipolar disorder. J

Clin Psychiatry 65 (Suppl 10):28–35.

Yick LW, So KF, Cheung PT, and Wu WT (2004) Lithium chloride reinforces the
regeneration-promoting effect of chondroitinase ABC on rubrospinal neurons after
spinal cord injury. J Neurotrauma 21:932–943.

Youdim MB and Arraf Z (2004) Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium:
involvements of Bcl-2 and Bax. Neuropharmacology 46:1130–1140.

Yu F, Wang Z, Tchantchou F, Chiu CT, Zhang Y, and Chuang DM (2012a) Lithium
ameliorates neurodegeneration, suppresses neuroinflammation, and improves be-
havioral performance in a mouse model of traumatic brain injury. J Neurotrauma
29:362–374.

Yu F, Zhang Y and Chuang DM (2012b) Lithium reduces BACE1 overexpression,
beta amyloid accumulation, and spatial learning deficits in mice with traumatic
brain injury. J Neurotrauma 29:2342–2351.

Yu IT, Park JY, Kim SH, Lee JS, Kim YS, and Son H (2009) Valproic acid promotes
neuronal differentiation by induction of proneural factors in association with H4
acetylation. Neuropharmacology 56:473–480.

Yu Z, Luo H, Fu W, and Mattson MP (1999) The endoplasmic reticulum stress-
responsive protein GRP78 protects neurons against excitotoxicity and apoptosis:
suppression of oxidative stress and stabilization of calcium homeostasis. Exp
Neurol 155:302–314.

Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, and Chen G (2001) The mood
stabilizer valproic acid activates mitogen-activated protein kinases and promotes
neurite growth. J Biol Chem 276:31674–31683.

Yucel K, McKinnon MC, Taylor VH, Macdonald K, Alda M, Young LT, and MacQueen
GM (2007) Bilateral hippocampal volume increases after long-term lithium treat-
ment in patients with bipolar disorder: a longitudinal MRI study. Psychophar-
macology (Berl) 195:357–367.

Yucel K, Taylor VH, McKinnon MC, Macdonald K, Alda M, Young LT, and MacQueen
GM (2008) Bilateral hippocampal volume increase in patients with bipolar disorder
and short-term lithium treatment. Neuropsychopharmacology 33:361–367.

Zádori D, Geisz A, Vámos E, Vécsei L, and Klivényi P (2009) Valproate ameliorates
the survival and the motor performance in a transgenic mouse model of Hun-
tington’s disease. Pharmacol Biochem Behav 94:148–153.

Zarate CA Jr, Singh J, and Manji HK (2006) Cellular plasticity cascades: targets for
the development of novel therapeutics for bipolar disorder. Biol Psychiatry 59:
1006–1020.

Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, and Raymond
LA (2001) Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 17:
41–53.

Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR,
and Raymond LA (2002) Increased sensitivity to N-methyl-D-aspartate receptor-

mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 33:
849–860.

Zhang B, West EJ, Van KC, Gurkoff GG, Zhou J, Zhang XM, Kozikowski AP,
and Lyeth BG (2008) HDAC inhibitor increases histone H3 acetylation and reduces
microglia inflammatory response following traumatic brain injury in rats. Brain
Res 1226:181–191.

Zhang F, Phiel CJ, Spece L, Gurvich N, and Klein PS (2003) Inhibitory phosphory-
lation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for
autoregulation of GSK-3. J Biol Chem 278:33067–33077.

Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, and Le W (2011a)
Long-term treatment with lithium alleviates memory deficits and reduces amyloid-
b production in an aged Alzheimer’s disease transgenic mouse model. J Alzheimers
Dis 24:739–749.

Zhang Y, Sun Y, Wang F, Wang Z, Peng Y, and Li R (2012a) Downregulating the
canonical Wnt/b-catenin signaling pathway attenuates the susceptibility to au-
tism-like phenotypes by decreasing oxidative stress. Neurochem Res 37:1409–1419.
Zhang Z, Qin X, Zhao X, Tong N, Gong Y, Zhang W, and Wu X (2012b) Valproic acid
regulates antioxidant enzymes and prevents ischemia/reperfusion injury in the rat
retina. Curr Eye Res 37:429–437.

Zhang Z, Tong N, Gong Y, Qiu Q, Yin L, Lv X, and Wu X (2011b) Valproate protects
the retina from endoplasmic reticulum stress-induced apoptosis after ischemia-
reperfusion injury. Neurosci Lett 504:88–92.

Zheng Z, Kim JY, Ma H, Lee JE, and Yenari MA (2008) Anti-inflammatory effects of
the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab
28:53–63.

Zhong J, Yang X, Yao W, and Lee W (2006) Lithium protects ethanol-induced neu-

ronal apoptosis. Biochem Biophys Res Commun 350:905–910.

Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams
P, Du J, Chen G, and Manji HK (2009) Evidence for selective microRNAs and their
effectors as common long-term targets for the actions of mood stabilizers. Neuro-
psychopharmacology 34:1395–1405.

Zhu ZF, Wang QG, Han BJ, and William CP (2010) Neuroprotective effect and cog-
nitive outcome of chronic lithium on traumatic brain injury in mice. Brain Res Bull
83:272–277.

Zhuang J, Li F, Liu X, Liu Z, Lin J, Ge Y, Kaminski JM, Summers JB, Wang Z,
and Ge J, et al. (2009) Lithium chloride protects retinal neurocytes from nutrient
deprivation by promoting DNA non-homologous end-joining. Biochem Biophys Res
Commun 380:650–654.

Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E, MacDonald M,
Fossale E, Zeitlin S, and Buckley N, et al. (2007) Widespread disruption of re-
pressor element-1 silencing transcription factor/neuron-restrictive silencer factor
occupancy at its target genes in Huntington’s disease. J Neurosci 27:6972–6983.
Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald
ME, Friedlander RM, Silani V, and Hayden MR, et al. (2001) Loss of huntingtin-
mediated BDNF gene transcription in Huntington’s disease. Science 293:493–498.
Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt
BR, Hayden MR, and Timmusk T, et al. (2003) Huntingtin interacts with REST/
NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet
35:76–83.
